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Abstract
The research within this thesis primarily concentrates on the two chemokine receptors 
CCR8 and CXCR4. The chemokine family is divided into 4 groups, where CCR8 and 
CXCR4 fall into each of the two main subfamilies. The first section focuses on the 
signalling pathways mediated by the CCL1/CCR8 chemokine/chemokine receptor pair. 
CCL1 is described as a potent Th2 lymphocyte chemoattractant and is therefore under 
investigation as a potential treatment for asthma. Thus, examination o f the ambiguous 
biochemical and functional pathways elicited by CCL1 would provide a novel insight 
for future drug developments. This study demonstrated for the first time that ligation of 
CCR8 leads to the activation o f both the ERK1/2 MAPK and PI3K/PKB pathways. In 
addition, the CCL1-stimulated migration of a leukaemic T cell line exhibited classic 
bell-shaped, concentration-dependent characteristics, a phenomenon widely associated 
with chemokine receptors in general. Taken together, these data show that CCR8- 
mediated responses appear to be analogous with that of other well-defined chemokine 
receptors.
The following 2 sections examined the chemokine receptor CXCR4 and its ligand 
CXCL12. CXCR4 is fundamental in organ development and has been identified as a co­
receptor for HIV. The first section aimed to determine the role of the inositol-lipid 
phosphatase SHIP in the inhibitoy regulation of chemokine signalling. Investigation into 
the negative regulation of chemokine-mediated signalling pathways by SHIP is ill- 
defined. Failure to initiate inhibitory feedback mechanisms results in profound immune 
defects, as seen in autoimmunity. This study demonstrates in B cells that co-ligation of 
the BCR and FcyRIIb receptor can not only attenuate BCR-mediated responses but also 
those induced by chemokine receptors. In addition, a T cell model that expresses a 
tetracycline-regulated, constitutively active SHIP mutant showed that SHIP can impinge 
on CXCL12-induced PI(3,4,5)P3 levels, PKB phosphorylation and chemotaxis. Thus, 
these data implicate a regulatory role for SHIP in chemokine-mediated responses.
The concluding section investigates the role of the class II PI3K-C2p in chemokine 
receptor recycling, which has been shown to be essential for chemokine-mediated cell 
migration. In summary, these data suggest that class II PI3Ks may co-localise with 
CXCR4 and AP2 and hence contribute to the local phosphoinositide levels that play a 
central role in receptor sequestration.
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Innate and adaptive immunity constitute a defence system that protects an organism 
from attack. In the event of tissue damage or invasion by foreign bodies, the innate 
response o f vascularized tissue, known as inflammation, is activated. This process is 
highly reliant on the inherent aptitude of leukocytes to gain access to the affected 
areas. An additional event required for the induction o f cellular immunity is for 
dendritic cells to migrate from the infected peripheral tissues to the draining 
lymphoid organ, bearing antigens from the infected agent (1). Upon arrival at the T 
cell area of draining lymph nodes, dendritic cells interact with rare antigen specific 
lymphocytes. The induction of T cell division by antigen-loaded dendritic cells is 
very rapid, even within 2 days some antigen specific T cells have already divided 
twice. A further 24-48 hours later, divided cells have acquired effector phenotype and 
migrate from the draining node to the periphery (2).
The adaptive immune system protects the host from succumbing to pathogens 
previously encountered. Antigen-specific memory lymphocytes generated during an 
initial infection or by vaccine administration, become rapidly mobilized to elicit a 
potent recall immune response to direct pathogen clearance (3).
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Each day the body produces billions of new leukocytes to replace those lost to normal 
cell turnover processes as well as to illness or trauma. This process known as 
haematopoiesis is dependent on migratory stimuli to guide differentiated progeny to 
sites where they can undergo correct development.
Thus, without doubt, an essential component of the immune system is the homing and 
control of cellular localisation. In its absence, the fate and function of leukocytes is 
abrogated and the defence system of the host fails. Moreover, inappropriate activation 
o f an inflammatory response leads to diseases such as atherosclerosis, arthritis, 
asthma and psoriasis. So how is leukocyte localisation regulated? Molecules 
expressed on the vascular endothelium are known to be involved in the regulation of 
leukocyte extravasation and include; selectins; integrins; cadherins; connexins and 
chemoattractants (prostaglandins, C5a, formyl peptide) (4) however it is without 
question that the chemokine family of secreted proteins play a central role in this 
process (5-9).
1.2 Chemokines
Chemokines are a superfamily o f low molecular weight proteins that include more 
than 40 members in humans (10). They were originally named according to their 
function by the scientists who discovered them. However, this system began to fail 
following the concurrent identification of the same chemokine by different groups.
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Consequently, the Nomenclature Committee o f the International Union of 
Pharmacology (NC-IUPHAR) led by Yoshie and Zlotnick was formed to develop a 
novel nomenclature system which was based on protein structure and a previous 
nomenclature for chemokine gene loci (11) (Table 1).















CXCX1 4ql2-ql3 GROo/MGSA-et C30CR2 > CCL1 17ql 1.2 1-309 CCR8
CXCL2 4ql2-ql3 GROp/MGSA-p O X 'R l CCL2 17qll.2 MCP-1/MCAF CCR2
C3CCL3 4ql2-ql3 GROy/MGSA-y CXCR2 CCL3 17ql 1.2 MIP-lcx/Lt>78a CCR1, CCR5
CXCL4 4ql2-ql3 PF4 CXCR2 CCL4 17ql 1.2 M IPl-p CCRJ
CXCL5 4ql2-ql3 ENA-78 Unknown CCL5 17qll.2 RANTES CCR1, CCR3,
CXEL6 4ql2-ql3 GCP-2 CXCR2 (CCL6) Unknown CCR5
CXCL7 4ql2-ql3 NAP-2 C30CR1, CXCR2 (mouse only) Unknown
CXCL8 4ql2-ql3 1L-8 CXCR2 CCL7 17ql 1.2 MCP-3 CCR1, CCR2,
CXCL9 4q21-21 Mig CXCR1, C3CCR2 CCL8 17ql 1.2 MCP-2 CCR3
CXCL10 4q21-21 IP-10 CXCR3 (CCL9/CCL10) Unknown CCR3
C30CL11 4q21-21 I-TAC C30CR3 (mouse only) Unknown
CXCL12 lO q ll.l SD F-la/p C3DCR3 CCL11 1 7 q l l2 Eotaxin CCR3
CXCL13 4q21 BLC/BCA-1 CXCR4 (CCL12) Unknowri Unknown
CXCL14 Unknown BRAK/bolekine CXCR5 (Jnouse only) CCR2, CCR3
CXCL13 Unknown Unknown Unknown CCL13 17ql 1.2 MCP-4 CCR1
(Lun^ine in Unknown CCL14 17ql 1.2 HCC-1 CCR1, CCR3
mouse) CCL15 17ql 1.2 HCC-2/Lkn-1/MOP-IS CCR1
CCL16 17ql 1.2 HCC-4/LEC CCR4
CCL17 16ql3 TARC Unknown
C Chemokine/Receptor Family CCL18 17ql 1.2 DC-CK1/PARC/AMAC-1 CCR7
CCL19 9ql3 MIP-3p/EL C/exodus-3 CCR6
Systematic Human Human Ligand Chemokine CCL20 2q33-q37 MIP-3a/SL C/exodus-1 CCR7
Name Chromosome Receptor(s) CCL21 9ql3 5 Ckine/SL C/exodus-2 CCR4
CCL22 16ql3 MDC/STCP-1 CCR1
XCL1 lq23 Lymphotactun JCCR1 CCL23 17ql 1.2 MPIF-1 CCR3
XEL2 lq23 SCM-lb XCR1 CCL24 7 q ll,23 MPIF-2/Eotaxin-2 CCR9
CCL25 19ql3.2 TECK CCR3
CCL26 7ql 1.23 Eotaxin-3 CCR10
CX3C Chemokine/Receptor Family CCL27 9ql3 CTACK/TLC
Systematic Human Human Ligand Chemokine
Name Chromosame Receptor(s)
CX3CL1 16ql3 Ffcactalkine CX3CR1
Table 1. The Chemokine Family
The new nomenclature system developed by A. Zlotnick and O.Yoshie in 2000. This table also 
includes the old nomenclature system and highlights the clusters o f  chem okines that are found on 
chromosome 4 (CXC) and 17 (CC).
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Classification of Chemokines
The chemokine family is divided into two major classes, CC ((3) and CXC (a), 
dependent upon the location of two highly conserved N-terminal cysteine residues, 
adjacent and separated by an intervening residue, respectively (12). The two minor 
families C (y) and CX3C (8) chemokines are at present constituted by the members 
XCL1 and 2 (lymphotactin a  and (3) and CX3CLI (fractalkine), respectively. The ‘C* 
family lack the first and the third cysteine of the typical chemokine structure (13), 
while CX3C chemokines contain three amino acids between the first two cysteines 
and is also the only membrane-bound chemokine, and contains a mucin-like stalk 
(14).
ELR Chemokines
CXC chemokines are further classified according to the presence of the tripeptide 
motif glutamic acid-leucine-arginine (ELR) N-terminal to the first cysteine. ELR- 
positive chemokines are known to function as potent angiogenic factors, able to 
stimulate endothelial cell chemotaxis. In contrast, ELR-negative chemokines are 
strong angiostatic factors, which inhibit endothelial cell chemotaxis induced by ELR- 
positive chemokines (15). ELR-positive chemokines predominantly bind to CXCR2 
with the exception of CXCL8/IL-8 which also binds CXCR1. ELR-negative 
chemokines bind to CXCR3, CXCR4 and CXCR5 (Table 2).
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Chemokines that act predominantly on T cells
A more useful classification of chemokines, more so of the CC family, distinguishes 
between molecules that are made in a tonic way (constitutive) and those that are made 
in response to diverse signals (inducible or inflammatory) (11,16) (Figure 1). The 
former are those constitutively expressed in a certain tissue or organ, suggesting a 
specific function involving cell migration. The inflammatory chemokines in contrast 
are strongly upregulated by inflammatory or immune stimuli in various cell types 
(macrophages, fibroblasts, T cells, etc.) and are thus likely to participate in the 
development o f immune or inflammatory reactions.
Genes encoding inflammatory chemokines are typically found in two major clusters 
on chromosomes 4 (CXC) and 17 (CC), whereas genes for homeostatic chemokines 
are located alone or in small clusters on chromosomes 1,2,5,7,9,10 and 16 (Table 1). 
This diversification likely reflects functional specialization that has developed during 
the evolution of this superfamily and suggests that those chemokines located in 
different chromosomal locations from the major clusters are probably older in 
evolutionary terms and have remained more conserved between species because of 
their specific functions. They are also less likely to share receptors or have 
overlapping functions with other chemokines. In contrast, the major cluster 
chemokines are likely to have been generated more recently in evolutionary terms.
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The fact that the genes encoding these chemokines were allowed by evolution to 
duplicate rapidly and form a cluster, suggests that their functions remained to a 
certain extent related. The functional specificities may therefore be less important for 
this type of chemokine; their main function is likely to be the attraction of neutrophils 
or monocytes, while their specificity may be a secondary function (11).
Constitutive Inducible
Figure 1. Functional classification of chemokines
According to the regulation o f  their production, chem okines can be classified as constitutive 
chemokines which regulate normal leukocyte trafficking or inducible chemokines that are associated 
with inflammatory and immune responses. However, som e chemokines play a pivotal role in 
homeostasis as w ell as in inflammatory responses.
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Constitutive/Homeostatic Chemokines
Constitutively expressed CC chemokines are produced in discrete microenvironments 
within lymphoid or non-lymphoid tissues and in general function to guide the normal 
traffic of leukocytes under normal conditions. For example, CCL17/TARC and 
CCL27/SLC control cutaneous memory T cell homing to the skin. In addition 
CCL21/6Ckine and CCL19/ELC help control lymphocyte entry into secondary 
lymphoid tissues (17,18).
CXCL12/SDF-1 and CXCR4
The ‘homeostatic’ chemokine CXCL12/SDF-1 falls into the CXC (a) family and has 
one receptor, known as CXCR4 (Table 1). The chemokine receptor CXCR4 was 
cloned in 1994 by Loetscher et al (19). It has since been found to be widely expressed 
on haematopoietic cell types including neutrophils, monocytes, T and B lymphocytes, 
B cell precursors, CD34+ progenitor cells from blood and bone marrow, blood 
derived dendritic cells, Langerhans cells, mature and immature T cells of the thymus, 
and macrophages. CXCR4 is also expressed on non-haematopoietic cells which 
include vascular endothelial cells, neurons of the central and peripheral nervous 
system, microglia and astrocytes (20).
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With respect to function, CXCR4 was identified in 1996 along with CCR5 as a co­
receptor for the T-tropic human immunodeficiency virus type I (HIV-I) (21), this led 
to a sudden surge of interest and subsequent growth in CXCR4 research. Mice 
deficient in either the CXCL12/SDF-1 or CXCR4 gene show major defects in 
cerebella development; cardiac septum formation; B cell lymphopoiesis; and 
gastrointestinal vascular development (Figure 2).
Inducible Chemokines
The role o f inducible chemokines is to regulate the recruitment o f leukocytes on 
demand, in response to immunological, inflammatory and infectious signals ( 1,22). 
Unfortunately, this functional division also has its limitations in terms of molecules 
and pathology. A number of molecules behave as both constitutive and inducible 
chemokines. For example, CCL19/ELC is not only constitutively expressed by 
stromal cells where it functions to guide naive T cells and maturing DC into the T 
zones of secondary lymphoid organs, but is also upregulated along with CCL21/SLC 
at sites of chronic inflammation (23). Similarly, CCL22/MDC was initially described 
as a chemokine constitutively expressed in certain cell types, most notably dendritic 
cells and in certain lymphoid organs, in particular the thymus (24). Subsequent work, 
prompted by the recognition that this molecule attracted preferentially polarized type 
2 T cells, has shown that CCL22/MDC is also expressed in a regulated way.
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Figure 2. Summary of CXCR4/CXC12 involvement in Human Physiology
Evidence suggests that CXCR4 and CXCL12/SDF-1 are involved in brain development, 
vascularization, embryogenesis, T-cell activation, migration, haematopoiesis and HIV pathogenesis 
(25).
CCR8 and its ligand CCL1
The ‘inflammatory’ chemokine receptor CCR8 is a member o f the CC (p) family of 
chemokines, and is activated following the binding of the potent chemoattractant 
CCL1 (Table 1) (26). In the old nomenclature system, CCL1 was called 1-309 
according to the identification number of its cDNA clone (27). As detailed 
previously, the new nomenclature system was proposed to overcome the many
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chemokine aliases that had accompanied the co-discovery of chemokines by multiple 
groups (10). In addition to CCL1, only virally encoded chemokines exhibit a high 
affinity for the CCR8 receptor; HHV8 encoded vMIP-I-like CCL1 is a specific 
agonist for CCR8, whereas HHV8 encoded vMIP-II and MCV encoded vMCC-I act 
as potent antagonists, binding to CCR8 without inducing signalling and blocking the 
effects of CCL1 and vMIP-I (28-30).
The tissue expression of CCR8 is unique, with constitutive mRNA expression 
occurring in the thymus (26,31). In the periphery, however, CCR8 is found to be 
expressed on Th2-polarized cells (32), IL-2-activated natural killer cells (33), Treg 
cells (34-36), endothelial cells (37,38) and eosinophils (39).
CCR8 has received considerable attention concerning its potential role in the 
pathogenesis of inflammation; however, despite the generation of several knockout 
models, the precise function remains unclear. Two studies on CCR8-deficient mice, 
based on an ovalbumin-induced model of asthma, reported to have no effect on the 
development of pulmonary eosinophilia and T helper type 2 (Th2) cytokine responses 
and concluded that CCR8 does not play an essential role in the pathogenesis of 
inflammation (40,41). However, a different group showed that mice genetically 
deficient in CCR8 had impaired Th2 cytokine production and eosinophil recruitment 
during Th2-mediated responses, with no abrogation of Thl-mediated responses (42). 
Bishop et al. subsequently demonstrated that CCL1 was up-regulated in the lung 
following allergen challenge. Moreover, a neutralising antibody to CCL1 was shown
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to markedly reduce eosinophil migration, but have no effect on the recruitment of 
Th2 cells to the lung following allergen challenge. Interestingly, there was also no 
change in airway hyperresponsiveness or levels of Th2 cytokines (43).
There is also some evidence to support the notion that CCR8 may function as a co­
receptor for HIV-1 infection (44-46), regulate the trafficking of Treg and memory T 
cells (47-49) and modulate endothelial cell function (50). In addition, one study links 
CCL1 to apoptosis, where it is thought to protect lymphomas against corticoid- and 
dexamethasome-induced apoptosis (51-53). In addition, CCL1 is thought to play a 
role in monocyte chemotaxis (54) and angiogenesis (37).
1.3 Chemokine Receptors
Chemokines interact with their target cells through heptahelical cell surface G 
protein-coupled receptors derived from the rhodopsin family (12,55,56). These 
receptors, known as chemokine receptors, are typically 340-370 amino acids in length 
and contain the conserved DRYLAIV amino acid sequence in the second intracellular 
loop. The DRYLAIV motif is known to be involved in G-protein coupling, exposed 
following activation of the chemokine receptor by ligand binding ( 10,20).
In general, chemokine receptors fall into two categories o f expression: those 
expressed exclusively on specific leukocyte subsets; and those that are more broadly
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expressed. The most widely expressed chemokine receptor is CXCR4, which is 
present on neutrophils, monocytes, T lymphocytes, B lymphocytes and blood-derived 
dendritic cells amongst others. CXCR1 and CXCR2 are expressed on most 
leukocytes, although appear to be only functionally significant for neutrophils, 
monocytes/macrophages and mast cells (10,57). CXCR3, CXCR5 and CXCR6 are 
exclusively expressed on lymphocytes (58-60). CCR1, CCR2, CCR4, CCR5, CCR6, 
CCR7, CCR8, CCR9 and CCR10 are expressed mainly on lymphocytes, monocytes 
and monocyte-derived dendritic cells (10). CCR3 has a unique expression pattern, as 
it is found on eosinophils, mast cells, basophils, Th2 lymphocytes, and certain 
dendritic cell populations (61,62).
A number of chemokine receptors are promiscuous in that they bind more than one 
chemokine, but not those outside o f their class. For example, the chemokine receptor 
CCR5 binds CCL3/M IP-la, CCL4/MIP-lp, CCL5/RANTES, CCL8/MCP-2 and 
CCL14/HCC-1, but does not bind ‘CXC’, ‘C’ or ‘CX3C’ chemokines (Table 1). The 
exact purpose why one chemokine binds many receptors may reflect their ability to 
regulate many different leukocyte subpopulations, especially in complex micro­
environments such as acute or chronic inflammatory responses.
One chemokine receptor that does not meet the criteria for the systematic 
nomenclature is ‘duffy antigen receptor for chemokines’ (DARC), a seven- 
transmembrane domain (7TMD) binding protein that appears not to signal. DARC
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also known as D6 is a highly promiscuous CC chemokine receptor, binding the 
majority of members of the CC chemokine family. However, it is specific for this 
family and shows no detectable affinity for members of the CXC, C or CX3C 
chemokines (63-65).
The expansion of pro-inflammatory chemokines may also be an evolutionary 
consequence of battles with pathogens, which would explain why constitutive 
chemokines are much less promiscuous because the ligands are not induced by the 
infectious agent. However, a recent study discovered that one of the ligands for 
CCR3, CCL11 /Eotaxin, binds with high affinity to CXCR3 (66). This suggests that 
CXCR3 may act as a decoy receptor, sequestering locally produced CCL11/Eotaxin. 
In addition, the ligands for CXCR3, CXCL9/MIG, CXCL10/IP-10 and CXCL11/I- 
TAC have been found to inhibit CCR3-mediated functional responses. Consequently, 
chemokines that attract Thl cells via CXCR3 can concurrently block the migration of 
Th2 cells in response to CCR3 ligands (67). These experiments demonstrate that 
some chemokines can bind receptors outside of their class, but appear to merely 
function antagonistically, or prevent the binding of other chemokines.
Chapter 1: Introduction 13
Chemokine
Receptor
Main Ligand Function Sub-
Class
CXC(a)
CXCR1 CXCL8 Neutrophil Migration; Innate immunity; 
Acute Inflammation
ELR+
CXCR2 CXCL1,2,3,5,6,7,8 Neutrophil Migration; Innate immunity; 
Acute Inflammation; Angiogenesis
ELR+
CXCR3 CXCL9,10,11 T h l Response, Angiostasis ELR-
CXCR4 CXCL12 B Cell lymphopoiesis; bone marrow 
myelopoiesis; central nervous system and 
vascular development; HIV Infection
ELR-
CXCR5 CXCL13 B-Cell Trafficking; lymphoid development ELR-
CXCR6 CXCL16 T Cell Migration
CC(P)
CCR1 CCL3,5,7,8,13,14,15,16,23 T cell and monocyte migration; innate and 
adaptive immunity; inflammation
CCR2 CCL2,7,8,13 T cell and monocyte migration; innate and 
adaptive immunity; T hl inflammation
CCR3 CCL5,7,8,11,13,15,24,26 Eosinophil, basophil and T cell migration; 
allergic inflammation
CCR4 CCL17,22 T cell and monocyte migration; allergic 
inflammation
CCR5 CCL3,4,5,8,14 T cell and monocyte migration; innate and 
adaptive immunity; HIV infection
CCR6 CCL20 Dendritic Cell Function
CCR7 CCL 19,21 Lymphocyte, Dendritic Cell Migration; 
lymphoid development; primary immune 
response
CCR8 CCL1 T cell trafficking
CCR9 CCL25 Lymphocyte Trafficking in 
Thymus and Small Intestine
CCR10 CCL26,27,28 Lymphocyte Trafficking in Skin and Colon
CX3C(5)
CX3CR1 CX3CL1
T and NK cell trafficking and adhesion; 
innate and adaptive 
immunity; T h l inflammation
C(Y)
XCR1 XCL1,2 T cell trafficking
Table 2: Chemokines and Chemokine Receptors
A list of CXC, CC, CX3C and XC chemokine receptors with their corresponding ligand(s) according to 
the systematic chemokine nomenclature system developed by Zlotnik and Yoshie in 1999. The function 
of each chemokine receptor pair and the ELR sub-class for CXC chemokines is also shown (10,20,68).
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1.4 The Process of Leukocyte Extravasation
An inflammatory response initiates the trafficking of leukocytes from the micro­
vasculature to the site o f action in the tissue. Inflammatory stimuli initiate the 
response by activating the endothelial expression of selectins, integrin ligands and 
chemokines. Selectins are essential for the initial tethering of the leukocyte to the 
endothelium. An ‘on’ ‘o ff  interaction between the selectins and their respective 
ligands provides a means for the leukocyte to ‘roll’.
Firm adhesion is under the control o f chemokines, lipid mediators and other pro- 
inflammatory molecules presented on the surface of the endothelium (Figure 3). 
Together, these molecules along with selectins activate adhesion molecules, namely 
the integrin ligands (ICAM-1, VCAM-1) which lead to firm adhesion.
Once firmly attached, the leukocytes transmigrate across the endothelium into the 
tissue, a complex process known as ‘diapedesis’. In short, the leukocyte extends 
itself by a pseudopod across the endothelial border, which requires the disassembly 
and subsequent reassembly of its cytoskeleton. Platelet-endothelial-cell adhesion 
molecule-1 (PECAM-1), CD99, and the junctional adhesion molecule-A and C (JAM 
A/C), are present on both the leukocyte and endothelial junctions and provide 
homophilic (bind to same molecule) interactions that promote diapedesis (69). 
Diapedesis is also dependent on an increase in intracellular free calcium within the
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endothelial cells between which the cells are passing (70,71). The rise in intracellular 
calcium has also been shown to activate myosin light chain kinases (MLCK) which 
are known to unfold myosin II and lead to endothelial cell retraction (72,73). There is 
also evidence that supports the notion that leukocytes can also migrate into sites of 
inflammation by passing directly through endothelial cells (74). Once the cells have 
extravasated, they may then be susceptible to chemokine gradients in tissues for 
directed cell migration to specific tissue locales, known as chemotaxis.
•  Chemotadic Gradient
Figure 3. Leukocyte migration
The multi-step movem ent o f  leukocytes from the micro-vasculature to the tissue involves tethering (1), 
rolling (2), firm adhesion (3), diapedesis (4) and chemotaxis (5). All stages are under the tight 
regulation o f  inflammatory m olecules (75).
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Chemotaxis
Chemotaxis is the process by which cells detect the direction and intensity of, and 
move toward, an extracellular chemoattractant gradient. When cells sense a 
chemoattractant gradient, they dramatically change their shape, polarizing in the 
direction o f the gradient (76). Polarity refers to the ability o f a migrating cell to 
determine back from front. The leading edge protrudes at the cell front followed by 
the retraction of the rear edge (uropod) (77). This intriguing process plays a central 
role in development, immunity and tissue homeostasis (78-80). During 
embryogenesis, movements of cells in response to chemotactic stimuli bring form and 
organisation to tissues and organs and steer axons in the formation of the nervous 
system (81,82). In the immune system, an elaborate network of chemoattractants 
directs leukocytes to their correct locations and facilitates cell-cell interactions. 
Chemotaxis is also central to wound healing and has been implicated in disease states 
such as metastasis and atherosclerosis (83-85).
1.5 Tissue-specific Lymphocyte homing Signals
Tissue cells express specific chemokines on their surface to attract tissue-specific 
lymphocytes bearing corresponding chemokine receptors and adhesion molecules. It 
is evident that the circulating memory lymphocyte pool constitutes two clearly 
separable subsets of lymphocytes with skin versus gut homing potential. The skin-
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homing circulating lymphocytes express cutaneous lymphocyte antigen (CLA), E- 
selectin, the integrin (X4P1, VCAM-1 (adhesion molecule) and the chemokine 
receptors CCR4 and CCR10. However, the gut homing lymphocytes express integrin 
(X4P7 and CCR9 (17).
More recently, a study investigating monocyte homing identified two principle 
subsets o f blood monocytes that differ in their chemokine expression profile. The 
short-lived, inflammatory subset, express CCR2 and home to inflamed tissue to 
trigger immune responses. The resident subset with a longer half-life, express 
CX3CRI and home to non-inflamed tissues including liver, lung, brain and spleen. 
Here, the monocytes serve as precursors for resident myeloid cells, including 
CD1 lc+I-A+ dendritic cells (86).
Dendritic cells are known to switch chemokine receptor expression during maturation 
which permits their entry into secondary lymphoid organs whilst retaining immature 
cells in inflamed tissue. Immature dendritic cells express CCR1, CCR2, CCR5 and 
CXCR1 and migrate into inflamed peripheral tissues where they capture antigens. 
Maturing dendritic cells attain expression of CCR7, up-regulate CXCR4, down- 
regulate CXCR1 and lose expression of CCR1 and CCR5. Following maturation 
these cells migrate to the lymph nodes where they stimulate T cells (87).
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So it is evident from the account above, that organ systems exhibit important 
differences in terms of their chemokine expression profile and are not 
immunologically uniform as first thought.
1.6 Genetically Modified Mice, Chemokines and Disease
The targeted deletion of chemokine receptors and the transgenic expression of their 
ligands have proven to be useful tools for determining the distinct biological role of 
these molecules in vivo. Table 3 and Table 4 outline the phenotypes that have been 
described for the various chemokines and chemokine receptors and Table 5 lists the 
effects seen following the transgenic expression of chemokines in vivo.
1.7 Differential expression of chemokine receptors within T cell subsets
The chemokine receptor expression profile differs within specific T cell subsets and 
will be discussed in more detail below.
Memory T Cells
In the last several years, functional diversity of the memory T-cell population has 
been attributed to memory T-cell subsets that differ in expression of homing and 
chemokine receptors. Two sets o f human memory CD45RO+ T cells have since been
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been identified based on differential expression of the CCR7 chemokine and homing 
receptor. CCR7 expression on lymphocytes facilitates their migration into T cell areas 
of lymphoid organs in search of antigen presented by dendritic cells. Sallusto et al. 
designated the CD45RO/CCR7' subset as ‘effector-memory’ based on its ability to 
produce effector cytokines with rapid kinetics and the CD45RO/CCR7+ subset as 
‘central memory’ because of its predominant production of IL-2 and ability to 
differentiate into effector-memory T cells upon further stimulation (88). However, 
Unsoeld et al. (89) questions the proposed concept and argues that CCR7+ and CCR7‘ 
memory T cells do not differ in their immediate effector cell function.
T Helper Cells
The existence of two functionally distinguished populations among T helper cells has 
also been established. Type 1 T helper (Thl) cells are involved in the defence against 
intracellular bacteria and many viruses, while type 2 Th cells (Th2) are the major 
actors in the response against parasites and play a central role in allergic 
inflammation. More recently, many studies have suggested that some chemokine 
receptors are tightly regulated on T cells, and in accordance with this selective 
expression, Thl and Th2 cells can be differentially recruited by specific chemokines 
to the inflammatory sites. Th2-associated chemokine receptors include CCR3, CCR4 
and CCR8, whereas Thl-associated chemokine receptors include CCR5 and 
CXCR3(90).






Imbalance in Thl/Th2 cytokines 
Reduced lung eosinophil recruitment in a murine model of asthma 
Resistance to EAE development
CCL3 /M IP -la  
(97)
Mediates macrophage chemotaxis 




Reduced macrophage recruitment to inflammatory stimuli 
Increased resistance to atherosclerosis 
Decreased bronchial hyper-reactivity in a murine asthma model 
Resistance to EAE
CCL2/MCP-1
(106,107) Imbalance of Thl/Th2 cytokines
CCR3
(108,109) Eosinophils fail to traffick to intestinal mucosa but not lung 
Absence of eosinophils in a model of skin allergic inflammation
CCR4
(110-113)
Resistant to LPS-induced endotoxemia 




Partial resistance to LPS-induced endotoxemia 
Enhanced T cell-dependent immune responses 
Protecting and exacerbating effects on macrophage recruitment
CCR6
(119-121)
Reduced airway resistance, fewer eosinophils around airways, reduced IL-5 in lung 
and reduced serum IgE was observed in CA model 
Altered leukocyte homeostasis and cytokine environment in the intestinal mucosa 
2-15-fold increase in specific T cell subsets within the mucosa
CCR7
(122,123)
Impaired B and T-lymphocyte migration 
Profound morphological alterations in all secondary lymphoid organs 
Upon activation DCs fail to migrate into draining lymph nodes
CCR8
(40-42)
Impaired Th2 cytokine production and eosinophil recruitment during Th2-mediated 
responses, with no abrogation of Thl-mediated responses 
No effect on the development of pulmonary eosinophilia and Th2 cytokine responses
CCR9
(124,125)
Intraepithelial T-cell-to-epithelial cell ratio is decreased in small intestine, effects of
this are unknown
Reduction in pre-pro-B cells but had no effect on generation of normal complement
of mature B cells
Table 3. CC Chemokine and Chemokine Receptor Knock-Outs
This table summarises the main effects seen in CC chemokine and chemokine receptor knock-out 
mice. It should be noted that the phenotype of the CCR8 knockout mouse has been published by three 
independent groups however their findings contradict one another.






Lymphadenopathy and splenomegaly, increased B cells 
Reduced neutrophilic infiltration in an acute model of gout 
Protection from septic injury 
Reduced progression of atherosclerosis
CXCR3
(132)
Profound resistance to development of acute allograft rejection
CXCR4
(133-135)
Lethal to embryo 
Critical in signalling progenitors to thymus for T cell differentiation 
Defective vascular development, haematopoiesis, cardiogenesis and 
derailed cerebellar neuronal migration.
CXCL12/SDF-1
(136,137)
Colonization of bone marrow by haematopoietic stem and myeloid cells 
severely impaired in embryo.
Colonization of gonads by primordial germ cells also affected
CXCR5
(123,138)
Altered B-cell migration and germinal centre formation in spleen 




Selective reduction in natural killer cells
Table 4. CXC and CX3C Chemokine and Chemokine Receptor Knock outs
This table summarises the main effects seen in CXC and CX3C chemokine receptor knock-out mice. 
CXCR4 is the only receptor known to be embryonically lethal.
Chemokine Effect of Transgenic Expression of Ligands
CXCL12/SDF-loc
(137,141,142)
Enhanced marrow and splenic myelopoiesis 
Increased progenitor cell cycling and numbers 
Recruitment of dendritic cells 
(Promoter constructs used include: RSV and RIP7)
CCL3/MIP-lot
(143)
Recruitment and activation of leukocyte populations 
(CMV promoter construct was used)
CXCL2/MIP-2
(144)
Inflammation of small intestine and colon 




Recruitment of inflammatory infiltrate 
Transient and severe encephalopathy 
(Promoter constructs used include: MBP and GFAP)
CCL19/ELC
(141)
Recruitment of lymphocytes and dendritic cells 
(RIP7 promoter construct was used)
CXCL 10/IP-10 
(148,149)
Recruitment of leukocytes to CNS 
Up-regulated in allergic pulmonary inflammation 
Contributes to airway hyperactivity and Th2 inflammation 




(RIP7 promoter construct was used)
Table 5. Transgenic Expression of Chemokine Ligands
This table summarises the main effects seen in response to the transgenic expression of chemokines.
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1.8 Chemokine Signalling
Some of the underlying principles behind the differential expression of chemokine 
receptors have been discussed above. The question now is; how do chemokines and 
their receptors induce functional responses such as cell movement? The answer lies 
within the complex system of signalling pathways, which will be discussed below.
Signalling is a process employed by chemokine receptors to transduce information 
supplied by extracellular stimuli into intracellular second messengers that are 
deciphered as meaningful signals by the cell. It involves the coupling of agonist- 
activated G-protein coupled receptors (GPCRs) to a wide variety of effector systems 
via their interaction to heterotrimeric G proteins. The binding of agonist to a GPCR 
selects for a receptor conformation state that promotes the exchange of GDP for GTP 
on the G protein a-subunit and is presumed to allow the dissociation of the G protein 
Ga_and Gpy. subunits (151).
The triggering of chemokines induces signalling pathways that may result in the 
control of a variety o f biological functions including chemotaxis, proliferation, 
apoptosis and adhesion, to mention a few (12). These pathways are very complex and 
intertwined, and despite substantial advances in our understanding, they remain 
unclear. Many signalling pathways rely on the metabolism o f plasma membrane
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phosphoinositide lipids. The next section therefore describes phosphoinositide (PI) 
lipids and their role in signalling events.
1.9 Phosphoinositide Lipids
PI is the basic building block for the intracellular inositol-containing lipids, which 
consist of a D-myo-inositol-1-phosphate (InsIP) linked via its phosphate group to 
diacylglycerol (Figure 4). The inositol head of PI has five free hydroxyl groups, 
however only those at positions 3, 4, and 5 can be phosphorylated, in different 
combinations. PI and its phosphorylated derivatives are collectively referred to as 
phosphoinositides or PI lipids. There are eight documented PI lipids, namely PI, 
mono-phosphates: PI(3)P, PI(4)P and PI(5)P, di-phosphates: PI(3,4)P2, PI(3,5)P2 and 
PI(4,5)P2 and tri-phosphate: PI(3,4,5)P3 (Figure 5). PI lipids all reside in membranes 
and are substrates for kinases, phosphatases, and lipases resident in or recruited to 
these membranes. One such enzyme that plays a key role in signal transduction is 
phospholipase C (PLC).
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Figure 4. Chemical Structure of phosphoinositide (PI)
Phosphoinositide (PI) is the basic building block for the intracellular inositol-containing lipids, which 
consist o f  a D-m yo-inositol-1-phosphate (InsIP) linked via its phosphate group to diacylglycerol. The 
inositol head group o f  PI has five free hydroxyl groups, however only those at positions 3, 4, and 5 can 
be phosphorylated in different combinations (152).
1.10 Phospholipase C (PLC)
The PLC family is subdivided into PLCP, -y, -5 and -e and differ in their structural 
organization and regulation. All members have multiple cellular regulators, but only 
the PLCp enzymes are regulated by heterotrimeric G proteins. PLCp signalling 
pathway is an important component in a network of signalling cascades that regulate 
cell function. Stimulation o f PLCp activity results in the rapid hydrolysis of 
PI(4 ,5 )P2, with production o f inositol-1,4,5-trisphosphate (IP3) and diacylglycerol
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(DAG), intracellular mediators that increase intracellular calcium levels and activate 
protein kinase C (PKC) activity, respectively (153). Equally as important as PLC is 
the enzyme phosphoinositide 3-kinase (PI3K) which also catalyzes the formation of 
lipid second messengers.
Ptdlns(3,5)P
Ptdlns(3)P , R d |n s ---------------------   Ptdlns(5)P
Ptdlns(3,4)P2 Ptdlns(4)P Ptdlns(4,5)P
Ptdlns(3,4,5)P
Figure 5. Phosphoinositide Lipid Metabolism.
The main pathways o f  PI synthesis and interconversions in mammalian cells. The black boxes with red 
text represent the phosphatases involved in the negative regulation o f  lipid metabolism. The red boxes 
with black text represent the enzym es that catalyse the phosphorylation o f  lipid substrates. (1) indicates 
the involvement o f  Class I PI3K and (II) indicates the involvem ent o f  Class II PI3K. PLC in yellow  is 
an additional enzym e that cleaves PI(4,5)P2 to produce diacyl glycerol (D AG ) and In s(l,4 ,5 )P 3 (IP3), 
important in the mobilization o f  calcium ions (154).
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1.11 Phosphoinositide 3-kinase
Following activation by any number of extracellular stimuli (e.g. antigen, 
cytokines/chemokines, co-stimulatory molecules), PI3Ks catalyze the 
phosphorylation of PI lipids at the D3 position of the myo-inositol ring to produce 
phosphoinositide 3-phosphate (PI(3)P), phosphoinositide 3,4-bisphosphate 
(PI(3,4)P2), and phosphoinositide 3,4,5-triphosphate (PI(3,4,5)P3) (155) (Figure 5). 
These lipids selectively bind signalling molecules that contain specialised lipid 
binding motifs such as pleckstrin homology (PH), Phox homology (PX) and FYVE 
domains (Table 6). FYVE domains are generally specific for PI(3)P, whereas distinct 
PX domains, in the same way as PH domains, display distinctive specificities (156). 
Thus the production of PI(3,4)P2 and PI(3,4,5)P3 serve both to recruit signalling 
proteins to the plasma membrane and possibly induce (activating) conformational 
changes in proteins. The activity of these proteins can be regulated by the action of 
PI3Ks.
Classification of Phosphoinositide 3-kinase
The multiple isoforms of PI3Ks can be divided into three classes according to 
structure and substrate specificity. All PI3K catalytic subunits share a homologous 
region that consists of a catalytic core domain (HR1; homology region 1) linked to 
PIK domain (PI Kinase homology domain) and C2 domain (157) (Figure 6).
















Table 6. Selectivity of PH Domain Containing Proteins.
This table describes the PH, PX and FYVE domain containing proteins that preferentially bind to 
PI(3,4,5)P3, PI(3,4)P2 and PI(3)P (158,159).
Class I PI3Ks
The class I group of PI3K is further divided into two sub-groups; prototypical class 
1A and IB. Class IA PI3K consists o f a catalytic 1 lOkDa subunit, which exists in a 
complex with an 85kDa adaptor/regulatory subunit. The 85kDa subunit is responsible 
for protein-protein interactions via the Src homology (SH2) domain, with 
phosphotyrosine residues of other proteins. The class IB family consists of a distinct 
lipid kinase termed PI3Ky which is activated by G protein-coupled receptors but does
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not interact with the SH2-containing adaptors that bind class IA PI3Ks. Instead the 
only identified member o f this family, pllOy, associates with a unique p i 01 adaptor 
molecule (160). Class I PI3Ks are activated by a variety of extracellular stimuli, and 
have been implicated in a wide range o f cellular processes, including cell cycle 




SH3 Pr BH Pr SH2 Iruer-SH2 SH2
Pr SH2 Iiuer SH2 SH2
Pr SH2 Iiuer-SH2 SI 12
SH3 Pr BH Pr SH2 Inner-SPG SH2
Pr SH2 Iiuer-SH2 SH2
PIK Catalytic domain p llO a , P, 5
C2 | PIK | Catalytic domain pHOy
plO l
Class n | PIK [ 1| PX | C2 | C2 a , p, y
Class III C2 PIK Catalytic domain
VpslSp (plSO)
Figure 6 Structural Characteristics of the Class I, II and III PI3K Family 
Enzymes
The PIK domain is a helical domain that is found in lipid kinases but not protein kinases. C2 domains 
bind phospholipid in a calcium-dependent and -independent manner; those o f  PI3Ks do so in a 
calcium-independent fashion and may recruit PI3Ks to the membrane. The inter-SH2 domain o f  p 85a  
p 55a, p50a , p85(3 and p55y constitutively interacts with the N-terminal domain o f  p i 10 a , (3, y. Dual 
SH2 domains bind to tyrosine-phosphorylated adaptor proteins, leading to activation o f  the kinase 
activity o f  the p i 10 subunits. p lO l specifically interacts with the N-terminal domain o f  pllO y. PX 
domains are known to bind PI(3)P and may recruit the class II PI3K to the membrane. Functions o f  the 
Ras-binding domain (Ras-B), SH3 and Bcr domains and the proline-rich region (Pr) are not fully 
understood. Vps34p, the class III PI3K, forms a com plex with a serine/threonine kinase, V psl5p  (161).
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The importance of PI3K in the signalling pathways that regulate these responses has 
been established through the use of pharmacological inhibitors such as wortmanin 
and LY294002, over expression of dominant-negative forms of PI3K or mutation of 
required sites on transmembrane receptors.
Class II PI3Ks
The class II PI3Ks (PI3K-C2ot/|3/y) are approximately 170kDa, and their defining 
feature is a C2 domain at the carboxy terminus. Class II PI3Ks utilise predominantly 
PI and PI(4)P as substrates in vitro, but when PI lipid substrates are presented in 
combination with phosphatidylserine, they can also phosphorylate PI(4,5)P2 (160).
Class III PI3Ks
The class III PI3K is the homologue of the vesicular-protein Vps34p found in yeast 
and of the p i 50 in mammals. Class III PI3Ks can utilise only PI as a substrate and are 
likely to be responsible for the generation of most of the PI3P in cells (152,157).
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1.12 Protein Kinase B (PKB)
PKB is a serine/threonine kinase belonging to the ‘AGC’ superfamily of protein 
kinases (of which there are over 80 members). Interest in PKB has been highlighted 
by its role in promoting cell survival signals through the PI3K pathway, leading to 
inactivation of a series of pro-apoptotic proteins. In quiescent cells, PKB resides in 
the cytosol in a low-activity conformation. Upon activation of PI3K, 
PI(3,4,5)P3/PI(3,4)P2 are synthesised at the plasma membrane where PKB selectively 
interacts through its PH domain with these lipids (Figure 7) (162,163).
PKB is activated by, and dependent upon, multisite phosphorylation. Phosphorylation 
o f PKB on Thr causes a charge-induced change in conformation allowing substrate
O /jO
binding and greatly elevated rate of catalysis. The phosphorylation of Thr strictly 
governs the activation of PKB, and its mutation to non-phosphorylatable alanine
iao #
greatly reduces activity (164). There is convincing evidence that Thr is 
phosphorylated by the upstream activating kinase, 3-phosphoinositide-dependent 
kinase-1 (PDK1) (163,165). PDK1 phosphorylates PKB in vitro, and overexpression
A Q
of PDK1 in cells also leads to elevated Thr phosphorylation in the absence of 
natural agonists.
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Figure 7. Activation Cycle of PKB
A: PKB is cytosolic and inactive. PDK1 has low activity, and Thr'08 phosphorylation is not favourable. 
B: PI3K-generated PI(3,4,5)P3 and PI(3,4)P2 recruit PKB and PDK l to the plasma membrane. PKB 
undergoes hydrophobic m otif (H M ) phosphorylation by the Ser473 kinase or by autophosphorylation. 
C: The HM o f  PKB stabilizes and activates P D K l, which then phosphorylates PKB on Thr308. D: The 
HM o f  PKB associates with and stabilizes its kinase domain. The fully active kinase phosphorylates 
cytosolic and nuclear targets. HM, hydrophobic motif; PH, pleckstrin hom ology domain; KD, kinase 
domain. Red circles indicate phosphorylation events (166).
The second important regulatory domain o f PKB is the C-terminal hydrophobic motif 
and its target residue Ser473 (167). The hydrophobic motif provides a docking site for 
PDKl, which if interrupted severely attenuates phosphorylation of the activation loop 
(168,169). More recent biochemical and structural studies have elegantly 
demonstrated that the hydrophobic motif also serves as an allosteric regulator of 
catalytic activity (170,171). Ser473 phosphorylation always parallels the activation of
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PI3K and full activation of PKB however the mechanism by which this occurs is not 
completely understood. There is some evidence suggesting both PKB 
autophosphorylation (172) and phosphorylation by distinct serine kinases, including 
the integrin-linked kinase (ILK) (173).
Role of PKB in Cell Growth
PKB has been implicated in the maintenance o f cell growth following a study in 
which its over-expression resulted in an anti-apoptotic effect and subsequent delay of 
cell death (174,175). This is evident in breast cancer where the expression o f both 
PK Ba and y are up-regulated (176,177). To date, no satisfactory explanation has been 
provided as to how PKB delays cell death. Research has mainly focussed on finding 
direct links between PKB and the cell-death machinery.
Components of apoptotic machinery -  targets of PKB
The following paragraphs will summarise the studies that have discovered links 
between PKB and cell death.
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BAD (Bcl-2/Bcl-XL-antagonist, causing cell death)
BAD forms a heterodimer with the anti-apoptotic proteins Bcl-2 or B c1-X l preventing 
them from exerting their anti-apoptotic function. PKB is known to phosphorylate 
BAD which leads to the dissociation of the heterodimer and enables Bcl-2 or B c1-X l 
to block apoptosis (178).
Forkhead (FH) transcription factors
The link between PKB and forkhead (FH) transcription factors (FKHR, FKHRL1 and 
AFX) was first established in C. elegans, where the insulin 
receptor/PI3K/PDKl/PKB pathway was shown to suppress the action of the DAF16 
gene which encodes a transcription factor belonging to the FH family. 
Phosphorylation of FH transcription factors by PKB promotes their translocation 
from the nucleus into the cytoplasm where they interact with 14-3-3 proteins, 
effectively holding them from their target genes in the nucleus (179).
IkB Kinases (IKKs)
NF-kB is sequestered in the cytoplasm when bound to the cytosolic inhibitor IkB. 
PKB has been reported to associate with and activate IkB kinases (IKKs) which 
phosphorylate and induce the degradation of IkB. This permits the translocation of
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NF-kB to the nucleus where it activates the transcription of anti-apoptotic proteins 
such as inhibitor-of-apoptosis (IAP) proteins c-IAPl and C-IAP2 (180).
Possible link between PKB and Raf protein kinase
The mitogen-activated protein-kinase (MAPK) pathway regulates many physiological 
processes such as proliferation, differentiation and apoptosis (discussed in detail in 
1.16). This pathway is highly reliant on the translocation and activation o f Raf to the 
plasma membrane by its interaction with activated Ras. Recent studies indicate that 
PKB can inhibit Raf by phosphorylating it at Ser . This leads to the interaction o f 
Raf with 14-3-3 proteins resulting in an inhibition of the Raf-MAPK signal 
transduction pathway (181). However, in a significant number of cell lines, PI3K 
inhibitors which block PKB, either have no effect on agonist-induced Raf activation 
or in some cases actually inhibit the activation o f Raf, suggesting that PKB can 
contribute to Raf activation under certain circumstances (182,183).
1.13 PI3K dependent signalling
Numerous studies using PI3K inhibitors, overexpression of mutated forms of PI3K 
and, more recently, gene knockout experiments in mice, have implicated PI3Ks in the 
regulation of a diverse array of cellular responses, including cell survival,
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mitogenesis, membrane trafficking, glucose transport, membrane ruffling and 
superoxide production, as well as actin reorganization and chemotaxis (157). Elegant 
molecular and pharmacological evidence first suggested that PI3K and its lipid 
products might play an important role in platelet-derived growth factor (PDGF)- 
dependent actin polymerization and cell migration (184-187). Moreover, selective 
activation of PI3K using constitutively active PI3K mutants or the addition of 
exogenous PI(3,4,5)P3 can initiate cell motililty and membrane ruffling (188,189).
Chemokine-mediated Lipid Accumulation
The technique commonly used to assess the activation of PI3K, is to measure the 
accumulation o f its lipid products following receptor stimulation. The method relies
T9on metabolic labelling of intact cellular pools of ATP with [ P]-Orthophosphate, 
receptor stimulation, followed by lipid extraction (190,191) and separation o f the
T9[ P]-labelled-D3 PI lipids by high-performance liquid chromatography (HPLC) 
analysis (192). Utilising this method, CXCL12/SDF-1 and certain CXCL12/SDF-1 
peptide analogues have been shown to stimulate the transient accumulation of 
PI(3,4,5)P3 in leukaemic T-cell lines and peripheral blood-derived T lymphocytes. In 
both cell types, the elevation of PI(3,4,5)P3 was found to be rapid and transient, being 
detectable within 15 seconds post-stimulation and returning to basal levels within 
5 min after chemokine treatment. Other studies have investigated the effect of 
CCL2/MCP-1 stimulation on PI lipid accumulation in the monocytic cell line THP-1.
Chapter 1: Introduction 36
This model revealed that CCL2/MCP-1 was also able to elicit rapid and transient 
accumulation o f PI(3,4,5)P3. It appears therefore that at least two different 
chemokines which bind to distinct receptors are able to activate PI3K in different cell 
systems.
The very first evidence for the involvement of PI3K in chemokine-stimulated cell 
migration was the demonstration that chemotaxis and polarization of T cells induced 
by CCL5/RANTES could be inhibited by PI3K inhibitors such as wortmannin and 
LY294002 (193). Subsequent studies by several groups have shown that other CC 
chemokines (e.g. CCL20/MIP-3oc and CCL2/MCP-1) as well as CXC chemokines 
(e.g. CXCL1/IL-8 and CXCL12/SDF-1) stimulate wortmannin-sensitive chemotaxis 
of eosinophils, THP-1 cells, as well as neutrophils and T lymphocytes, respectively 
(194-197). Thus, it seems probable that the production and degradation o f 3-PI lipids 
is crucial in maintaining chemotactic signalling gradients.
The role of PI3K isoforms in chemokine-mediated PI(3,4,5)P3 
Accumulation
It is a common phenomenon that chemokine receptors are G-protein coupled, which 
implicates PI3Ky in mediating PI(3,4,5)P3 accumulation. CXCL12/SDF-1 and 
CCL2/MCP-1-mediated accumulation of PI(3,4,5)P3 were found to be abrogated 
following pre-treatment with the Gaj specific inhibitor, pertussis toxin (PTX)
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(198.199). In addition CXCL12/SDF-1 and CCL2/MCP-1 have also been shown to 
stimulate an increase in the in-vitro lipid kinase activity present in anti-PI3Ky 
immunoprecipitates derived from Jurkat and natural killer cells respectively
(195.200). Leukocytes derived from genetically engineered mice deficient in PI3Ky 
also fail to produce PI(3,4,5)P3 in response to CXCLl/GROa (201). However, this 
study did not investigate the effects o f CXCL12/SDF-1-mediated PI(3,4,5)P3 
accumulation in these knock-out mice. So it seems that PI3Ky plays an important role 
in chemokine-mediated accumulation of lipids, however it does not appear to be the 
only isoform to be activated by chemokines. The p85/p ll0  heterodimer has been 
shown to be activated by CXCL12/SDF-1 and CCL5/RANTES in T cells (193,195) 
and by CCL2/MCP-1 in THP-1 cells (197). In addition, class II PI3K has been 
implicated as a down-stream effector o f chemokine receptors, as demonstrated by the 
activation o f PI3K-C2a in response to CCL2/MCP-1 stimulated THP-1 cells (197).
1.14 Regulation of PI3K-dependent pathways
PI3K-mediated signalling, in addition to its positive regulation, is subject to potent 
negative regulation by two inositol lipid phosphatases responsible for the
degradation of PI(3,4,5)P3; namely the 5’ phosphatase SHIP (Src homology 2 
domain-containing inositol polyphosphate) and the 3’ phosphatase PTEN 
(Phosphatase and tensin homologue deleted on chromosome 10) (167,202,203).
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SHIP 1/2
SHIP1 is a haematopoietic-restricted enzyme that plays a crucial role in the negative 
regulation of immunocompetent cells (204). A study using leukaemic cells 
demonstrated that a mutation within the active site of SHIP1 resulted in an enhanced 
PKB phosphorylation, promotion of cell survival and resistance to apoptosis (205). 
SHIP2, whose expression is ubiquitous, has been implicated in the genetic 
susceptibility of type 2 diabetes (206-208).
PTEN
PTEN plays a pivotal role in the down-regulation of PDK-1 and PKB-dependent 
pathways. Mutations that abolish its catalytic activity therefore result in increased cell 
survival, growth and proliferation (209-211). Failure to initiate inhibitory feedback 
mechanisms results in profound immune defects ranging from hyper-proliferation (as 
seen in cancers), to debilitating autoimmunity (212).
Regulation of PI3K within a B Cell Model
The regulation of PI3K-dependent signalling in B cells is a well characterized model 
system, based on two important receptors that are expressed on B cells, namely the B 
cell receptor (BCR) and the low affinity receptor for the Fc portion of 
immunoglobulin G (IgG), FcyRIIb. The FcyRIIb receptor enables B cells to
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discriminate between free antigen, and immune complexes composed of antigen 
bound to IgG antibodies and thus dampen active humoral immune responses (213). 
Immune complexes co-ligate the BCR with the FcyRIIb receptor inducing src kinase, 
lyn-dependent phosphorylation o f the immunoreceptor tyrosine-based inhibitory 
motif (ITIM), located in the cytoplasmic domain o f FcyRIIB (213-215). Subsequent 
recruitment o f active SHIP to the membrane results in the enzymatic degradation of 
PIP3, preventing translocation o f PH domain containing proteins such as Btk (2 lb- 
22 l)(Figure 8).
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Figure 8. Model for the Negative Regulation of PI3K Signalling in B Cells
Activation o f  the BCR mediates a PI3K-dependent accumulation o f  PI(3,4,5)P3 (PIP3). This induces 
the translocation o f  PH domain containing proteins such as Btk to the membrane leading to the 
activation o f  calcium-dependent responses. Co-ligation o f  the BCR and FcyRIIb receptor, in short, 
leads to the recruitment o f  SHIP which de-phosphorylates PIP3 to PI(3,4)P2, thus attenuating the 
responses downstream o f  the BCR.
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Regulation of the MAP Kinase Pathway
FcyRIIB-mediated inhibition of the MAP kinase ERK1/2 may occur as a result of the 
catalytic or adaptor function of SHIP. Firstly, inhibition of ERK1/2 may be 
attributable to the SHIP-mediated reduction in PI(3,4,5)P3 accummulation, by 
inhibiting the recruitment of Btk to the membrane. Btk-dependent PLCy activation 
cleaves PI(4,5)P2 generating the second messengers IP3 and DAG, required for 
calcium mobilization and PKC activation respectively (222,223). The subsequent 
decrease in PKC activation contributes to the inhibition of ERK1/2 as found by 
Hashimoto et al. (1998) (224).
Secondly, the adaptor function of SHIP exposes binding sites for the SH2-domain 
containing She or the phosphotyrosine binding (PTB) domains of p62dok (Figure 9). 
Following a BCR induced signal, She forms a complex with Grb2 and Sos that leads 
to the activation of the Ras-mediated ERK1/2 MAPK pathway. However, an 
inhibitory response promotes the association of She with SHIP preventing the 
formation of this complex and thus inhibiting the phosphorylation of ERK1/2 (225). 
Alternatively the scaffolding effect of active SHIP, p62dok and RasGAP leads to the 
inhibition of Ras-mediated ERK1/2 by reducing Rasoip to RasoDP (226,227). 
Ultimately, SHIP affects proliferation, cell survival, protein synthesis and multiple 
other effector functions (228).












Figure 9. A Diagram High-lighting the Adaptor Function of SHIP in the 
Inhibitory Regulation of BCR-mediated ERK1/2 Phosphorylation
Stimulation o f  the BCR with antigen leads to activation o f  the ERK1/2/M APK pathway via assembly 
o f  the Shc/Grb2/Sos com plex (1). Two mechanisms involving the adaptor function o f  SHIP have been 
proposed to inhibit the ERK1/2/MAPK. pathway: SHIP competes with Grb2 for binding to She and 
blocks the formation o f  the Shc/Grb2/Sos com plex (1 A); or SHIP is recruited to the FcyRIIb receptor 
and binds the RasGAP docking protein p62dok, inhibiting the ERK1/2/M APK pathway through 
inactivation o f  Ras (IB ).
It is evident from the account above that SHIP is imperative in the inhibitory 
regulation o f BCR-mediated responses; however it is unclear as to whether SHIP may 
regulate responses on a more global basis. Given that signalling through CXCR4 is 
known to require PI(3,4,5)P3 in both T (229) and B cells (230), it is plausible that 
FcyRIIb-mediated recruitment o f SHIP may regulate chemokine-induced responses.
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1.15 Calcium
As described above, PI3Ks play an important role in the regulation o f many 
signalling pathways that are reliant on binding to D3-phosphorylated 
phosphoinositides. However, PI3Ks are not the only molecules that participate in the 
positive regulation of responses. Calcium acts as an intracellular second messenger, 
relaying information within cells to regulate their activity. The versatility of calcium 
is reflected in the diverse functions with which it is involved, including fertilization, 
cell development and differentiation, mediation of cell activity and death. The 
following section describes the role, function, regulation and release mechanisms of 
calcium from internal stores.
Calcium is a ubiquitous second messenger involved in the regulation of a variety of 
cellular processes, including gene transcription, proliferation and muscle contraction. 
The mechanisms that regulate the intracellular Ca concentration include channels 
located at the endoplasmic (ER) and sarcoplasmic reticulum (SR), as well as at the
o i
plasma membrane which regulate the supply of Ca from the stores and extracellular 
space respectively. Removal o f calcium is achieved by the combined action o f buffers
^  i
(calmodulin, calbindin and parvalbumin), pumps (Ca -ATPase) and exchangers 
(Na+/Ca2+ on mitochondria) (231).
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Calcium Release from Internal Stores
The two major intracellular stores of calcium are primarily found in the endoplasmic 
reticulum (ER), which specialize in the accumulation, storage and release of calcium 
(Figure 10). Channels which control the release of calcium from the stores include the 
IP3 (IP3R) and ryanodine receptors (232,233). IP3 known to activate the IP3R, is 
cleaved along with diacyl glycerol (DAG) from PI(4,5)P2 by the enzyme PLC (231). 
The isoform of PLC involved is dependent on the activation mechanism. For 
example, G-protein-coupled receptors are known to activate PLC (3, tyrosine-kinase- 
coupled receptors activate PLCy, a rise in calcium concentration activates PLC8 and 
stimulation through Ras activates PLCe (234). Pharmacological inhibitors such as the 
PLC inhibitor, U-73122 ( I C 5 0  between 1.0 - 2.1 jxM), its less effective analogue U- 
73343 and the IP3 inhibitor, 2APB can be used to determine whether the intracellular 
calcium release in response to receptor stimulation occurs in this way. The Ca 
activating ryanodine receptor, modulated by cyclic ADP ribose (cADPR) (235) is 
also activated by low concentrations o f ryanodine, however, at high concentrations, 
ryanodine has been shown to inhibit the release of calcium from the stores (236).





Figure 10. Calcium Release from Internal Stores
Various second messengers or modulators regulate the release o f  calcium from internal stores by the 
inosito l-1,4,5-trisphosphate receptor (In s(l,4 ,5 )P 3R) or the ryanodine receptor (RYR). These release 
channels are sensitive to factors that function from the cytosol and from within the lumen o f  the 
endoplasmic/sarcoplasmic reticulum (ER/SR). The ln s(l,4 ,5 )P 3R is regulated by inositol-1,4,5- 
trisphosphate (In s(l,4 ,5 )P 3, which is generated by various signalling pathways by PLCfk
1.16 MAP-kinase Pathway
One o f the most studied signalling pathways described so far is the MAPK pathways, 
which are known to control intricate programs, such as embryogenesis, 
differentiation, proliferation, homeostasis and cell death (237,238). The MAP- 
kinases are a family of serine/threonine kinases used by eukaryotic cells to transmit
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extracellular signals from the membrane to nuclear and other intracellular targets 
thereby regulating gene expression (239,240). In mammalian systems five 
distinguishable MAPK modules have been described so far (Figure 11). These 
include the extracellular signal-regulated kinase ERK1/2 (p42/44) (241) which 
preferentially regulate cell growth and differentiation, as well as the c-Jun NH2- 
terminal kinase (JNK p46/54) (242) and p38apy8 (243) which function mainly in 
stress responses like inflammation and apoptosis, and regulate a large variety of 
cellular processes such as cell growth, differentiation, development, cell cycle, death 
and survival (244). The pathways differ in their upstream activation sequence and in 
their downstream substrate specificity but are all organized in a three-kinase 
architecture consisting o f a MAPKK-kinase that phosphorylates and activates a 
MAPK-kinase, which in turn activates MAPK (Figure 11). The arrangement of this 
pathway promotes signal amplification.
Multiple messengers acting through GPCRs lead to the activation of MAPK cascades, 
including ERK1/2 (245). The role of G-protein subunits in the activation o f this 
pathway will now be discussed.
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Figure 11. Mammalian MAP-kinase Pathway
The MAP-kinase pathways differ in their upstream activation sequence and in their downstream  
substrate specificity but are all organized in a three-kinase architecture consisting o f  a MAPKK-kinase 
that phosphorylates and activates a M APK-kinase, which in turn activates MAP-kinase, that ultimately 
leads to activation o f  transcription factors.
The Link between GPCRs and MAPK Pathways
GPCRs are known to interact with heterotrimeric G proteins, that include a-, (3-, and 
y subunits. Receptor-mediated exchange of GTP on the a-subunit o f the heterotrimer 























MEK1/2 MKK3/IS MKK4/7 MKK5
Chapter 1: Introduction 47
Both of these components are active signalling molecules that modulate an array of 
downstream effectors. The Ga proteins are classified into four different families -  
Gas» Gaj, Gaq and Gai2*
The primary effect of the Gas family is to stimulate the intracellular messenger 
adenylyl cyclase (AC), which catalyzes the conversion of cytoplasmic ATP to cyclic 
AMP (cAMP). cAMP has been claimed to activate the small GTP-binding protein 
Rapl which links to the MAPK pathway through the activation of B-Raf (246). Gaj 
and Gaq-coupled receptors can stimulate the MAPK in either a PKC-dependent and 
Ras-independent manner or in a PKC-independent but Ras-dependent manner. 
Second messengers generated as a consequence o f Gai and Gaq stimulation can 
provoke Ras activation through RasGRF and RasGRP, two tissue-restricted guanine 
exchange factors (GEFs) for Ras and Ras-related GTPases (Figure 12).
Gpy subunits have been shown to induce ligand-independent tyrosine phosphorylation 
o f receptor tyrosine kinases (RTKs) such as EGFR (247,248) and PDGFR (249). 
This, known as ‘Transactivation’, is thought to occur either in a PI3Ky-dependent or 
independent manner (250) via the non-receptor-tyrosine-kinase (NRTK) Src (251), 
resulting in the formation of the Shc-Grb2-Sos complex. Other NRTKs, which 
include C-terminal Src kinase (Csk), Lyn, Bruton’s tyrosine kinase (Btk) and proline- 
rich tyrosine kinase 2 (PYK2), have also been proposed to mediate the activation of 
MAPK by Gaj- and Gaq-coupled receptors in a variety of cell types (246) (Figure 12).




















Figure 12. Multiple pathways link GPCRs to MAPKs
Biochemical routes initiated by fty-subunits can stimulate Ras by the activation o f  receptor and non­
receptor tyrosine kinases, which results in the recruitment o f  Sos to the membrane and the exchange o f  
GDP for GTP bound to Ras. Activated G a q can stimulate Rafl through protein kinase C (PKC) or by 
stimulating Ras by the Ca2"-dependent activation o f  RasGRF and tyrosine kinases acting on Sos. Gotj, 
G a0 and G a s can also use tissue-restricted pathways regulating Rap, which can stimulate B -R af and 
lead to the activation o f  MAPK. Activated MAPK translocates to the nucleus and phosphorylates 
nuclear proteins, including transcription factors, thereby regulating gene expression. Arrows represent 
positive stimulation and broken lines represent inhibition. Abbreviations: EPAC, exchange protein 
activated by cAMP; GAP, GTPase-activating protein; GRF, guanine-nucleotide releasing factor; MEK, 
MAPK kinase; PI3K, phosphoinositide 3-kinase; PKA, protein kinase A; PLC, phospholipase C; RTK, 
receptor tyrosine kinase (252).
1.17 CXCL12 mediated Signalling through CXCR4
CXCR4 is one of the best described members of the large family o f 7-transmembrane 
domain receptors coupled to heterotrimeric Gj proteins (253,254). The exclusive
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ligand for CXCR4, CXCL12/SDF-1; was first described as a powerful 
chemoattractant for peripheral blood lymphocytes (255), CD34+ progenitor cells 
(256) and pre and pro-B cell lines (257). CXCL12-mediated CXCR4 leads to the 
activation of a multitude of signalling molecules which result in the establishment o f 
diverse signalling pathways. Increased phosphorylation has been observed in the 
focal adhesion molecules, Pyk-2, pl30Cas, focal adhesion kinase (FAK), paxillin, 
Crk and Crk-L (258). In addition CXCL12 has been shown to induce the activation of 
ERK1/2, PLCy, PKC, PI3K, Janus kinase signal transducers, and NFkB (258). 
CXCL12 triggers the C-terminal-mediated internalization o f CXCR4, involving G 
protein-coupled receptor kinases (GRKs), followed by binding of p-arrestin 
(254,259). This process is not only essential for the desensitisation of membrane 
bound receptors but is also thought to activate several pathways and functions, such 
as chemotaxis (260) and ERK1/2 (261,262). There are however conflicting studies 
which indicate that chemotaxis (263) and ERK1/2 activation (264) are independent of 
GPCR endocytosis.
1.18 CCL1 mediated Signalling through CCR8
CCR8-dependent signal transduction pathways are ill defined; to date only activation 
o f the Ras/MAPK pathway is shown to mediate anti-apoptotic activity of CCL1 and 
vMIP-I (265). We set out to further define the pathways responsible for the 
phosphorylation of ERK1/2 and PKB, and determine possible routes in which CCL1
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mediates calcium mobilization and chemotaxis in either CCR8-transfected Rat 
Basophilic Leukaemia cells or in the T cell line HUT-78.
Signalling pathways are not only regulated by lipid phosphatases but also by the 
recycling of receptors. This process involves receptor internalisation, re-sensitization, 
recycling and degradation, all of which will be discussed in more detail below.
1.19 Receptor Desensitization
Ligand binding to GPCRs not only results in their activation but also in their 
desensitization. Desensitization is an adaptive response used by cells to arrest G 
protein signalling, therefore preventing the potentially harmful effects that can result 
from persistent receptor stimulation. The universal mechanism employed by all cells, 
involves the coordinated actions of two families of proteins, the G protein-coupled 
receptor kinases (GRKs) and the arrestins (266) (Figure 13). GRKs phosphorylate the 
serine and threonine residues of agonist-occupied GPCRs in their third intracellular 
loop and C-terminal domains. Since GRK phosphorylation alone has little effect on 
receptor-G-protein coupling in the absence of arrestins, the role o f GRK 
phosphorylation appears to increase the affinity of the receptor for arrestins (267). 
Based upon mutagenesis studies, the (3-arrestins are comprised of two major 
functional domains, an N-terminal domain responsible for recognition of activated 
GPCRs and a C-terminal domain responsible for secondary receptor recognition
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(268). p-arrestin binding sterically precludes coupling between the receptor and 
heterotrimeric G proteins, leading to termination of signalling by G proteins effectors
(269). Receptor-bound p-arrestins also act as adapter proteins, binding to components 
of the clathrin endocytic machinery including clathrin and p2-adaptin (AP-2). 
(270,271). Formation of the clathrin coated vesicle (CCV) is dependent on the 
cytoplasmic GTPase dynamin as discovered using dominant-negative mutants of 
dynamin which blocked the internalization o f EGF receptors (272). Once internalised 
the receptor complex is transported by the clathrin-coated vesicle to early endosomes, 
a diverse population of membrane compartments with tubular-vesicular morphology 
(273). The endosomes sort receptor-complexes and deliver them to either late 
endosomes for divergent recycling or lysosomes for degradation. In general, receptor 
endocytosis results in the rapid desensitisation of signalling activity. This can either 
be restored by receptor recycling which promotes the re-sensitisation of receptors, or 
prolonged following lysosomal degradation (274). The key factors, which dictate the 
outcome of the receptor, include the de-phosphorylation of residues on the 
cytoplasmic tail o f the receptor which promotes recycling (275) and ubiquitination. 
Ubiquitination is a process in which ubiquitin modifies lysine residues located in the 
carboxyl-terminal domain and promotes the trafficking of endocytosed receptors to 
the lysosomes (276).
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Regulation of Endosomes by Rab GTPases
Intracellular trafficking of membrane receptors is tightly regulated by a subfamily of 
Rab GTPases. The family of Rab GTPases consist of 60 members and are known to 
regulate vesicle formation, motility, docking and fusion within the endocytic and 
secretory pathways (277). Among them, Rab 5 is considered to transport and catalyze 
the fusion of endocytic vesicles with the early endosome. Rab 4 is localised in the 
early and recycling endosomes, where it ensures the recycling tubules return and fuse 
to the early endosome compartment in a Rab 5 dependent manner. Rab 11 however, 
is primarily found in association with the recycling endosomes and the trans-Golgi 
network (TGN) and regulates trafficking through these compartments (278). 
Similarly, Rab 7 and 9 occupy distinct domains within late endosomes (279).
Internalisation of CXCR4
CXCR4 has the capacity to interact with the endocytic adaptor P-arrestin (259). P- 
arrestin interacts with the C-terminus of CXCR4 and results in the attenuation of 
chemokine-mediated G protein activation.
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Figure 13. Receptor Mediated Endocytosis.
The mechanism o f  receptor cycling is a multi-step process regulated by adaptors such as P-arrestin and 
AP2. P-arrestins sterically prevent receptor interaction with heterotrimeric G proteins and directly link 
receptors to clathrin-coated pits. The clathrin coated pits are small areas o f  the plasma membrane that 
can invaginate inwards, and recruit ligand (chem okine) bound receptor com plexes for internalisation. 
Clathrin-coated vesicles (CCV) are formed and enter the cytoplasm where they become un-coated 
(clathrin removed) and fuse with specialised membrane organelles known as endosom es (Early 
Endosome EE, Late Endosome LE and Recycling Endosome RE). The endosom es are responsible for 
the sorting o f  receptors, which are either removed from the cell by lysosom es or recycled back to the 
plasma membrane. These compartments are under the tight control o f  Rab GTPases (Rab 5, 7 and 
11a).
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The role of Class I PI3K in GPCR internalisation
In addition to phosphorylating activated P adrenergic receptors (pARs) the GRK p 
adrenergic receptor kinase 1 (PARK1) recruits class I PI3Ks to the receptor complex. 
This leads to an increase in the production of D3 lipid molecules which regulate the 
recruitment o f the clathrin adaptor adaptin-2 (AP-2), and the receptor/p-arrestin 
complex, to clathrin coated pits (280). Tyrosine- and dileucine-based motifs represent 
two sorting signals contained within the cytoplasmic portion of several receptors and 
transmembrane glycoproteins. Such motifs mediate interactions with either the p2 
subunit of AP-2 to select proteins for inclusion into the vesicle and facilitate their 
transfer from one part o f the cell to another (281,282). Class I PI3Ks have also been 
shown to be required for the endocytosis of transferrin receptors which in this system 
occurs directly from the early endosome and independently of the recycling 
endosome (283).
Similarly, internalisation of the ATi angiotensin II (Ang II) GPCR has been shown to 
occur via multi-vesicular bodies, and recycle to the cell surface by a rapid PI3In­
dependent recycling route, in addition to a slower pathway that is less sensitive to 
PI3K inhibitors (284).
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Class II PI3K in the regulation of membrane trafficking
Class II PI3K enzymes include PI3K-C2a, PI3K-C2(3 and PI3K-C2y. Little is known 
about the role o f PI3K-C2|3 and C2y in receptor sequestration; however the 
localization and function of C 2a is becoming more apparent. PI3K-C2a has been 
demonstrated to be co-purified with a population of CCVs originating from rat brain 
homogenates. In addition, the PI3K activity within these CCV preparations was 
refractory to wortmanin treatment, consistent with the presence of PI3K-C2a. 
Immunofluorescence analysis revealed that the distribution of PI3K-C2a closely 
paralleled that of y-adaptin, a component of the AP-1 adaptor. While CCVs derived 
from the TGN and plasma membrane both contain clathrin as a major component, the 
two types can be distinguished by their adaptor protein (AP). Thus, AP-1 is present 
on vesicles derived from the Golgi apparatus while AP-2 is found on vesicles 
produced from the plasma membrane. More recently, PI3K-C2a has been shown to 
play an important role in the formation and un-coating of endocytic vesicles 
(285,286).
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1.20 Aims of the study
It is clear from the above overview that some chemokine receptors have received 
more attention than others, with the most well documented chemokine receptor 
system being CXCR4 (25). CXCL12, the ligand for CXCR4, is a highly efficacious 
lymphocyte chemoattractant known to induce a Gaj-dependent increase in 
intracellular free calcium and chemotaxis of CXCR4-expressing cells (255,260,287- 
290). PI3K has been shown to be required for CXCL12-mediated PKB 
phosphorylation and chemotaxis, but not for the activation of the MAPK pathway 
(258,291,292). In contrast, the signalling pathways and function of CCR8 remain 
ambiguous.
This thesis aims to assess CCR8 receptor signalling pathways. Specifically, the 
project will investigate 3 main areas as outlined below. The first considers:
• Activation of the MAPK and PKB pathways by CCL1
• Examination of calcium responses and functional chemotaxis assays mediated 
by CCL1.
• Use o f pharmacological inhibitors to identify some of the proteins that are 
involved within the signalling pathways o f interest.
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Regulation of signalling pathways is a fundamental process that maintains 
homeostasis, thus failure to initiate inhibitory mechanisms results in profound 
immune defects ranging from hyper-proliferation as seen in cancers, to debilitating 
autoimmunity (212). Two ways in which cells regulate responses are by receptor 
recycling and the function of lipid phosphatases. This thesis examines both processes 
in the CXCR4/CXCL12 receptor system. Regulation of PI3K-dependent signalling in 
B cells is a well characterised model system used to determine the role of the lipid 
phosphatase SHIP in inhibitory regulation. FcyRIIb-induced recruitment of SHIP has 
been implicated in the regulation o f BCR-mediated responses in B cells (213-215) 
however the role o f SHIP in regulating independently activated receptors, such as 
chemokine receptors is unknown. The second area therefore aims to:
•  Investigate the tyrosine phosphorylation of SHIP following stimulation o f the 
either the BCR, FcyRIIb or CXCR4 receptor.
• Verify the effect of SHIP on BCR-mediated responses.
• Investigate the effect of co-ligation of the BCR and FcyRIIb on CXCL12- 
mediated responses.
• Utilise a membrane-localised constitutively active SHIP mutant expressed in 
the Jurkat T cell line (293) using a tetracycline (Tet)-regulated expression 
system, to verify that SHIP can contribute to the regulation of chemokine- 
induced PIP3 accumulation, phosphorylation o f PKB/ERK1/2 and chemotaxis.
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The second regulatory process, known as chemokine receptor recycling is an 
important process governing receptor desensitisation and resensitisation. This 
mechanism not only functions to recycle receptors for further stimulation but also 
enables cells to downregulate receptor expression in diverting them to the lysosomes 
for degradation. The receptors are channelled through endosomes which are regulated 
by enzymes, namely Rab GTPases and PI3Ks. The roles of certain enzymes have 
been investigated however the P isoform of class II PI3K and the enzyme which 
regulates the recycling endosome, Rab 11, have not been examined in the 
CXCR4/CXCL12 receptor system. The objectives of this final part o f the study are 
to:
• Generate an EGFP-CXCR4 construct, to transfect into HEK-293 cells
• Use a GST-AP2P fusion protein to determine whether PI3K-C2P associates 
with AP2P.
• Investigate the co-localisation of PI3K-C2P with the adaptor AP2P
• Study the co-localisation of PI3K-C2p with enzymes known to be involved in 
receptor recycling, namely Rab 11a.
• Perform gradient chemotaxis experiments of CXCL12, in order to determine 
whether PI3K-C2p is involved at the leading edge using the technique of 
semi-confocal microscopy.
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The Hypotheses:
1. CCL1 can induce cell migration and phosphorylation of ERK and PKB.
2. SHIP can modulate CXCR4-mediated responses in B and T cells.
3. CXCR4 is internalised in response to CXCL12 and co-localises with AP2 and 
PI3K-C2P.
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Chapter 2: Materials
2.1 Antibodies and Plasmids
Antibody Species Mono/Polyclonal Source
F(ab’)2 anti-mouse 
IgG
Goat Polyclonal Zymed Laboratories, San 
Francisco, USA
Anti-mouse IgG Rabbit Polyclonal Zymed Laboratories, San 
Francisco, USA
Anti-p85a Mouse Monoclonal Doreen Cantrell, School of 
Life Sciences, Dundee
Anti-pi 108 Rabbit Polyclonal Bart Vanhaesebroeck, 
Ludwig Institute, London
Anti-pllOy (clone H- 
199)
Goat Polyclonal Santa Cruz, California, USA
Anti-SHIP Goat Polyclonal Santa Cruz, California, USA
Anti-hCD3 UCHT1 Mouse Monoclonal Doreen Cantrell, School of 
Life Sciences, Dundee
Anti-mCD3 2C11 Mouse Monoclonal Daniel Olive, INSERM, 
Marseille
Anti-phospho ERK1/2 Rabbit Polyclonal NEB, New England, USA
Anti-ERKl/2 Rabbit Polyclonal NEB, New England, USA
Anti-phospho PKB308 Rabbit Polyclonal NEB, New England, USA
Anti-phospho PKB4'4 Rabbit Polyclonal NEB, New England, USA
Anti-PKB Goat Polyclonal NEB, New England, USA
Anti-phosphotyrosine
(4G10)
Mouse Polyclonal Upstate Biotechnology, NY, 
USA
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Anti-Mouse HRP Rabbit Polyclonal DAKO, Cambridgeshire, UK
Anti-Goat HRP Sheep Polyclonal DAKO, Cambridgeshire, UK
Anti-Rabbit HRP Sheep Polyclonal DAKO, Cambridgeshire, UK
Anti-PI3K-C2p Mouse Monoclonal BD Biosciences, San Jose, 
USA
Anti-AP2 Mouse Monoclonal
Kind Gift from Prof. A. 
Richmond, Vanderbilt 
University, Tennessee, USA
Cyanine 3 Fluorophore 
(596 nm) (Red Dye)
Mouse Monoclonal
Cyanine 5 Fluorophore 







ChemoTx disposable chemotaxis 
chambers
Neuro Probe Inc, Gaithersburg, MD
Conical Centrifuge 15 ml Tubes BD Biosciences, San Jose, USA
Conical Centrifuge 50 ml Tubes BD Biosciences, San Jose, USA
Cryovials Fisher Scientific, Loughborough, UK
Disposable 30 ml Pipettes NUNC, UK
Disposable 10 ml Pipettes NUNC, UK
Eppendorf Centrifuge 1.5 ml Tubes NUNC, UK
Filter Paper (3 MM) Whatman, Maidstone, UK
Flasks 25 cm2 Tissue Culture NUNC, UK
Flasks 80 cm Tissue Culture NUNC, UK
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Flasks 175 cm2 Tissue Culture NUNC, UK
Gel Loading 100 |il Tips Fisher Scientific, Loughborough, UK
Gilson Tips 10, 100, 1000 jil Gilson, USA
Glass Cover Slips Fisher Scientific, Loughborough, UK
Haemocytometer Fisher Scientific, Loughborough, UK
MACS LS Column Miltenyl Biotec, UK
Needles ‘Butterfly’ Terumo, Belgium
Nitrocellulose Blotting Membrane Fisher Scientific, Loughborough, UK
Parafilm Fisher Scientific, Loughborough, UK
Pastettes 3 ml plastic Alpha Lab, Hampshire, UK
PCTE-framed 5 jim-pore PVPF filters 
with adhesive
Porvair Sciences Ltd. UK
Petri Dishes for Tissue Culture NUNC, UK
Plastic 60 ml Pots with Lids Sterilin, UK
Polyproylene FACS tubes BD Biosciences, San Jose, USA




Screw-lid Centrifuge 1.5 ml Tubes Starsted, Germany
Syringes 5, 20, 60 ml Terumo, Belgium
Syringe Filters for Filter Sterilisation 
0.2 jim-pore
Terumo, Belgium
Thin wall 0.2 ml PCR Tubes with lids Promega, WI, USA
Tissue Culture 6-well plates NUNC, UK
Tissue Culture 24-well plates NUNC, UK
Tissue Culture 96-well plates NUNC, UK
White Opaque 96-well plates NUNC, UK
X-omat Film Kodak, Harrow, UK
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2.3 Reagents
Acetone Fisher Chemicals, Loughborough, 
UK
Acrylamide Biorad, California, USA
Agarose (Molecular Biology Grade) Sigma, Poole, UK
Ammonium Phosphate (NPL^PC^ Sigma, Poole, UK
Ampicillin Sigma, Poole, UK
APS Sigma, Poole, UK
ATP (lOOmM aq. Stock (-20°C), dissolved 
in lOOmM Tris pH 7.4
Sigma, Poole, UK
Bovine Serum Albumin (Tissue Culture Grade) Sigma, Poole, UK
Bovine Foetal Calf Serum (Heat Inactivated) Life Technologies, Paisley, 
Scotland
Bromophenol Blue BDH, Poole, UK
Black 96-Well Plates Coming Costar, High Wycombe, 
UK
Butanol BDH, Poole, UK
Calcein-AM Molecular Probes, Eugene, OR, 
USA
Calcium Chloride Sigma, Poole, UK
Coomassie Blue Sigma, Poole, UK
Chloroform BDH, Poole, UK
Cell Titer 96 AQue0us One Solution Reagent Promega, WI, USA
Deoxynucleoside Triphosphates: dATP, 
dCTP, dGTP and dTTP
Boehringer Mannheim, Germany
Dissociation Buffer Life Technologies, Paisley, 
Scotland
Digitonin BDH, Poole, UK
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DMSO Sigma, Poole, UK
DNA 1 kB Ladder NEB, New England, USA
EDTA Sigma, Poole, UK
EGTA Sigma, Poole, UK
ECL Amersham, Oxfordshire, UK
Ethanol 99.1% BDH, Poole, UK
Ethidium Bromide Sigma, Poole, UK
Ethyl Formate Fisher Chemicals, Loughborough, 
UK
Flo-Scint IV Scintillation Liquid Canberra Packard, UK
Folsch Lipids from Bovine Brain Sigma, Poole, UK
Fluo-4 Molecular Probes, Eugene, OR, 
USA
Fura-2 AM acetoxymethyl ester Sigma, Poole, UK
Geneticin (G418) Life Technologies, Paisley, 
Scotland
Glacial Acetic Acid BDH, Poole, UK
Glucose Fisher Scientific, Loughborough, 
UK
Glutathione Sepharose Beads Sigma, Poole, UK
Glutaraldehyde Sigma, Poole, UK
Glycerol Fisher Scientific, Loughborough, 
UK
Glycine Sigma, Poole, UK
HEPES 1 M Buffer Solution Sterile Life Technologies, Paisley, 
Scotland
HBSS (without calcium and magnesium) Life Technologies, Paisley, 
Scotland
HC1 BDH, Poole, UK
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HPLC Column (Sax Partisphere) Whatmann, UK
Hygromycin B Calbiochem, Nottingham, UK
Interleukin-2 (IL-2) Chemicon, Hampshire, UK
1-309 (CCL1) Chemokine (Recombinant 
Human)
R&D Systems, Minneapolis, USA
Ionomycin Calbiochem
IPTG Sigma, Poole, UK
Kanamycin Sigma, Poole, UK
Lauryl Sulphate (SDS) Sigma, Poole, UK
Leupeptin Sigma, Poole, UK
LiCl2 Sigma, Poole, UK
LB Agar Sigma, Poole, UK
LB Broth (Miller) Sigma, Poole, UK
LipofectAMIE Plus Reagent Invitrogen, Paisley, Scotland
Magnesium Chloride BDH, Poole, UK
Marvel Supermarket, UK
Mercaptoethanol Sigma, Poole, UK
Methanol BDH, Poole, UK
Methylamine (25-30% in dH20 ) Fisher Chemicals, Loughborough, 
UK
Molecular Weight Markers Life Technologies, Paisley, 
Scotland
N-Butanol Fisher Chemicals, Loughborough, 
UK
NaF Sigma, Poole, UK
NP-40 1% Fisher Chemicals, Loughborough, 
UK
NaCl Sigma, Poole, UK
Orthophosphoric Acid [J2P] 5mCi/ml NEN, Stevenage, UK
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Paraformaldehyde Sigma, Poole, UK
Phosphate Buffered Saline Sigma, Poole, UK
Penicillin/Streptomycin Life Technologies, Paisley, 
Scotland
Pepstatin Sigma, Poole, UK
Petroleum Ether (bp 40-60 °C) BDH, Poole, UK
Phenyl Methyl Sulfonyl Flouride Sigma, Poole, UK
Phosphoric Acid Fisher Chemicals, Loughborough, 
UK
Pluronic Acid Molecular Probes, Eugene, OR, 
USA
Phorbol 13-Myristate 12-Acetate Calbiochem, Nottingham, UK
Poly-L-Lysine Sigma, Poole, UK
Ponceau S Sigma, Poole, UK
Potassium Acetate Sigma, Poole, UK
Probenecid Sigma, Poole, UK
Propan-2-ol BDH, Poole, UK
Propan-l-ol BDH, Poole, UK
Protein A Sepharose Amersham, Oxfordshire, UK
Protein G Sepharose Amersham, Oxfordshire, UK
Pd(N)6 random nucleotide hexamers Boehringer Mannheim, Germany
Potassium Oxalate Sigma, Poole, UK
Restriction Enzymes (BamHI, Xho-I, Hindlll) Promega, UK
Staphylococcal Enterotoxin B (SEB) Sigma, Poole, UK
SDF-1 (CXCL12) (Recombinant human) R&D Systems, Minneapolis, USA
Sodium Hydroxide BDH, Poole, UK
Sodium Orthovanadate Sigma, Poole, UK
Sodium Azide Sigma, Poole, UK
Tetrabutyl Ammonium Hydrogen Sulphate Sigma, Poole, UK
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(TBAS)
TEMED Sigma, Poole, UK
Tetracycline Sigma, Poole, UK
Tris, Hcl Sigma, Poole, UK
Trypan Blue Sigma, Poole, UK
Trypsin, EDTA Life Technologies, Paisley, 
Scotland
Tween 20 Sigma, Poole, UK
Versene Life Technologies, Paisley, 
Scotland
2.4 Cells, Bacteria and Media
BALB/c mouse B lymphoma line, 
A20
Kind Gift from Dr. D. Cantrell, School of Life 
Sciences, Dundee
DH5-a Bacteria Kind Gift from Prof. A. Richmond, Vanderbilt 
University, Tennessee, USA
HUT-78 Cells Kind Gift from Prof. J. Westwick, Novartis 
Pharmaceuticals, Horsham, UK
HEK-293 Kind Gift from Prof. A. Richmond, Vanderbilt 
University, Tennessee, USA
Jurkat Cells Kind Gift from Dr. Andres Alcover, Paris, 
France
Nut Mix F12 (HANS) Glutamax Life Technologies, Paisley, Scotland
Rat Basophilic Leukaemia CCR8 
Stable Transfectants
Kind Gift from Prof. J. Westwick, Novartis 
Pharmaceuticals, Horsham, UK
RPMI 1640 Culture Medium Life Technologies, Paisley, Scotland
SHIP clones Dr. S. Ward, University of Bath, UK
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2.5 Kit Assays and Inhibitors
Fluorokine, Human I-309/CCL1 Biotin Conjugate R&D Systems, Minneapolis, USA
Gel Extraction Kit Qiagen Ltd, Crawley, UK
QIAquick (Purification of DNA) Qiagen Ltd, Crawley, UK
Mini Prep Kit Qiagen Ltd, Crawley, UK
Maxi Prep Kit Qiagen Ltd, Crawley, UK
LY294002 Calbiochem, Nottingham, UK
RO320432 Calbiochem, Nottingham, UK
PD98059 Calbiochem, Nottingham, UK
U73443 Calbiochem, Nottingham, UK
U73122 Calbiochem, Nottingham, UK
2APB Calbiochem, Nottingham, UK
Pertussis Toxin Sigma, Poole, UK
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Chapter 3: TECHNIQUES
3.1 Freezing Down of Cells
Freezing down of cells for long term use is necessary to minimize genetic change and 
avoid the aging and transformation of cell lines. Firstly, cells were grown to an 
optimum density, washed and counted. Their viability was checked using trypan blue, 
a negatively charged chromophore whose activity is dependent on damaged
n
membranes. Cells at a concentration of 1x10 /ml were subsequently re-suspended in 
freezing medium (10% dimethyl sulfoxide, 90% foetal bovine serum (FBS)) and 
aliquoted into cryovials. To avoid artifacts the cells were frozen slowly (1°C per 
minute) in a ‘MR Frosty’ cooler at -80°C. 12 hours later the cryovials were 
transferred into canes for storage in liquid nitrogen cylinders (294).
3.2 Thawing of Cells
Cells were recovered from liquid nitrogen, thawed immediately in a 37°C water bath 
and diluted into pre-warmed media. Following gentle mixing, cells were centrifuged, 
re-suspended in 10 ml of complete medium (20% FBS and 100 U/ml Penicillin and 
100 Jig/ml Streptomycin) and transferred into a 20 cm flask for overnight culture.
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Cells were subjected to visual assessment over subsequent days, then once confluent 
and recovered, they were transferred into larger tissue culture flasks.
3.3 Cell Culture
This section outlines the methods used to maintain the different types of cells used 
within this study. All cells were cultured in humidified incubators at 37°C, 5% (v/v) 
C 0 2.
Suspension Cells
The human leukaemic T cell line, HUT-78 (295) were maintained in RPMI-1640, 
supplemented with 10% heat inactivated FBS, 100 U/ml Penicillin and 100 |Lig/ml 
Streptomycin. Cells were grown in suspension in 175 cm2 tissue culture flasks. Cells 
were passaged 3 times per week, by splitting each flask 1:5 into the original volume 
of pre-warmed full growth medium.
Tet-Off Jurkat cells express a membrane-localised constitutively active SHIP mutant 
and incorporate a tetracycline (Tet)-regulated expression system (293). These clones 
were maintained in RPMI supplemented with 10% (v/v) heat-inactivated FBS, 100 
U/ml Penicillin and 100 pg/ml Streptomycin, 2 ng/ml of tetracycline, geneticin (500 
jLig/ml), and hygromycin B (300 fig/ml). Cells set-up in preparation for experiments 
were washed three times in RPMI and seeded at lx l0 5/ml overnight in complete
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media with or without tetracycline (2 ng/ml). Removal of tetracycline from the cell 
culture for 48 hours induces the expression of the SHIP mutant.
Semi Adherent Cells
The BALB/c mouse B lymphoma line, A20 (296) were maintained in RPMI 1640, 
supplemented with 10% FBS, 100 U/ml Penicillin and 100 pg/ml Streptomycin and 
50 jliM (3-mercaptoethanol. These cells grew in a semi-adherent manner and adherent 
cells were harvested before passaging by moderate agitation of the culture flask. The 
resultant suspension was split 1:3, three times a week.
Adherent Cells
Rat basophilic leukaemia (RBL) (297) CCR8 stable transfectants were maintained in 
Nut Mix F I2 (HANS) Glutamax supplemented with 10% FBS, 100 U/ml Penicillin 
and 100 Jig/ml Streptomycin and 250 pg/ml o f geneticin. Confluent cells were 
removed of media, washed with PBS, overlaid with dissociation buffer and left to 
incubate at 37°C for approximately 5 minutes. The cells were subsequently dislodged 
by moderate agitation and dissociation buffer neutralized with complete media. Cells 
were split 1:3 twice a week.
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Human embryonic kidney cells (HEK293) were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% FBS and 100 U/ml Penicillin and 
100 pg/ml Streptomycin. HEK293 cells were transfected with the plasmid encoding 
CXCR4 using lipofectAMINE Plus reagent (described in full later in this section). 
Cells were harvested by moderate agitation, the resultant suspension was split 1:3, 
three times a week.
3.4 Transient Transfection of HEK293 cells
Cells at a concentration of 5 x 105/ml were plated into Petri dishes containing 6 
cover-slips and left overnight to adhere. The medium was replaced the following day 
with 5 ml of serum-free medium and returned to the incubator until required. 
Meanwhile, 750 pi of medium was combined with 30 pi of lipofectamine in a 15 ml 
tube. In a separate 15 ml tube 30 pi of Plus reagent and 5 pg of DNA plasmid were 
added to an additional 750 pi of medium. Plus reagent is used in conjunction with 
lipofectamine to enhance transfection in adherent cell lines. Volumes were multiplied 
up according to the number of plates to be transfected. Tubes were then left to 
incubate at room temperature (RT) for 15 minutes, mixed together and then left for a 
further 15 minutes. 1.5 ml o f this mix was then added to the cells already containing 5 
ml of medium and left in a humidified incubator at 37°C, 5% (v/v) CO2 for 3 h. 
Following the 3 h incubation the medium was replaced with complete medium and 
returned to the incubator. The cells were used 48 h post-transfection.
Chapter 3: Techniques 73
3.5 Detection of CCR8 using the Fluorokine System
Cells to be stained were pretreated with purified human IgG (10 pi o f 1 mg/ml/106 
cells) for 15 minutes at room temperature in order to block Fc-mediated interactions. 
In a separate tube, 20 jllI of anti-human CCL1 antibody was mixed with 10 (Lil of 
biotinylated CCL1/I-309 and allowed to incubate for 15 minutes at room temperature. 
In a volume of no more than 25 pi, 1x10s Fc-blocked cells were subsequently added 
to this mixture. A negative staining control was also set up, consisting of 10 jlxI of 
negative control reagent (protein biotinylated to the same degree as CCL1) mixed 
with an identical sample of cells. All samples were left to incubate for 60 minutes at 
4°C. 10 pi of avidin-FITC reagent was then added to each tube and incubated for a 
further 30 minutes at 4°C in the dark. Finally the cells were washed twice with 2 ml 
of IX cell wash buffer (buffered saline-protein solution) to remove un-reacted avidin- 
fluorescein and resuspended in 200 pi of IX wash buffer for cytometric analysis.
3.6 Cell Stimulations
Cells were harvested according to the cell culture protocol. All cell lines were 
pelleted by centrifugation at 1840 x g at room temperature. Cell pellets were pooled 
and subsequently washed 3 times in serum-free media. Finally cells were assessed for 
viability, counted with a haemocytometer and resuspended in the appropriate volume
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of 0.1% BSA serum-free medium. The suspension of cells were then aliquoted in 0.5 
ml volumes into 1.5 ml eppendorf tubes and left to equilibrate for 30 minutes in a 
37°C water bath prior to stimulation.
Cells were stimulated with agonist at the required concentration for the specified 
time. Reactions were terminated by pelleting at 4,500 x g for 10 seconds, removing 
supernatant and adding 500 |il o f ice-cold lysis buffer (appendix 1). Samples were 
subsequently vortexed and rotated at 4°C for 20 minutes. Finally, cell debris was 
removed by spinning in a cold microfuge, at 15,000 x g for 10 minutes, and 
supernatants transferred to clean eppendorf tubes.
Whole Cell Lysates
Sample buffer was added to the supernatants following the removal of cell debris. 
Whole cell lysates were subsequently boiled for 5 mins on a hot block prior to 
running on SDS-PAGE.
Immunoprecipitation from Cell Lysates
Cell lysates were pre-absorbed with 20 j l l I  of a 50:50 protein-A/G sepharose slurry for 
30 minutes on a rotator at 4°C. Samples were then spun at 15,000 x g to pellet the 
sepharose beads and supernatants transferred to clean eppendorf tubes. Lysates were
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then incubated with 2-5 jug of antibody and rotated for 2-4 h at 4°C. Then, 20 jil o f a 
50:50 pre-washed proteinA/G sepharose slurry was added to the lysates and incubated 
for a further 1-2 h on the rotator. For immunoblotting, beads were then washed three 
times in ice-cold lysis buffer and resuspended in 10-20 jil o f sample buffer and boiled 
for 5 minutes.
3.7 Western Blotting 
SDS-PAGE
Immunoblot analysis requires the separation of isolated cellular proteins according to 
size by SDS polyacrylamide gel electrophoresis. The apparatus used was the Bio-Rad 
mini-protean-III gel equipment, which was assembled according to the 
manufacturer’s guidelines. The resolving gel was prepared at the desired percentage 
(appendix 1), poured between the two glass plates and overlaid with water. Once 
polymerisation had occurred the water was aspirated and the stacking gel was poured 
(appendix 1). A 15-well comb was inserted to create the wells for the loading of the 
protein samples. Once set, the comb was removed and the gel was placed into a gel 
tank containing IX SDS-PAGE running buffer (appendix 1). The protein samples 
were run through the stacking gel at 80 V and the resolving gel at 170 V until the 
bromophenol blue dye front had reached the bottom of the gel. The gel was 
subsequently removed from the apparatus and soaked in semi-dry transfer buffer
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(appendix 1). The separated proteins were transferred from the gel and immobilised 
onto nitrocellulose by semi-dry transfer using Pharmacia-Biotech Multiphor II 
electro-blotting equipment. Upon the bottom (positive) of the two graphite electrodes 
a stack was made consisting of 4 pieces of gel-sized 3MM Whatman paper, a piece of 
nitrocellulose membrane, the gel and another 4 pieces of 3MM Whatman paper (all 
soaked in the transfer buffer). Any air bubbles were expelled before the upper 
(negative) electrode, dampened with semi-dry transfer buffer, was gently lowered 
into place. The gel was transferred for 60 min at a constant 0.8 mA per cm of 
membrane.
Immunostaining
Following transfer, blots were rinsed in TBS washing buffer (appendix 1) and then 
blocked overnight in 1% BSA TBS + 0.1% azide. Primary antibodies were diluted 1 
in 1000 in TBS + 0.1% azide. Primary antibodies were applied for 3-4 h at room 
temperature or overnight at 4°C depending on the antibody used. Blots were 
subsequently washed 4 times with TBST (appendix 1) for 10 minutes each wash. 
Antibody bound proteins were detected using a secondary antibody bound to 
horseradish peroxidase (HRP), which was relevant to the species in which the 
primary antibody had been raised. Secondary antibodies were diluted between 1 in 
10,000 and 1 in 20,000 in 0.5% powdered milk (marvel) TBST depending on the 
antibody and applied for a minimum of 1 h. Membranes were then washed twice in
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TBST and twice in TBS (10 mins per wash) and incubated for 1 minute in enhanced 
chemiluminescence (ECL) reagent. Reactive protein bands were visualised by 
exposure of the membrane to Kodak X-AR5 film, followed by developing with the 
RGII Fuji X-ray film developer.
3.8 Stripping of Membranes
Membranes were submerged in stripping buffer (appendix 1) and incubated in a 60°C 
water bath for 30 minutes. Following rigorous washing with TBST, membranes were 
blocked overnight in 1% BSA TBST. Immunostaining was then carried out as 
previously described.
3.9 Calcium Mobilization
The following section describes the methods used to investigate the calcium 
mobilisation of adherent and suspension cells. Using either of the calcium-sensitive
I
fluorochromes Fura-2 or Fluo-4 AM, intracellular [Ca ] can be readily measured. 
Both Fura-2 and Fluo-4 are coupled to the acetoxymethyester (AM) which permits 
entry into cells. Following entry, AM is cleaved by endogenous esterases, preventing 
the escape o f the fluorochrome from the cells. On binding to calcium ions, the 
fluorescence excitation maximum of the fluorochrome transfers to a lower
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wavelength without any alteration in the emission spectrum, thereby enabling Fura-2 
and Fluo-4 to be used as a dual excitation indicator.
Fura-2 (AM) is ratiometric and ultra-violet (UV) light excitable, with an excitation 
ratio of 380/340 nm (free-calcium/bound-calcium). Ratioing considerably reduces the 
effects of uneven dye loading, leakage of dye and photobleaching. Fluo-4 (AM) has 
an excitation wavelength o f 488 nm by argon-ion laser sources, ideal for confocal 
laser-scanning microscopy.
Adherent cells -  FLIPR 96
RBL-CCR8 cells at 3x l05/ml in growth medium were plated in clear, flat-bottom 
black-walled 96-well plates. The flat bottom ensures that the cellular fluorescence is 
localised to a single horizontal plane, while the black-walls prevent well-to-well 
crosstalk. Plates were incubated at 37°C / 5% CO2 for 24 h to allow the cells to 
recover. Cells were subsequently washed with Assay Buffer (HBSS/ 20 mM HEPES 
(without Phenol Red indicator) + 0.1% BSA w/v), resuspended in 100 pi of Loading 
Buffer (22 ml of Assay Buffer supplemented with Fluo-4, probenecid (2.5 mM final) 
and Brilliant Black (100 pM final)) and left to incubate for 30 minutes at 37°C / 5% 
CO2. The anion exchange protein inhibitor, probenecid, was used to prevent the 
extrusion of Fluo-4 from the cells by organic ion transporters. Washing of the cells 
following incubation with Fluo-4 was not necessary due to the presence of brilliant 
black in the assay buffer. The PLC inhibitor (U73122) was added along with the
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Fluo-4 whilst the PTX was added 4 h prior to the start o f the experiment. 
Chemokines were aliquoted in a separate 96-well plate at 3X the required 
concentration to compensate for the dilution factor experienced on addition to the cell 
plate. The extent o f calcium mobilisation was determined using a 96-well fluorescent 
imaging plate reader (FLIPR-96).
Raw data from the FLIPR was analysed using FLIPR software to produce the 
minimum and maximum fluorescence for each well (Figure 14). The data was then 
normalised for cell number using the following formulae:
Normalised fluorescence = Fluorescence maximum -  Fluorescence minimum
Fluorescence minimum
W e l l  O  1
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Figure 14. Determination of Minimum and Maximum Fluorescence
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Suspension Cells -  Flow cytometric analysis
The fluorimeter was first calibrated by monitoring the fluorescent changes in cell 
suspensions following the addition o f 0.16 Jig/ml digitonin (to lyse cell membranes 
and expel intracellular calcium). Fluorescence was monitored using a dual 
excitation/dual emission spectrofluorimeter (Photon Technologies) for 30 seconds 
followed by the addition of 40 mM sodium hydroxide (NaOH) and 4 mM EGTA.
Conversion of the fluorescence ratios at two wavelengths into intracellular calcium
concentration was achieved using the equation developed by Grynkiewicz et al (298).
[Ca2+]i= K d  R -R m in S n  
Rmax “ R  Sb2
Where,
• Kd = effective dissociation constant for Fura-2 (2.24 x 10'7 M)
y  I y  I
• R = Ca bound/ Ca free fluorescence ratio
• Rmin = fluorescence ratio with zero calcium
• Rmax = fluorescence ratio under saturating conditions
y_i y »
• Sf2/Sb2 = ratio of fluorescence values for Ca / Ca free indicator measured at 
the wavelength used to monitor Ca2+ - free indicator (denominator wavelength 
of R) i.e. at 380 nm.
y  i
Intracellular free calcium concentration ([Ca ] j )  of A20 cells was determined by pre- 
loading the cells (2x l06/ml/sample) with 5 (xM of Fura-2 AM at 37°C for 30 minutes.
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Cells were washed free of excess Fura-2 using HBSS buffer supplemented with 100
9 4 - 9 +  f\pM Ca and 1 mM Mg and re-suspended at 2x10 /ml. Fura-loaded cells were 
aliquoted into a 2-ml cuvette. To the cell suspension 20 pi of a 100 mM calcium 
chloride stock (final [1 mM]) was added and allowed to equilibrate at 37°C in the 
spectrofluorimeter for 5 minutes. Prior to the addition of the agonists, a basal calcium 
measurement was taken for 30 seconds. The agonist-induced response was monitored 
for at least 500 seconds and was detected on the spectrofluorimeter (Photon 
Technologies).
3.10 Chemotaxis Assays
Two methods o f the chemotaxis assay were used in this thesis.
ChemoTx Chamber
The transmigration o f cells in response to chemokine was determined using a 
disposable ChemoTx chamber consisting of a 96-well plate, a hydrophobic 
polycarbonate filter (5 pm-pore size) and an attachable lid (Figure 15). Cells were 
washed twice with RPMI and re-suspended in 0.1% BSA RPMI at 4x l07/ml. lxlO 7 
cells were then loaded with 5 pg of Calcein-AM on a rotator for 30 minutes at 37°C. 
Following incubation, cells were washed twice with RPMI and re-suspended at the
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required concentration in 0.1% BSA RPMI. The bottom wells of the plate were 
carefully loaded with 29 pi of agonist, avoiding the formation of air bubbles, and then 
overlaid with a hydrophobic polycarbonate filter (5 pm poresize). 25 pi of calcein- 
loaded cells were subsequently aliquoted on top o f the filter, covered with a lid, and 
incubated for 90 minutes in a 37°C incubator. Following incubation, the non­
migrated cells were removed from the top o f the filter using PBS. The cells that had 
migrated through the filter were assessed by recording the fluorescence signal using a 
Fluoroscan II plate reader at 485 nm excitation and 538 nm emission using the 
bottom reading mode.
Figure 15. Neuroprobe ChemoTx Disposable Cham ber 
(ref.www.neuroprobe.com)
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Boyden Chamber
Chemotaxis was examined using a Boyden 96-well chemotaxis chamber (Figure 16). 
Cells were washed twice in serum-free RPMI 1640 and resuspended at a density of 
lx l0 6cells/ml in RPMI with 0.1% (w/v) BSA. Cells were serum-starved for 1 hour at 
37°C. During the starvation period, a 96-well plate was carefully positioned into the 
chemotaxis chamber and loaded with 395 jllI chemokine (0-1 nM final concentration) 
so as to form a positive meniscus within the well. A 5 pm filter was lowered on top of 
the 96-well plate, taking great care not to form air bubbles. The gasket was positioned 
onto pins on the underside of the chamber lid and the lid gently closed, applying even 
pressure to the top of the chamber. l x l 06cells/ml were then added to the wells of the 
chemotaxis chamber, covered with parafilm, and incubated in a humidified cell 
incubator at 37°C for 1.5 h. Some cells were retained and serially diluted to give a 
standard curve ranging from 2x10 to 1x10 cells/100 pl/well in a 96-well plate, which 
was also incubated at 37°C. At the end of the incubation period, any remaining cells 
were aspirated from the upper wells of the chamber, 200 pi of versene was added per 
well and the chamber incubated at 4°C for 20 minutes. After aspirating off the 
versene, the chamber was carefully opened and the 96-well plate removed, without 
detaching the filter on top. The plate together with the filter was spun at 1511 x g for 
10 minutes in a Beckman GS-15R centrifuge (S2096 rotor) to pellet migrated cells. 
Cells were resuspended in 100 pi RPMI and 20 pl/well cell titre reagent added to 
both the chemoataxis and standard curve plates. Plates were incubated at 37°C for a
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further 1-2 h, after which the absorbance was measured at 490 nm in a 96-well 
microplate reader (Dynatech MR5000). The number of migrated cells was calculated 





Figure 16. MBB96 Boyden Cham ber (ref. www.neuroprobe.com)
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3.11 Chemotactic Index
ChemTx Assay:
The chemotactic index was calculated by dividing the mean fluorescence signal of 
migrated cells in chemokine-containing wells by the mean fluorescence signal of cells 
that migrated spontaneously toward media alone.
Boyden Chamber Assay:
The chemotactic index was calculated by dividing the number of migrated cells in 
chemokine-containing wells by the number of cells that migrated spontaneously 
toward media alone.
3.12 Statistics
Statistical analysis was performed on mean intra-experimental values from 3 or more 
experiments using a Student t test. For multiple comparisons, the significance was 
determined using the Student t test with Bonferroni’s correction for multiple 
comparisons. In all chemotaxis experiments data are presented as mean ± SEM for n 
= 3 replicates.
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3.13 Measurement of D-3 Phosphoinositide Lipids in A20 cells
In order to measure D-3 inositol lipid accumulation, cells must be depleted of 
phosphate prior to labelling by washing three times in 50 ml phosphate-free balanced 
salt solution, incubating for 10 minutes at 37°C between washes. Cells were 
resuspended in 10 ml of balanced salt solution supplemented with 5% dialyzed FCS
'X')and 20 mM HEPES. 1 mCi of [ P]Pi was added to the suspension of cells and 
incubated at 37°C for 2 h. After incubation at 37°C, cells were washed 3 times in 50 
ml of phosphate free media to remove any unincorporated [ P]Pi and resuspended at
n
a concentration o f 2x10 cells/ml in a final volume of 120 pi per point. Cells were 
stimulated as normal and reactions terminated by addition of 
500 pi chloroform/methanol/FLO (32.6/65.3/2.1 v/v) to produce a homogeneous 
primary extraction phase. Phases were separated by addition of 200 pi chloroform 
containing 10 pg/ml Folsch lipids and 200 pi of 2.4 M HC1, 5 mM 
tetrabutylammonium sulphate followed by vortexing and centrifugation at 1000 x g 
for 5 minutes. Lower phases were harvested into fresh tubes containing 400 pi of 1 M 
HC1, 5 mM EDTA, vortexed and centrifuged for a further 5 minutes at 1000 x g. 
Lower phases were once again removed into fresh tubes and dried in vacuo. The 
extracted lipids were then subjected to a deacylation step to remove the sugar 
backbone from the lipid. This was achieved by the addition of 1 ml 25% (w/v) 
methylamine/methanol/N-butanol (4:4:1) followed by incubation at 53°C for 40 
minutes. Samples are then cooled rapidly on ice for 5 minutes and dried in vacuo
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overnight. Samples were then resuspended in 0.5 ml H2O followed by the addition of
0.6 ml N-butanol/petroleum ether/ethyl formate (20/4/1 v/v), vortexed and 
centrifuged for 5 minutes at 1000 x g. The upper organic phase was removed and 
discarded whilst the lower was washed with a further addition of 0.6 ml of butan-1- 
ol/petroleum ether/ethyl formate mix. After vortexing, centrifugation and removal of 
the upper phase as before, the lower phase was dried in vacuo. Finally pellets were re­
dissolved in 90 pi H20 and analysed by HPLC using a 12.5 cm Whatman Partisphere 
SAX column (299).
3.14 GFP-CXCR4 Construct
The following steps were carried out to make green fluorescent protein (GFP) tagged 
CXCR4-expressing HEK-293 cells.
Polymerase Chain Reaction (PCR)
PCR is an in vitro technique, where a given DNA sequence is identically copied. The 
number of copies rises exponentially, since every newly synthesized DNA-sequence 
is also a matrix for the next copy. The PCR-reaction is subdivided into three steps:
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1. Denaturation
During denaturation, the template-DNA is separated (denaturated) into its two 
separate strands by heating up the temperature to 95°C.
2. Annealing
The temperature is lowered to a degree specific for the primer (oligonucleotide), 
which generally lies between 50°C and 70°C. This guarantees, that the primer takes 
its place at the specific DNA-recognition-sequence of the single-stranded DNA- 
template-sequence.
3. Synthesizing
The third step, the sythesizing, takes place at a temperature of 71°C degrees. This 
corresponds to the optimal temperature for the Taq-polymerase enzyme to work. The 
polymerase ensuingly prologues the paired short oligonucleotides according to the 
DNA-matrix, until the double-stranded DNA-molecule is complete again.
PCR Primers
The dried oligonucleotides (primers) (200 nM) were first diluted to 25 pM with dT^O, 
and subsequently added to the PCR Master Mixtures detailed in appendix 1. The 
master mixtures were mixed and run on a PCR machine overnight. The temperatures
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set up on the machine were 95°C, followed by 51°C, followed by 71°C, each for 30 
cycles.
Purification of PCR product
Sequencing of the PCR product was not necessary because the template used for the 
PCR was a CXCR4 plasmid previously sequenced by Prof. Ann Richmond from 
Vanderbilt University. However, a sample of PCR product was run on a 1% agarose 
gel containing 5 pi o f a 10% stock of ethidium bromide solution to check for dDNA 
(CXCR4). The gel was run in TAE buffer (appendix 1) at 100 V.
The PCR product was then purified from the reaction mixture using a QIAquick PCR 
Purification kit (QIAGEN) according to the manufacturer’s protocol. In summary, 
250 pi PB buffer was added to 50 pi o f PCR product, and filtered through a mini­
column by spinning the tube for 1 minute at 16100 x g. The supernatant was 
discarded and a further 750 pi o f PE buffer was added to wash the DNA trapped on 
the filter. The tube was spun again and supernatant discarded. The column was 
subsequently transferred to a fresh tube and eluted with the addition of 30 pi o f dH20 
and spun once more.
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Digestion of PCR product and EGFP-N1 Vector
The next step was to digest the PCR product and EGFP-N1 vector using 2 restriction 
enzymes (Promega) (Figure 17). The buffers used were matched according to 
efficiency data provided by the company data sheet. In this case, both restriction 
enzymes Xhol and Hindlll gave maximal efficiency when using buffer B. Digestion 
Mixtures were made up as described in appendix 1. The mixtures were briefly 
centrifuged and incubated in a 37°C water bath for 3-4 h. The digested vector and 
DNA were subsequently run on a 1 % agarose gel to separate the ligated vector from 
the target gene insertion site and the CXCR4 sequence from the extra 
oligonucleotides.
pEGFP-N1 Vector Information PT3027-5
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Figure 17. pEGFP-Nl Vector Information
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Gel Purification
The identified DNA bands for CXCR4 and the vector were cut from the gel and 
placed into separate eppendorf tubes. DNA fragments were purified from agarose 
gels using the QIAquick gel extraction kit (QIAGEN) according to the 
manufacturer’s protocol. In summary, the weight of the gel within each tube was 
determined and 3 times the volume of QG buffer was added. The gel was melted by 
incubating the tubes for 10 minutes at approximately 50°C. The solutions were then 
added to Eppendorf columns, centrifuged and washed with PE buffer. The columns 
were finally transferred to fresh tubes and plasmid DNA eluted with 20 pi of dP^O.
Ligation Step
Two ligation mixtures were set-up containing different ratios of vector plasmid:DNA 
insert, a 1:2 and 1:3. 20 pi volumes of ligation mixtures contained 2 pi IX T4 DNA 
ligase buffer, 4 or 6 pi DNA insert, 2 pi DNA vector, 1 pi o f IX T4 DNA ligase and 
11 or 9 pi dP^O. The ligation mixtures were then left at room temperature for 2 h.
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Transformation into Bacteria
Two tubes were set up with 100 pi of DH5-a bacteria containing either 4 pi of 
plasmid from tube 1, or 4 pi from tube 2. The bacteria were then placed on ice for 10 
minutes, transferred to a 42°C water bath for 50 seconds and returned to ice for a 
further 2 minutes. The bacteria were then spread on agar plates containing kanamycin 
and incubated overnight at 37°C.
Purification of Plasmid DNA
A single colony was selected from the kanamycin resistant plates and added to 3 ml 
of LB broth, labelled and incubated overnight. At least 8 colonies were selected at 
any one time.
Mini Prep using a Qiaquick kit
1.5 ml of bacteria from the mini culture were transferred into an eppendorf tube, 
labelled and centrifuged for 5 minutes at 16100 x g. The supernatant was discarded 
and the pellet gently resuspended in 250 pi of PI buffer. 250 pi of P2 buffer (lysis 
buffer) was then added and mixed followed by 350 pi o f P3 buffer (neutralization 
buffer). The cell debris was removed by centrifuging for 10 minutes, and supernatants
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transferred to the top of a fresh tube containing a column insert. This was then 
centrifuged for 1 minute, supernatant removed and column washed with 750 pi of PE 
buffer. Finally 16 pi of dFLO was added to elute the plasmid.
3.15 Digestion of plasmid DNA
To purify the plasmid DNA the Digestion Reaction Mixture was made up as 
described in appendix 1. The above reaction mixtures were left to digest in a 37°C 
water bath for 1 h, then run on a 1% agarose gel to separate the 1 kb CXCR4 from the 
4.7 kb vector. The bands were cut from the gel and purified using the gel extraction 
kit as described above.
Maxi Prep of positive clones
200 pi of bacteria (positive clone identified from the mini prep) were incubated 
overnight in a conical flask containing 200 ml of LB broth and 100 pg/ml of 
kanamycin.
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Purification of Plasmid from Maxi Prep
The majority of bacteria from the mini culture were transferred into large centrifuge 
bottles, labelled and centrifuged for 10 minutes at 6000 x g. The supernatant was 
discarded and the pellet gently resuspended in 10 ml of PI resuspension buffer. 10 ml 
of P2 buffer (lysis buffer) was then added and mixed followed by 10 ml of P3 buffer 
(neutralization buffer). The mixture was then poured into the barrel of a QIA filter 
cartridge and left to stand for 10 minutes at room temperature. Meanwhile the 
columns were equilibrated and washed with QBT buffer. The DNA was then eluted 
by adding 15 ml of elution buffer and precipitated with 10.5 ml of isopropanol. The 
DNA was then centrifuged at 20,000 x g for 30 minutes at 4°C, supernatant removed 
and pellet washed with 70% ethanol. The pellet was air dried and dissolved in 250 \i\ 
of dH20 .
Digestion of Plasmid DNA
Two separate digests were then carried out to ensure the plasmid DNA was CXCR4. 
The first contained the restriction enzymes Xhol and Hindlll and the second, BamHI 
and Xhol. The protocol was followed as described above for the digestion and gel 
purification of the PCR product and vector.
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3.16 Preparation of GST Fusion Proteins
1 pi of GST-AP2 or 1 pi of GST alone was added to two separate tubes containing 
100 pi of bacteria. The transformation of bacteria was carried out as described above, 
however bacteria were spread onto agar plates containing ampicillin not kanamycin. 
The mini prep and maxi prep were also followed as described above. The fusion 
protein was then transfected into HEK-293 cells as previously described.
GST-AP2 Purification
This part of the experiment was carried out entirely on ice. The bacteria from the 
maxi prep were centrifuged for 10 minutes at 400 x g and lysed with 2 ml o f lysis 
buffer containing 100 pg/ml of PMSF. The bacteria were resuspended, sonicated, 
transferred to eppendorf tubes and centrifuged for 10 minutes at 4°C. The recovered 
protein was pooled and the concentration determined by Bradford assay (Biorad). 
Using 10 pi of protein, serial dilutions in water were made and added to 50 pi 
Bradford reagent. Protein concentration was determined by optical density readings at 
595 nm and comparison to a range of known protein standards (2 mg/ml -  0.05 
mg/ml). Glutathione beads were then washed to remove the ethanol using lysis buffer 
and added (200 pi) to GST-AP2 and GST containing tubes. Protein complexes were 
adsorbed through the addition of 30 pi GST sepharose slurry, and rotation for 1 h at
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4°C. Adsorbed proteins were recovered via sedimentation o f the sepharose beads by 
centrifugation, followed by 5 washes with lysis buffer. Finally, beads were 
sedimented and drained with a Hamilton syringe, prior to boiling in 30 |il SDS- 
Laemmli sample buffer.
Incubation of lysates with GST alone or GST-AP2
Lysates were prepared as described previously and incubated overnight with either 
GST-AP2 or GST alone at 4°C. Samples were subsequently washed in lysis buffer, 
followed by the addition o f 35 jil o f sample buffer and boiled for 5 minutes. Gradient 
gels were set-up and samples run as previously described for SDS PAGE and 
Western Blotting.
3.17 Co-localisation Assay by Confocal Microscopy
Cells were plated at 5x l05/ml in 10 ml of complete media in the presence o f 6 
coverslips (0.1% glycine treated) and incubated overnight. Cells were stimulated with 
ligand for the indicated time points and fixed in methanol. Cells were washed in PBS, 
incubated with primary anitbody (1:50) for 30 minutes followed by secondary 
antibody (1:1000) for 30 minutes. The cells were washed in PBS, inverted onto slides 
using mounting media and viewed by confocal microscopy.
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3.18 Co-localisation during Chemotaxis
Parental cells were plated at 5 x l05/ml with coverslips and incubated overnight. The 
following day the cells were transfected with CXCR4 as described previously. Prior 
to stimulations, coverslips were clipped with tweezers to note the direction of 
chemokine. A lid o f a Petri dish was adapted with a filtered well to allow the 
chemokine to be released in a gradient manner (Figure 18). Stimulations were carried 
out as described in the co-localisation assay, followed by incubations with antibodies 




Lid of Petri Dish
Cover Slips
Figure 18. The adaptation of a Petri dish for a gradient chemotaxis assay.
A hole was made in the lid o f  the Petri dish with a filtered well glued to it, to allow the addition and 
slow  release o f  chemokine. The triangles in the cover slips represent the direction o f  the chemokine 
gradient.
The following chapters provide the results o f the experiments carried out.
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Chapter 4
Results: Signalling Events mediated by CCL1/CCR8 ligand-receptor pair
4.1 Introduction
Many studies have investigated possible roles for CCR8 however the exact 
intracellular signalling pathways involved remain unknown. Research into the 
chemokine receptor CCR8 and its respective ligand CCL1 has been sparse as outlined 
in Chapter 1. This chapter provides the results of experiments which aim to identify 
the effectors and reveal the pathways and functional responses mediated following 
the ligation of CCR8 by CCL1 in transfected cell models and leukaemic T cell lines.
The ERK1/2 and PKB signalling pathways regulate cell differentiation, proliferation 
and cell survival, and are two of the best characterised signalling cascades. Both 
pathways have been demonstrated to be activated downstream of chemokine 
receptors in a variety o f situations (287,300). However, activation of these cascades 
in response to CCR8 ligation has yet to be determined. This study aims to establish 
and define the activation of these signalling modules using two different cell systems 
and compare them to previously reported studies. These include the adherent rat 
basophillic leukaemia cells (RBLs) stably transfected with CCR8, and the leukaemic 
T cell line HUT-78. RBL cells were chosen because they do not endogenously 
express CCR8. This permits the authenticity of the CCLl/CCR8-mediated response 
to be verified. Unfortunately, the coupling of receptors to downstream biochemical 
events may not accurately reflect the situation in physiological conditions. Therefore
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HUT-78 cells which endogenously express CCR8 were additionally used to dissect 
CCL1-mediated signalling cascades. The fact that HUT-78 cells are a suspension cell 
line enabled a technically more straightforward investigation of CCL1-mediated 
directed T cell migration.
4.2 Analysis of CCR8 Signal Transduction in RBL Cells 
Surface Expression of CCR8 on RBL Cells.
The expression of CCR8 was investigated on RBL cells stably transfected with 
CCR8. Rabbit polyclonal antibodies against human CCR8 have been developed by 
Alexis, abeam, Imgenex and Exalpha biologicals; however none of these were able to 
detect the expression of hCCR8 on RBL-CCR8 cells by FACs analysis (Brown Z. 
Novartis Pharmaceuticals, personal communication). As an alternative approach the 
expression levels of CCR8 were determined indirectly using a kit which relies on the 
binding of biotinylated chemokine (CCL1) and avidin-fluorescein (See chapter 3 for 
more details). Cells expressing the specific chemokine receptor (CCR8) are 
fluorescently stained, with the intensity o f staining being proportional to the density 
o f the receptor. Relative receptor density is then determined by flow cytometric 
analysis using 488 nm wavelength laser excitation. The histogram represents analysis 
of 10,000 events acquired in the total population (Figure 19).
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Figure 19. CCR8 expression on RBL-CCR8 Cells
(A) CCR8 expression was detected using the ‘Fluorokine’ kit from R&D. (B) Cells 
were first pre-treated with human IgG to reduce non-specific binding (10 pi of 1 
mg/ml stock/106 cells) for 15 minutes at RT. 1 x 105 cells were then incubated with a 
pre-mixed cocktail o f 20 pi o f anti-human CCL1 antibody and 10 pi of biotinylated 
CCL1 (The antibody functions to amplify the signal). The green line corresponds to 
the negative control (a protein biotinylated to the same degree as CCL1) and the pink 
line corresponds to an increase in fluorescence demonstrating the positive expression 
o f CCR8 on these cells. Data are from a single experiment representative of 2 others.
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Use of PTX to Elucidate the Gaj dependency of CCL1-mediated Ca2+
Mobilization in RBL-CCR8 Cells
A common indicator of biochemically functional chemokine receptors is the 
mobilisation of intracellular calcium. Chemokines are mainly known to signal 
through seven-transmembrane GPCR (301) that activate a G«i protein. Gai association 
with several chemokine receptors has been described (302,303); most responses to 
chemokines are therefore inhibited by the Gaj-specific inhibitor, PTX, although there 
are examples of PTX-insensitive G proteins being coupled to certain chemokine 
receptors (e.g. Gaq couples to CCR2 in HEK-293 cells) (304). PTX catalyzes the 
ADP-ribosylation of the a  subunits of the heterotrimeric regulatory G proteins. This 
prevents the G protein heterotrimers from interacting with receptors, thus blocking 
their coupling and activation. Experiments were carried out to determine whether 
CCL1-mediated calcium mobilisation was reliant on the coupling of Gtti to CCR8. 
CCR8-transfected RBL cells demonstrate a concentration dependent calcium 
response to CCL1 as indicated by the intensity of Fluo-4 (Figure 20). Pre-incubation 
of these cells with PTX (100 ng/ml) for 4 h prevented CCL1, at all concentrations,
• *7 Ifrom inducing a Ca response.














■  V e h i c l e














C C L 1  (n M )
1.2
1
0.8 ■  V e h i c l e
■  + U 7 3 1 2 2





0 2 5 5 0 7 5 1 0 0  1 2 5
C C L 1  (n M )
Figure 20 CCL1 mediates a Gaj and PLC-dependent Ca 
CCR8 Cells.
2+ Mobilization in RBL-
RBL cells were aliquoted in a 96-well plate at 3x l05/ml in complete media and 
incubated overnight to allow cells to adhere. Cells were pre-incubated with vehicle or 
with either (A) PTX (100 ng/ml) for 4 h prior to loading with Fluo-4 (30 minutes) or
(B) pre-incubated with the PLC inhibitor, U73122 (1 pM) at the same time as Fluo-4 
(30 minutes). Cells were subsequently stimulated with CCL1 at concentrations 
between 1 and 100 nM and analysed using the FLIPR-96 in association with FLIPR 
software as described in materials and methods. Data are from a single experiment 
representative of 4 others.
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CCLl-stimuIated Ca2+ Mobilisation in RBLs is PLC-dependent
Calcium is an important and fundamental intracellular second messenger that relays 
information within cells to control processes as diverse as fertilization, proliferation, 
development, learning and memory, contraction and secretion (231). The release of 
calcium from internal stores held within the membrane systems of the ER is 
controlled by various channels of which the IP3R has been studied most extensively 
(305). IP3 is cleaved along with DAG from PI(4,5)P2 by the receptor-activated 
enzyme PLC. Calcium-mobilising second messengers, such as IP3, are generated 
when stimuli bind to cell surface receptors, diffuse into the cell to engage the IP3RS 
and release calcium from the ER. To determine whether the increase in intracellular 
calcium following ligation of CCR8 is a result o f the enzymatic function of PLC, we 
used U73122, a pharmacological inhibitor of PLC. The concentration-dependent 
calcium response to CCL1 (Figure 19) was abrogated following a 30 minute pre­
treatment of RBL-CCR8 cells with 1 j iM  of U73122. 1 pM of U73122 was used in 
this experiment because many studies have reported the IC50 of this inhibitor to be 
between 500 nM and 2.1 pM depending on the cell system involved (306-308). To 
verify that neither PTX nor the PLC inhibitor affect loading of cells with Fluo-4, the 
fluorescence of Fluo-4 loaded cells in the absence/presence of inhibitors was 
routinely analysed. Hence, fluorescence values were 10005 ± 9 1  and 9947 ± 90, 
11218 ± 180 and 11020 ± 1 5 3  (mean ± SEM) in the absence and presence o f PTX 
and PLC, respectively.
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CCL1 stimulates the Phosphorylation of ERK1/2 in RBLs Transfected 
with CCR8
Activation of the MAPK pathway by other chemokines is well documented, and is 
usually represented by phosphorylation of ERK1/2. CCL1 induces a transient and 
time-dependent phosphorylation of ERK1/2 in RBL-CCR8 cells. The maximum 
intensity was consistently reached between 2 and 5 minutes post-stimulation. The 
phorbol ester 12-myristate 13-acetate, PM A, was used as a positive control for 
ERK1/2 activation. PM A activates PKC directly and links to the 
Ras/Raf/MEK/ERKl/2 pathway through the activation of the Ras guanyl nucleotide- 
releasing protein, Ras-GRP (309). The optimum concentration of CCL1 for maximal 
ERK1/2 phosphorylation was also investigated, and found to be between 3 and 10 nM 
(Figure 21).







p44 PanERK 1/2 
p42 J
C 30” 1* 2’ 5’ HP 15’ 5’












Figure 21. CCL1 induces the Phosphorylation of p42/44 ERK1/2 in Stably 
Expressing CCR8 transfected RBL cells.
RBL cells were aliquoted in 0.5 ml at 2 x l06cells/ml and left unstimulated (C) or 
stimulated at 37°C with either the indicated concentration of CCL1 or 100 nM PMA. 
PMA was used as a positive control for ERK1/2 activation. The equivalent to 2 x l0 5 
cells of each sample was separated by SDS-PAGE. The non-stimulated control 
corresponds to both upper and lower blots as these data are derived from one 
experiment. Immunoblotting with the p44/42 phosphospecific ERK1/2 antibody was 
used to detect phosphorylated ERK1/2 proteins. The immunoblot was stripped and 
reprobed with the pan-ERK antibody that recognises both phosphorylated and non- 
phosphorylated forms o f ERK1/2 to allow parity o f loading to be examined. Data are 
from a single experiment representative of 2 others.
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Figure 22. CCL1 induces Ser473 phosphorylation of PKB in CCR8-stably 
transfected RBL cells.
RBL cells were aliquoted in 0.5 ml at 2 x l06cells/ml and left unstimulated (C) or 
stimulated at 37°C with the indicated concentration of CCL1. CEM cells were used as 
a positive control for phosphorylated PKB due to their known high basal levels of 
Ser473- phosphorylated PKB (293). The equivalent to 2 x l0 5 cells of each sample was 
separated by SDS-PAGE. The non-stimulated control corresponds to both upper and 
lower blots as these data are derived from one experiment. Immunoblotting with the 
phosphospecific Ser473 PKB antibody was used to detect phosphorylated PKB 
proteins. The immunoblot was stripped and reprobed with the pan-PKB antibody that 
recognises both phosphorylated and non-phosphorylated forms of PKB to allow 
parity o f loading to be examined. Data are from a single experiment representative o f 
2 others.
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CCL1/CCR8 Stimulates Activation of PI3K/PKB in RBL Cells
PI3K is an important enzyme involved in transducing signals from activated receptors 
(152). PKB is the major downstream effector of PI3K, its phosphorylation being 
dependent on D-3 phosphoinositide lipid formation. The phosphorylation of PKB is 
therefore used as an indirect marker of PI3K activation (299). A similar magnitude of 
PKB phosphorylation was observed at different concentrations of CCL1 between 1 
and 100 nM. However, in previous studies using other chemokine receptors, a 
chemokine concentration of 10 nM has frequently been used (160) and consequently 
this concentration was chosen for this study. At 10 nM, CCL1 was shown to induce a 
transient but robust phosphorylation of PKB between 30 seconds and 5 minutes 
(Figure 22).
Use of Pharmacological Inhibitors to Abrogate CCR8-induced
Phosphorylation of ERK1/2 and PKB
The following experiments were designed to identify the pathways that lead to the 
phosphorylation of ERK1/2 and PKB by utilising various pharmacological inhibitors. 
The use of these inhibitors facilitates the identification o f molecules that are involved 
in certain cellular events. The majority of inhibitors are limited by their specificity, 
but if  used at rational concentrations they can give a good indication of signalling 
pathways. The inhibitors chosen for this part of the study were the PI3K inhibitor 
LY294002, the MEK inhibitor PD98059 and the PKC inhibitor RO320432. The
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mechanisms by which some of these inhibitors mediate their effects are unclear. 
LY294002 is reported to act on the ATP-binding site of PI3K, yet PD98059 does not 
compete for ATP binding or MAPK binding to MEK1 and most likely inhibits 
through an allosteric mechanism (310). Alessi et al. also found that PD98059 does 
not inhibit Raf-activated MEK1 but prevents the activation of MEK by Raf in vitro 
(311).
Using the inhibitors described above, experiments were carried out to determine the 
role of PI3K, MEK and PKC in the activation of both the ERK1/2-MAPK and PKB 
pathways. The effect o f inhibitor concentration was investigated by using each 
inhibitor at concentrations of 3, 10 and 30 pM, based on published work (312-314). 
Unstimulated controls were incubated with the highest concentration of inhibitor (30 
|iM) to ensure they were not having any adverse effects. RBL-CCR8 cells were pre- 
incubated with each o f the inhibitors for the same length of time as reported in other 
studies (312-314): LY294002 and RO320432 for 30 minutes; and PD98059 for 1 h. 
Cells were subsequently stimulated for 5 minutes with 10 nM of CCL1, as it had been 
previously demonstrated that CCL1 induces a maximum ERK1/2 phosphorylation at 
both 2 and 5 minutes (Figure 20), and a maximum PKB phosphorylation at 30 
seconds, 1, 2 and 5 minutes (Figure 21).
As expected, a 5 minute stimulation of RBL-CCR8 cells with 10 nM of CCL1 
resulted in a robust ERK1/2 phosphorylation above control levels (Figure 23). In the
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presence of the PI3K inhibitor LY294002, the ERK1/2 phosphorylation was partially 
inhibited at all concentrations examined (3-30 pM). The MEK inhibitor PD98059 
however, reduced the ERK1/2 phosphorylation in a concentration-dependent manner 
at 10, 20 and 30 pM. In contrast, the PKC inhibitor RO320432 had only a moderate 
effect on the phosphorylation of ERK1/2 at 30 jliM (Figure 23).
A 5 minute stimulation of RBL-CCR8 cells with CCL1 resulted in the 
phosphorylation of PKB which in the presence of all concentrations of LY294002 
was dramatically inhibited. In contrast, the MEK inhibitor PD98059 had a small 
effect on the PKB phosphorylation induced by CCL1. However, 10 and 30 pM 
RO320432 inhibited the phosphorylation of PKB whereas 3 pM had no effect (Figure 
23).
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Figure 23. The Effect of PI3K, MEK and PKC Inhibitors on CCLl-mediated 
ERK1/2 and PKB Phosphorylation in RBL-CCR8 Cells
RBL cells were aliquoted in 0.5 ml at 2 x l0 6cells/ml and pre-incubated with inhibitors 
for either 30 minutes in the case of LY294002 and RO320432 or 1 hr for PD98059. 
Cells were subsequently either left unstimulated (C) or stimulated at 37°C for 5 
minutes with 10 nM CCL1. The equivalent to 2 x l0 5 cells of each sample was 
separated by SDS-PAGE. Immunoblotting with either the p44/42 phosphospecific 
ERK1/2 or Ser473 PKB antibody were used to detect phosphorylated ERK1/2 and 
PKB. The immunoblot was stripped and reprobed with the pan-PKB antibody that 
recognises both phosphorylated and non-phosphorylated forms of PKB to allow 
parity o f loading to be examined. Data are from a single experiment representative of 
2 others.
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4.3 CCR8 Signal Transduction in HUT-78 Cells
Several suspension cells, including in vitro differentiated human Th2 cells and Jurkat, 
HUT-78 and CEM T cell lines, were screened for CCL1-mediated responses. The 
leukaemic T cell line, HUT-78, were the only cells found to respond to CCL1 as 
demonstrated in both biochemical and functional responses. The use of HUT-78 cells 
would permit the investigation of CCL1-directed T cell migration and, since 
CCL1/CCR8 has been implicated in the recruitment of T cell subsets to the airways in 
a murine model of asthma (42,315,316), represents a more physiologically applicable 
system than that of transfected cells. Given that a transfected cell line may not 
contain the same expression profile of G proteins (among other molecules) as a cell 
line which has endogenous receptor expression, the first two experiments were 
designed to determine if HUT-78 cells responded to CCL1 stimulation in a similar 
way to that o f RBL-CCR8 cells.
CCL1 Induces Ser473 Phosphorylation of PKB in HUT-78 Cells
HUT-78 cells stimulated with 10 nM CCL1 showed a rapid and transient, time- 
dependent phosphorylation of PKB (Figure 24). The T cell line CEMs were used as a 
positive control in this experiment for PKB phosphorylation because they have been 
shown to have constitutive PKB phosphorylation compared to peripheral blood 
lymphocytes, possibly due to the lack of PTEN (293). A similar phosphorylation of
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PKB was observed in HUT-78 cells at different concentrations of CCL1 between 1 
and 100 nM. However, in previous studies using other chemokine receptors, a 
chemokine concentration of 10 nM has frequently been used (287) and consequently 
this concentration was chosen for this study.
Use of Pharmacological Inhibitors to Elucidate the Mechanisms involved in 
CCLl-stimulated PKB Phosphorylation
The CCLl-stimulated signalling pathways in HUT-78 cells were examined using the 
pharmacological inhibitors described previously, in order to compare the sensitivity 
to these inhibitors relative to RBL-CCR8 cells. Only the PKB pathway was 
investigated, due to the surprising high basal levels of ERK1/2 found in this cell line. 
In this experiment, the HUT-78 cells were stimulated with 10 nM of CCL1 at their 
optimum time point for PKB Ser473 phosphorylation of 30 seconds (Figure 24).
A 30 second stimulation o f HUT-78 cells with 10 nM of CCL1 resulted in the 
prominent phosphorylation of PKB which was inhibited by the PI3K inhibitor 
LY294002 in a concentration-dependent manner. In contrast, the MEK inhibitor 
PD98059 had a very limited effect on the PKB phosphorylation induced by CCL1. 
Only the highest concentration (30 pM) of PD98059 showed a modest inhibitory 
outcome. Moreover, the PKC inhibitor RO320432 also inhibited the phosphorylation 
o f PKB in a concentration-dependent manner (Figure 25).
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Figure 24. CCL1 Induces Ser473 Phosphorylation of PKB in HUT-78 Cells.
HUT-78 cells were aliquoted in 0.5 ml at 2 x l06cells/ml and left unstimulated (C) or 
stimulated at 37°C with the indicated concentration of CCL1. Unstimulated CEM 
cells were used as a positive control for phosphorylated PKB due to their known high 
basal levels (293). The equivalent to 2 x l0 5 cells of each sample was separated by 
SDS-PAGE. Immunoblotting with the phosphospecific Ser473 PKB antibody was used 
to detect phosphorylated PKB proteins. The immunoblot was stripped and reprobed 
with the pan-PKB antibody that recognises both phosphorylated and non- 
phosphorylated forms of PKB to allow parity o f loading to be examined. Data are 
from a single experiment representative of 2 others.
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Figure 25. Effect of PI3K, PKC and MEK inhibitors on CCL1-mediated Ser473 
PKB Phosphorylation in HUT-78 Cells
HUT-78 cells were aliquoted in 0.5 ml at 2x l06cells/ml and pre-incubated with 
inhibitors for either 30 minutes in the case o f LY294002 and RO320432 or 1 hr for 
PD98059. Cells were subsequently either left unstimulated (C) or stimulated at 37°C 
for 30 seconds with 10 nM CCL1. The equivalent to 2 x l0 3 cells of each sample was 
separated by SDS-PAGE. Immunoblotting with the Ser473 PKB antibody was used to 
detect phosphorylated PKB. The immunoblot was stripped and reprobed with the 
pan-PKB antibody that recognises both phosphorylated and non-phosphorylated 
forms o f PKB to allow parity of loading to be examined. Data are from a single 
experiment representative of 2 others.
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In vitro Chemotaxis of HUT-78 cells in Response to CCL1
Having established that activation of PI3K/PKB occurs following CCL1 stimulation 
o f CCR8, this study sought to determine the functional significance of these pathways 
in the HUT-78 cell model. Chemotaxis, which is commonly used as a functional 
readout, is the process by which cells detect the direction and intensity of, and move 
toward, an extracellular chemoattractant gradient. This intriguing process plays a 
central role in development, immunity and tissue homeostasis (78-80). The migratory 
response of these cells to CCL1 was determined using disposable ChemoTx plates 
from Neuroprobe. These chemotaxis chambers enable the experiments to be carried 
out using small volumes of reagents. The CCLl-stimulated migration of HUT-78 
cells exhibited classic bell-shaped concentration-dependent characteristics associated 
with chemokine responses in other systems (287,317) (Figure 26). Moreover, the 
chemotactic indices in response to all concentrations of CCL1 were greater than 4, 
and were found to be statistically significant. The chemotactic indices were calculated 
by dividing the mean fluorescence signal of migrated cells in chemokine-containing 
wells by the mean fluorescence signal o f cells that migrated spontaneously toward 
media alone. Maximal responses were always observed with 1 nM CCL1 reaching a 9 
fold chemotactic index over basal.
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The Effect of PTX on CCLl-mediated Chemotaxis in HUT-78 Cells
♦ ?  4- •Having previously demonstrated that CCLl-mediated Ca mobilisation in RBL- 
CCR8 cells was dependent on Gtti (Figure 18), this study aimed to determine whether 
CCL1-directed cell migration of HUT-78 cells was also dependent on the Gaj subunit. 
HUT-78 cells were pre-treated with PTX (100 ng/ml) for 4 h and then subjected to a 
chemotaxis assay alongside untreated cells in response to CCL1 (1 nM). PTX 
treatment resulted in 86% inhibition of CCL1 stimulated chemotaxis (Figure 27). 
This inhibitory effect was found to be statistically significant. In order to ascertain 
whether PTX was affecting the viability of the HUT-78 cells, samples of cells, one 
treated with PTX and one untreated, were tested using trypan blue as a marker. 
Microscopic examination showed that there was no difference between the two 
samples, confirming that the PTX did not have a detrimental effect on cell viability.




Figure 26. In vitro Chemotaxis of HUT-78 Cells in Response to CCL1
HUT-78 cells were loaded with Calcein-AM dye for 30 minutes. The cells were then 
washed and re-suspended at 2 .8xl06/ml in 0.1% BSA RPMI. 29 pi o f either CCL1 
(between 0.03 and 100 nM) or buffer alone was added to the base of a disposable 
chemotaxis chamber. The 5 pm filter was attached as described in Material and 
Methods and 25 pi of cells added to the top. The chemotaxis plate was incubated for 
90 minutes at 37°C, 5% CO2, then washed o f residual cells and read on a fluorescent 
plate reader at 485 nm excitation and 538 nm emissions using the bottom reading 
mode. Data were analysed by Student’s t test to determine the significance of CCL1 
concentration compared to cells migrating randomly in response to media alone (**, p 
< 0.0002; ***, p < 0.00005). The horizontal line at a chemotactic index of 1 
represents unstimulated basal migration and is shown for ease o f comparison with 
stimulated levels. Data are from a single experiment representative of 3 others.
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Figure 27. CCLl-m ediated Chemotaxis of HUT-78 Cells is Gaj-dependent
HUT-78 cells were treated with PTX for 4 h prior to loading with Calcein-AM for 30 
minutes. The cells were then washed and re-suspended at 2.8x106/ml in 0.1% BSA 
RPMI. 29 pi o f either CCL1 (1 nM) or buffer alone was added to the base of a 
disposable chemotaxis chamber. The 5 pm filter was attached as described in 
Material and Methods and 25 pi of cells added to the top. The chemotaxis plate was 
incubated for 90 minutes at 37°C, 5% CO2, then washed of residual cells and read on 
a fluorescent plate reader at 485 nm excitation and 538 nm emissions using the 
bottom reading mode. Data were analysed by Student’s t test to compare responses in 
the presence and absence of PTX ( ***, p < 0  .00005). The percentage inhibition of 
migrating cells as a result of PTX treatment is indicated on the graph. The horizontal 
line at a chemotactic index of 1 represents unstimulated basal migration and is shown 
for ease of comparison with stimulated levels. Data are from a single experiment 
representative o f 3 others.
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The Importance of PI3K in CCLl-mediated Chemotaxis of HUT-78 Cells
Until recently, PI3K was believed to be crucial for chemokine-mediated chemotaxis 
(160). However, Smit et al (317) recently reported the PI3K-independent chemotaxis 
of human T cells in response to CXCR3 ligands. Similarly, chemotaxis of CCR4- 
expressing CEM cells in response to CCL22/MDC and CCL17/TARC have been 
shown to be insensitive to the PI3K inhibitors LY294002 and Wortmannin at 30 pM 
and 300 nM respectively (Cronshaw and Ward, unpublished data).
This section aims to examine whether PI3K is required for the movement of HUT-78 
cells in response to CCL1. HUT-78 cells were pre-treated with LY294002 at 3, 10 
and 30 pM and subsequently incubated in a standard chemotaxis assay with 1 nM 
CCL1, the concentration found to elicit maximal chemotactic response. In this 
experiment CCL1 alone induced a chemotactic index of greater than 2.5 in HUT-78 
cells, whilst pre-treatment with the PI3K inhibitor LY294002 abrogated chemotaxis 
in a concentration-dependent manner (Figure 28).
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Figure 28. CCLl-m ediated Chemotaxis of HUT-78 Cells is PI3K-dependent
HUT-78 cells were pre-loaded with Calcein-AM for 30 minutes, washed and re­
suspended at 2.8x106/ml in 0.1% BSA RPMI. LY294002, at the indicated 
concentrations, was incubated with cells for 30 minutes prior to loading with Calcein. 
29 pi o f either CCL1 (1 nM) or buffer alone was added to the base o f a disposable 
chemotaxis chamber. The 5 pm filter was attached as described in Material and 
Methods and 25 pi o f cells added to the top. The chemotaxis plate was incubated for 
90 minutes at 37°C, 5% CO2, then washed o f residual cells and read on a fluorescent 
plate reader at 485 nm excitation and 538 nm emissions using the bottom reading 
mode. Data were analysed by Student’s t test to compare responses in the presence 
and absence of LY294002 (*, p < 0.002; **, p < 0.00005; ***, p < 0.000005). The 
percentage inhibition of migrating cells as a result o f LY294002 treatment is 
indicated on the graph. The horizontal line at a chemotactic index o f 1 represents 
unstimulated basal migration and is shown for ease o f comparison with stimulated 
levels. Data are from a single experiment representative o f 3 others.
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Use of Inhibitors to Elucidate the Role of PLC-dependent Signalling Pathway in 
Chemotaxis
To establish which pathways are involved in CCLl-mediated chemotaxis of HUT-78 
cells, a selection of inhibitors were used to examine the role of PLC, IP3-mediated 
intracellular Ca2+ release and PKC. These were the PLC inhibitor U73122, U73343 (a 
weak analogue of the PLC inhibitor) (318) and the PKC inhibitor RO320432. A 
compound termed 2APB, has been reported to inhibit Rem ediated calcium release 
without blocking the binding of IP3 to its receptor (319) and this reagent was also 
used in this study. Shown in Figure 29 is a representative result of chemotaxis assays 
performed on the HUT-78 cells. Cells were pre-treated with the above inhibitors for 
30 minutes prior to the assay. CCL1 (1 nM) stimulated the chemotaxis of HUT-78 
cells alone with a chemotactic index of greater than 4. Treatment with the PLC 
inhibitor U73122 (3 pM) resulted in a 70% inhibition of migration of HUT-78 cells; 
however the weak analogue o f U73122, U73343 failed to block the chemotaxis of 
cells (5% inhibition) in response to CCL1. To identify whether the source of calcium 
that regulates chemotaxis is dependent on IP3, cells were pre-incubated with the 
inhibitor 2APB (50 and 75 pM). At 50 pM, 19% inhibition was found; whilst at 75 
pM  inhibition was 45%. Finally the PKC inhibitor, RO320432 (10 pM) was found to 
inhibit the chemotactic response of HUT-78 cells by 60% whilst the MEK inhibitor 
PD98059 was only able to reduce the CCLl-mediated migration of HUT-78 cells by 
18%.
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Figure 29. Effect of Pharmacological Tools on CCLl-mediated Chemotaxis of 
HUT-78 Cells
HUT-78 cells were pre-loaded with Calcein-AM for 30 minutes, washed and re­
suspended at 2.8x106/ml in 0.1% BSA RPMI. Inhibitors at the indicated 
concentrations were incubated with cells for 30 minutes prior to loading with Calcein. 
29 pi of either CCL1 (1 nM) or buffer alone was added to the base o f a disposable 
chemotaxis chamber. The 5 pm filter was attached as described in Material and 
Methods and 25 pi of cells added to the top. The chemotaxis plate was incubated for 
90 minutes at 37°C, 5% CO2, then washed o f residual cells and read on a fluorescent 
plate reader at 485 nm excitation and 538 nm emissions using the bottom reading 
mode. Data were analysed by Student’s t test with Bonferroni’s correction for 
multiple comparisons to compare responses in the presence and absence of inhibitors 
(*, p < 0.00048; ***, p < 0.00000006). The percentage inhibition of migrating cells 
as a result o f inhibitor treatment is indicated on the graph. The horizontal line at a 
chemotactic index of 1 represents unstimulated basal migration and is shown for ease 
of comparison with stimulated levels. Data are from a single experiment 
representative o f 3 others.
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Summary of Findings
• CCR8 was confirmed to be expressed on RBL-CCR8 cells.
• CCL1 mediates a G«i- and PLC-dependent calcium mobilisation in RBL- 
CCR8 cells.
• CCL1 induces a time- and concentration-dependent activation of the MAPK 
pathway in RBL-CCR8 cells.
• Activation of the MAPK pathway is dependent on MEK, partially dependent 
on PI3K and independent of PKC in RBL-CCR8 cells.
• CCL1 induced a time-dependent phosphorylation of PKB in both RBL-CCR8 
and HUT-78 cells.
• Activation of PKB is dependent on PI3K, partially dependent on PKC but 
independent of MEK in both RBL-CCR8 and HUT-78 cells.
• CCL1 stimulates the chemotaxis o f HUT-78 cells in a concentration- 
dependent manner with bell-shaped characteristics.
• The chemotactic response of HUT-78 cells to CCL1 is dependent on G«j, 
PI3K, PLC and PKC and partially dependent on IP3.
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4.4 Discussion
Detecting the Expression of CCR8 on Cell Membranes
Detecting the expression o f human CCR8 on the surface of cells used in this study 
was restricted by the availability of a reliable antibody for this receptor; a few have 
been marketed but none to date have been successful (Brown Z. Novartis 
Pharmaceuticals, personal communication). An alternative method was used to 
detect the expression of CCR8 through the binding of a biotinylated CCL1 and 
avidin-fluorescein. However, it seemed that this method was only useful for the 
detection of high levels of receptor expression, because CCR8 could not be detected 
on HUT-78 cells or T-lymphoblasts even though biochemical responses through 
CCR8 were prominent in these cells. Alternatively, it is possible that an additional 
un-characterised receptor for CCL1 exists.
CCLl-mediated Calcium Mobilisation is Abrogated by PTX and the PLC 
Inhibitor, U73122
The results in this study reveal that CCL1 mediates a PLC-activated calcium flux in 
RBL-CCR8 cells that is entirely PTX-sensitive. Whilst PTX does indicate that a 
response is dependent on Gai-coupling, it does not distinguish between the 
involvement of either the a i or py subunits mediating activation of various pathways. 
Indeed, there is also no evidence for G ttj binding to PLCP, and it is well established
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that Ca signalling by many Gaj -coupled receptors is via Gp-y-mediated activation of 
PLCp (320-322). Each of the four identified PLCP isoforms can be stimulated by Gpy 
subunits (323 ,324) with marked differences in their sensitivities (323). The majority 
o f chemokine-mediated calcium responses are PLCP-dependent, however in contrast 
to the results presented in this thesis, not all are reliant on the coupling of the G«j 
subunit to the receptor. One study reported that chemokine-elicited intracellular 
calcium responses in freshly isolated and cultured cerebellar Purkinje and granule 
neurons were PTX-insensitive (325).
CCR8-mediated Chemotaxis of HUT-78 Cells
The crucial role of G proteins in chemotaxis of lymphocytes is well known. It is 
commonly accepted that all chemokine receptors couple to Gab although some 
chemokine receptors can also couple to G aq, Gan , Gai4, and G«i6 proteins (326,327). 
Pre-treatment of HUT-78 cells with PTX completely blocks CCR8-mediated 
chemotaxis, suggesting that this response is entirely dependent on Gai-coupling.
Activation of PI3K and the accumulation of its lipid product, PI(3,4,5)P3, is not only 
essential for the establishment o f the leading edge of a migrating cell but is also 
required for cell polarization and directional movement in simple organisms such as 
Dictyostelium discoideum , as well as in more complex mammalian cells (328-330).
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Furthermore, it has been demonstrated that protein kinase B (PKB), a major effector 
of the PI3K-dependent signaling cascade that interacts with PI(3,4,5)P3 and PI(3,4)P2 
via its PH domain, colocalizes with these lipids and filamentous actin at the leading 
edge (331). The data from our study demonstrate for the first time that CCL1-directed 
cell migration is dependent on PI3K in HUT-78 cells. Despite these exciting 
developments, it is unclear which PI3K isoforms are involved in the accumulation of 
PI(3,4,5)P3 and PI(3,4)P2 in response to chemokines. The G protein-sensitive PI3Ky is 
an obvious candidate for the accumulation of PI(3,4,5)P3 in response to chemokine 
stimulation of G protein-coupled chemokine receptors, as it is activated by GPy 
following ligation of GPCRs (332). However, there is evidence that GPCRs are able 
to activate class IA PI3Ks. The class IA, p i 108 has been shown to be important for 
both fMLP-induced neutrophil migtration and in controlling the directionality of 
EGF-driven breast cancer cell migration (333,334). In addition, recent work suggests 
that the optimal chemotactic response of leukaemic T cells to CXCL12/SDF-1 
requires activation of both class IA and IB PI3Ks (287).
The PI3K isoforms that are responsible for CCL1-directed, PI3K-dependent 
migration of HUT-78 cells have not been investigated in this thesis. However, since 
HUT-78s express all class IA and IB PI3K isoforms, in addition to the class II 
isoforms, C 2a and C2P, then it is plausible that p i lOy and p i 108 may have roles to 
play in CCL1-directed cell migration of HUT-78 cells. To date, research on class II 
PI3Ks is limited, although activation o f PI3K-C2a by the chemokine CCL2/MCP-1
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has been shown in THP-1 cells (197). LY294002 is reported to inhibit all PI3K 
isoforms with an IC50 in the 1-50 pM range (335). In our hands, low concentrations 
of LY294002 (3 pM) can only inhibit class I PI3Ks, whereas class II PI3Ks begin to 
be inhibited by LY294002 at approximately 30 pM (Kouroumalis and Ward, 
unpublished data). Given that CCL1-directed migration of HUT-78 cells was 
inhibited by the PI3K inhibitor, LY294002, at 3 pM, it is more likely that class I 
PI3Ks are involved.
The activity o f PI3K and thus accumulation of PI(3,4,5)P3 at the sides and back of the 
cell are restricted by the lipid phosphatase PTEN. PI(4,5)P2 has been reported to be 
responsible for the localisation of PTEN to the plasma membrane at the back of the 
cell. Such models imply that PI(4,5)P2 is depleted from the leading edge in order to 
prevent the recruitment of PTEN, this is believed to occur not from its 
phosphorylation by PI3K, but from the action of PLC induced by chemokine 
signalling (328,329).
The Role of Calcium and PKC in Cell Migration
The presence o f the PLC-signaling pathways in T cells and the ability of chemokines 
to activate this system were previously demonstrated for CXCL8/CXCR2 (336). 
Moreover, PLC(3 activation o f heterologously expressed chemokine receptors was 
shown for CCR1 and 2 (326). The role o f PLC as a determinant o f chemokine-
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mediated chemotaxis has recently been demonstrated in two diverse systems by Smit 
et al and Soriano et al. The PLC inhibitor, U73122 (10 pM) was shown to abolish 
both CXCL11/I-TAC-directed cell migration of activated human T lymphocytes 
(317) and CXCL12/SDF-1-directed cell migration of MOLT4 cells in vitro (290). 
Similarly, this study reveals that migration of HUT-78 cells in response to CCL1 is 
dependent on PLC, as demonstrated using 3 |iM of U73122. Together with the data 
reported in this section, the PLC pathway appears to play a role in chemokine- 
mediated T cell migration.
The Role of Calcium and PKC in CCLl-directed Cell Migration of HUT-78 
Cells
The hydrolysis o f PI(4,5)P2 by PLC, generating the second messengers IP3 and DAG 
is well documented. The binding of IP3 to the IP3R present on the surface of ER/SR
9+induces the release of calcium into the cytoplasm. Changes in cytosolic Ca 
concentrations evoke a wide range of cellular responses and intracellular calcium-
94- ♦binding proteins are the key molecules to transduce Ca signalling via enzymatic 
reactions or modulation o f protein/protein interactions. These include the 
calcium/phospholipid binding proteins like PKCoc/p which are activated by Ca2+ and 
DAG and ‘EF hand’ proteins like calmodulin (CaM) and S I00 proteins, which are
9+considered to exert Ca -dependent actions in the nucleus or the cytoplasm. The 
binding of Ca2+/CaM to the myosin light-chain kinase (MLCK) modulates the
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functional association between actin and myosin II and thus provides the force 
necessary for lamellipod extension and uropod retraction (231).
Chemokines have been reported to mobilise Ca2+, although the requirement for 
calcium for chemokine-mediated cell migration remains ambiguous. Immediately 
after the initial Ca release from the central store, in both the giant newt eosinophil 
(337) and Dictyostelium (338), the Ca2+ concentration falls most rapidly in the part of
2 “b  •the cell nearest the chemoattractant source so that a back-to-ffont Ca concentration 
gradient forms. This small gradient, from 250 nM in the uropod to -100 nM in the
2d-lamellipod, could be responsible for the differing functions o f Ca -dependent 
processes in the newly polarised cell. In migrating fibroblasts, a similar gradient in 
the distribution of Ca2+/CaM has also been reported (339). The Ca2+ gradient could be 
because of the relative distributions of IP3 and DAG in the newly stimulated cell 
(340). Thus giant newt eosinophils and Dictyostelium amoebae become polarized, not 
only in the distribution of major components of the cytoplasm such as nucleus and 
granules, but in the gradients of cytosolic free Ca2+ concentration and DAG 
distribution (337). A Ca gradient of this type has been difficult to demonstrate or is 
apparently absent in smaller cell types, such as human neutrophils (341), and these 
cells are able to undergo actin polymerization (342) and effective chemotaxis (343) in 
the absence of, or incidental to (344) Ca2+ signaling, which seems to be necessary for
94-eosinophil chemotaxis (345). These observations may suggest that a Ca signal is not 
essential for the generation of polarity. In the giant newt eosinophil, establishment of
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a polarized morphology may depend on elongation of the cell along an innate axis, 
determined by the arrangement of microtubules, rather than the chemotactic gradient 
(346).
This study utilised the pharmacological inhibitor 2APB which at high concentrations 
is described as an inhibitor of IP3-mediated calcium release. CCL1-mediated 
chemotaxis of HUT-78 cells was shown to be diminished in the presence o f 50-75
9-1-pM 2APB, implicating a role for Ca in CCL1-mediated T cell migration. In 
contrast, chemotaxis of CCR4-expressing CEM cells in response to CCL22/MDC 
have been shown to be insensitive to 2APB (75 pM) (Cronshaw and Ward, 
unpublished data). Taken together, these data would suggest that the dependency on
9 +Ca is cell-type, as well as chemokine receptor specific.
The second product o f PLC-mediated hydrolysis of PI(4,5)P2 is DAG, which is 
known to activate PKC. The family o f PKC consists of at least 10 isoforms, and each 
of them exhibits a unique pattern of tissue distribution, subcellular translocation, and 
function (347). The PKC isoforms can be divided into three subfamilies: classical 
PKCs (cPKCs), such as a , pi, pil, y require both Ca2+ and DAG for activation; novel 
PKCs (nPKCs), such as 8, e, ri,0, are DAG-dependent but Ca2+-independent; and 
atypical PKCs, such as £ and X require neither Ca2+ or DAG. PKC has been studied in 
many different cell types and has been shown to be important in chemotaxis in
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response to different stimuli (348-351). An impressive study which used antisense 
oligodeoxyribonucleotides (ODN) to specifically inhibit PKC(3 demonstrated that 
PKC(3 is essential for MCP-1 stimulated chemotaxis of human monocytes (352). 
PKC£ has been shown to be essential in mediating both IL-8 and fMLP-induced 
neutrophil chemotaxis and regulating the polarity of astrocytes during wound healing 
process (353,354). This study relied on the use of the pharmacological inhibitor, 
RO320432 to block PKC, which is reported to be 10-fold more selective for PKCa 
and 4 fold more selective for PKCpI over PKCS (355). CCL1-mediated cell 
migration of HUT-78 cells was abrogated in the presence of 10 j iM  RO320432. Since
^  I
the migration o f HUT-78 cells in response to CCL1 is Ca - and PKC-dependent, 
then it is likely that one of classical PKC isoforms is required for CCL1-mediated 
migration of HUT-78 cells.
Chemokines Induce a PKC-dependent Phosphorylation of PKB
The dependency on PKC in the activation of the PKB pathway is complex due to the 
differing functions o f the many PKC isoforms. Only a small number of isoforms have 
been investigated with respect to PKB, so the precise role of each isoform remains 
ambiguous. PKCs (356) (and more specifically PKC£ (357)) have been described to 
function as negative regulators of PKB activity where pre-incubation of cells with 
inhibitors led to enhanced PKB phosphorylation. In contrast, the vascular endothelial
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growth factor (VEGF) is reported to induce PKC-dependent PKB activation (358) 
which implies PKC resides upstream of PKB in this system. Similarly, PKB 
activation by a synthetic chemoattractant peptide (WKYMVm) was found to be 
dependent not only on PI3K but also on the PKC pathway (359). The data presented 
in this study is in agreement with the notion that PKC lies upstream of PKB, as 
CCL1-mediated Ser473 phosphorylation o f PKB was markedly inhibited by the PKC 
inhibitor, RO320432 in both RBL-CCR8 and HUT-78 cells.
This Study Provides the First Evidence that CCR8 is Coupled to the 
PI3K/PKB Signalling Pathway
All stimuli in lymphocytes that induce the production of D-3 phosphoinositides 
including antigen receptors, cytokines and chemokines are now known to activate 
PKB. Thus it does not come as a surprise that CCL1 stimulates the phosphorylation 
of PKB in both CCR8-expressing RBL and HUT-78 cells in this study. The 
magnitude and duration of the PKB response induced by antigen receptors and IL-2 
are similar and PKB activation by these stimuli is maintained for several hours (360). 
In contrast, chemokine activation of PKB in lymphocytes is very transient and only 
sustained for a few minutes (361). These kinetics are evident in this study where 
CCL1 stimulates the phosphorylation of Ser473 PKB as early as 30 seconds in both 
RBL and HUT-78 cells, with a diminished Ser473 phosphorylation by 1 minute in 
HUT-78 cells and 10 minutes in RBL-CCR8 cells. It is quite possible that different
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lymphocyte subpopulations will differ in their kinetic rate of PKB inactivation 
because they differ in the regulation of protein phosphatases, such as PP2A, that 
remove the activating phosphates on PKB. In addition, given that (i) the expression of 
dominant-negative constructs of class IA and class IB PI3Ks leads to partial 
inhibition o f CXCL12-stimulated PKB (287) and that (ii) activation of PKB by 
CXCL12 is prevented by PI3K inhibitors (195), it is not surprising that CCL1- 
mediated phosphorylation of PKB is also abrogated in the presence of the PI3K 
inhibitor LY294002.
Cross-talk between MAPK and PI3K/PKB Pathways
The serine/threonine kinase PAK has emerged as a molecule that can link PI3K/PKB 
to the ERK MAPK pathway. Receptor-mediated activation of Raf, the upstream MAP 
kinase kinase kinase in the ERK cascade, is Ras-dependent and involves recruitment 
of the kinase to the plasma membrane. Several groups have reported synergism 
between Rho GTPases and this pathway. It is widely reported that overexpression of 
a Rho GTPase cannot in itself lead to ERK activation, however, dominant-negative 
Rac can block Ras-dependent ERK activation in human kidney fibroblast 293 cells 
(362). Furthermore, Rac or Cdc42 can synergize with Raf to promote ERK activation 
and this synergy has been reported to occur at the level of the MAP kinase kinase, 
MEK1 (363). It turns out that PAK, which is a Cdc42 and Rac target, can 
phosphorylate MEK1 on Ser298 in a region that mediates the interaction of MEK1
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with Raf. More recent work has introduced more complexity to this cross-talk 
mechanism, since PAK can also phosphorylate Raf on Ser338, and this appears to be 
essential for integrin-mediated activation o f ERK in COS7 cells (364). Activation of 
PAK in these cells is dependent upon PI3K-dependent activation o f Rac (365), 
though in Rat-1 cells, PAK activation occurs through a PI3K-mediated activation of 
another serine/threonine kinase, PKB and independently of Rac (366). Data from our 
study showed that stimulation of RBL and HUT-78 cells with CCL1 resulted in a 
MEK-independent phosphorylation o f PKB, implying that the MAPK pathway is not 
required for the activation of PKB in this model system. Similarly, IL-3 and GM-CSF 
stimulated MC/9 cells were shown to induce a MEK-independent phosphorylation of 
PKB (367). Taken together, these published studies suggest that there is a link 
between the PI3K/PKB and Ras/Raf/MEK/ERK pathway, although PKB appears to 
lie upstream and converges with MEK through activation o f the serine/threonine 
kinase PAK.
Robust phosphorylation of ERK1/2 by CCR8 in transfected RBL cells
In accordance with the role o f the MAPK pathway in regulating cell growth and 
differentiation, activation of this pathway has been shown to mediate anti-apoptotic 
activity o f CCL1 and vMIP-I in the BW5147 lymphoma (368), however, the 
molecular machinery that links CCR8 signalling to ERK 1/2 activation in T cells has 
not been fully characterised. This study shows for the first time that CCL1-mediated
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ERK 1/2 activation follows a similar pathway to that seen by other chemokines. 
Multiple studies have implicated MEK and PKC as positive regulators of MAPK 
activation in response to various mitogenic stimuli (369-371). O f particular 
resemblance to the current investigation, activation of PKCe, MEK and ERK 1/2 were 
recently shown to participate in the regulation of MCP-1 expression on vascular 
endothelial cells by shear stress. Pharmacological inhibitors of PKCp/e (Calphostin 
C) and MEK (PD98059) were demonstrated to inhibit MCP-1 mediated ERK1/2 
activation in addition to repressing MCP-1 induction (370). The specific inhibitor of 
PKCP (Go96976) however, had no effect on either ERK 1/2 activation or MCP-1 
induction, further supporting a role for PKCe in this system. The ERK 1/2 pathway 
has, more specifically, been attributed to the regulation of thymocyte development. 
Werlen et al showed that a motif in the aP  T-cell receptor (TCR) controls positive 
thymocyte selection by modulating ERK 1/2 activity (372). Having demonstrated in 
this study that stimulation of CCR8-expressing RBL cells with CCL1 leads to 
activation o f the ERK 1/2 MAPK pathway and CCR8 is preferentially expressed in 
the thymus (31), one might speculate that CCR8 may play a role in the regulation of 
thymocyte development through activation of the ERK 1/2 MAPK cascade. Similarly, 
because the ERK 1/2 pathway also contributes to T lymphocyte immune activation 
(373), ERK1/2 activation is likely involved in the regulation of these processes by 
CCL1.
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Identification of the pathways that lead to ERK1/2 phosphorylation
Protein phosphorylation is an important molecular mechanism by which extracellular 
signals produce biological responses in cells; therefore this study examined the ability 
of CCL1 to activate protein kinase pathways in RBL-CCR8 cells. A recent study 
reports that CCR8-dependent activation of the Ras/MAPK pathway mediates anti- 
apoptotic activity of CCL1 and vMIP-I, yet the mechanisms by which this occurs has 
not been investigated. GPCRs are known to activate ERK 1/2 by numerous 
mechanisms which remain the subject of intense investigation (252), although the 
pathways that lead to chemokine-mediated ERK 1/2 phosphorylation appear to have 
some similarities. To dissect the cascade o f events leading to MAPK activation upon 
CCR8 receptor stimulation, several inhibitors of signal transduction proteins were 
used in RBL cells transfected with CCR8 receptors. This study shows that ERK1/2 
activation by CCL1 is dependent on MEK, partially dependent on PI3K and 
independent of PKC. In comparison to the well-characterised CXCR4/CXCL12 
receptor chemokine system, the signalling pathways that lead to ERK 1/2 
phosphorylation following ligation of CCR8 with CCL1 are surprisingly analogous. 
The only controversial issue with CXCL12-mediated ERK 1/2 phosphorylation is the 
dependency on PI3K. Some studies have reported ERK1/2 activation to be dependent 
on PI3K (195,374) yet others believe that it is independent (287).
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The importance of PI3K within the ERK1/2 MAPK pathway is far less understood. 
Previously, many groups have shown that chemokine-stimulated ERK1/2 activation 
in various leukocytes is inhibited by PI3K inhibitors, suggesting a PI3K-dependent 
activation of the MAPK pathway (194,195,375). IL-8, for example, was reported to 
activate the Ras/Raf/ERKl/2 pathway in human neutrophils in a PI3K-dependent 
manner. However in other studies chemokine-mediated activation of ERK 1/2 has 
proven to be refractory to PI3K inhibition (287,376). Jurkat T cell clones stably 
expressing dominant-negative constructs o f class IA and IB PI3K were shown to have 
no effect on CXCL12-induced phosphorylation of the MAPK ERK1/2 (287). 
Similarly, our study demonstrates that CCL1-mediated ERK1/2 phosphorylation is 
independent of PI3K in CCR8-expressing RBL cells. These discrepancies may be 
explained in terms of different chemokines coupling to MAPK activation via distinct 
signalling pathways.
The Role of ERK/MAPK in Chemokine-mediated Cell Migration
While MAPK signalling has been associated with the regulation of gene 
transcriptional events, evidence now suggests that MAPK can promote cell migration 
on the extracellular matrix in a transcription-independent manner. MAPK has been 
reported to directly phosphorylate MLCK, thereby increasing its ability to 
phosphorylate MLC, which promotes cytoskeletal contraction necessary for cell 
movement (377,378). Inhibition of ERK activation by the use of ERK inhibitors such
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as PD98059 abrogates CXCL12/SDF-1, M IP-3a and eotaxin-induced actin 
polymerisation and/or migration of T cells or eosinophils (195,196). However, 
chemotaxis of neutrophils in response to the chemokine IL-8 (194) or non-chemokine 
chemoattractants such as fMLP and C5a is not blocked by the MEK inhibitor 
PD98059 (379-381). Similarly, the results presented in this study revealed that 
CCL1-mediated cell migration of HUT-78 cells was also insensitive to PD98059. The 
different sensitivity to MEK inhibition of cell migration in response to chemokines 
and other chemoattractants, suggests that there are multiple pathways leading to 
leukocyte chemotaxis and highlights the fact that even though different chemokine 
receptors can share biochemical signalling pathways, there is sometimes a degree of 
redundancy with respect to the importance of those pathways in evoking a 
chemotactic response.
4.5 Concluding Remarks
This section has identified some of the signalling pathways that are mediated by the 
CCL1/CCR8 chemokine/chemokine receptor system. Firstly, this study has shown 
that CCL1 mediates a Gaj- and PLC-dependent calcium mobilisation which could 
lead to either a Ras-dependent or -independent phosphorylation o f ERK 1/2 MAPK. 
The Ras-dependent pathway may also be activated by the py G-protein subunits that 
have been previously reported to activate the Ras/ERKl/2 MAPK pathway. In 
addition, this study has shown that PI3K is partially involved in CCL1-mediated
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ERK 1/2 phosphorylation, which suggests that the PI3K-mediated Ras-dependent 
pathway can be utilised but appears not to be essential. This study has also 
demonstrated that PI3K is required, in addition to PKC, for CCL1-mediated PKB 
phosphorylation. In accordance with previously published studies, CCL1 could 
induce phosphorylation of PKB in a PLC- and PKC-dependent pathway (Figure 30). 
Finally, the data presented in this study reveals that CCL1-mediated chemotaxis of 
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Figure 30. A Model of the Signalling Pathways mediated by CCR8/CCL1
The solid lines represent pathways which have been shown in this study to be 
involved in CCL1-mediated responses. The dotted lines show potential pathways that 
have been demonstrated in different systems as outlined in chapter 1.
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Figure 31. A Model of the Signalling Pathways in CCLl-m ediated Chemotaxis
Proposed routes are shown by which PI3Ky and p85/pl 10ap5 PI3K may contribute 
to CCL1-stimulated functional events via 3'-phosphoinositide lipid dependent and/or 
protein serine kinase-dependent activity.
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Chapter 5
Results: The Role of SHIP in Regulating Chemokine-mediated Responses 
5.1 Introduction
B cells express receptors that mediate positive and inhibitory signals within the cell, 
namely the BCR and FcyRIIb receptor respectively (Figure 32). Stimulation of the 
BCR with antigen results in proliferation and secretion of soluble antigen-specific 
immunoglobulin. Co-ligation of the BCR and FcyRIIb receptor by immune 
complexes down-regulates BCR-mediated responses and prevents excess 
immunoglobulin production (382,383). The function o f the FcyRIIb receptor 
therefore prevents over-reaction of immune responses and protects against 
autoimmunity (384,385). B cells also express a small subset o f chemokine receptors 
that guide the movements o f re-circulating B cells within lymphoid tissues and 
include CXCR5, CCR7 and CXCR4 (386).
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Figure 32 Positive and Negative Signalling in B Cells
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Previous research has shown that the FcyRIIb-mediated inhibitory effects are largely 
dependent on the 5’ lipid phosphatase SHIP, where SHIP catalyzes removal of the 5- 
phosphate of PI(3,4,5)P3 and thus reduces the levels of PI(3,4,5)P3 within the cell. 
The purpose of this study was to investigate whether the FcyRIIb-mediated 
recruitment/activation of SHIP is able to regulate PI(3,4,5)P3 accumulation and 
PI(3,4,5)P3-dependent biochemical and functional events elicited by G protein- 
coupled chemokine receptors. The GPCR investigated in this section of the study was 
the chemokine receptor CXCR4, since it is constitutively expressed on lymphoid 
cells. In addition, it is the best characterised chemokine receptor, so tools and 
reagents are readily available for its biochemical and functional analysis.
The functional role o f SHIP in the regulation of BCR-mediated responses was first 
examined using a B cell model in which the effects of co-ligating the BCR and 
FcyRIIb receptor on BCR-mediated responses were examined. Co-ligation o f the 
BCR and FcyRIIb receptor was shown to attenuate BCR-mediated calcium 
mobilisation (387), ERK1/2 (225) and PKB phosphorylation (216) The initial 
experiments were designed to verify that co-ligation of the BCR and FcyRIIb receptor 
resulted in (i) the tyrosine phosphorylation of SHIP, and (ii) impaired BCR-mediated 
responses, such as calcium mobilisation, PI(3,4,5)P3 accumulation and ERK 1/2 and 
PKB phosphorylation in the B lymphoma cell line A20. The aim was then to 
determine if the FcyRIIb-mediated tyrosine phosphorylation of SHIP inhibited the 
responses induced by independently activated receptors, such as the chemokine
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receptor CXCR4. This study also utilized a Jurkat T cell model that expresses a 
tetracycline-regulated, constitutively active SHIP mutant, in order to study the direct 
effects of SHIP activity on CXCL12-mediated responses.
In this study, F(ab’)2 fragments of rabbit anti-mouse IgG (RAMIG) were used to 
stimulate the murine BCR and intact RAMIG was used to co-ligate the BCR with the 
FcyRIIb receptor.
Co-aggregation of the BCR and FcyRIIb Receptor Blocks Downstream 
Responses in A20 cells
Engagement of the BCR with antigen induces the PI3K-dependent accumulation of 
PI(3,4,5)P3 leading to the recruitment of PH domain-containing proteins such as the 
protein tyrosine kinase, Btk. Phosphorylation and activation of PLCy by Btk results in 
the hydrolysis of PI(4,5)P2 generating IP3 and DAG. The release of calcium, in 
response to IP3/IP3R ligation, regulates many cellular processes, including gene 
transcription, proliferation and antibody production. To verify that co-ligation o f the 
BCR and FcyRIIb receptor inhibits BCR-mediated calcium mobilisation, A20 cells 
were pre-loaded with Fura-2 (5 pM) for 30 minutes and then stimulated with either 
10 JLig/ml of F(ab’)2 fragments of RAMIG or 15 jig/ml of intact RAMIG. These 
results show that stimulation of the BCR alone with F(ab’)2 fragments of RAMIG
1
leads to an increase of intracellular Ca from a basal level of 100 nM to 1000 nM.
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IThe BCR-induced Ca signal was notably inhibited following co-ligation of the BCR 
and FcyRIIb receptor with intact RAMIG (Figure 33).
Recruitment o f SHIP to FcyRIIb and its subsequent activation following co-ligation 
o f the BCR and FcyRIIb receptor has been reported (221,383). A20 cells were 
stimulated at intervals between 1 and 60 minutes with either 10 pg/ml of F(ab’)2 
fragments of RAMIG or 15 |Lig/ml of intact RAMIG. Western blot analysis of anti- 
SHIP immunoprecipitates, probed with an anti-phospho tyrosine antibody, 4G10, 
revealed a modest and transient tyrosine phosphorylation o f SHIP at 5 minutes 
following activation of the BCR alone. However, subsequent to co-ligation o f the 
BCR and FcyRIIb receptor with intact RAMIG, the tyrosine phosphorylation of SHIP 
was shown to be prolonged and more robust between 1 and 30 minutes (Figure 34).
Previous reports have shown that tyrosine phosphorylation of SHIP leads to an 
enhanced catalytic activity o f SHIP, that is the ability of SHIP to reduce PI(3,4,5)P3 
to PI(3,4)P2 (388). To verify that the enhanced tyrosine phosphorylation o f SHIP 
correlated with increased catalytic activity following BCR and FcyRIIb receptor co­
ligation, PI(3,4,5)P3 levels and PKB phosphorylation were monitored. Since PKB is 
fundamentally dependent on PI(3,4,5)P3 accumulation, then inhibition of PI(3,4,5)P3 
accummulation should be reflected in the attenuation of PKB phosphorylation. A20 
cells stimulated for 1 minute with F(ab’)2 fragments of RAMIG led to an increase of 
PI(3,4,5)P3 above control. This response was abrogated following the co-ligation of
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the BCR and FcyRIIb receptor with intact RAMIG (Figure 35). Similarly, stimulation 
o f A20 cells with F(ab’)2 fragments of RAMIG for 5 minutes resulted in a marked 
phosphorylation o f PKB above control levels, yet stimulation of cells with intact 
RAMIG reduced this response to basal levels (Figure 36).
In addition to its catalytic activity, SHIP has been reported to function as an adapter. 
The SH2 domain o f SHIP is thought to interact with the PTB domain o f She, 
displacing the Shc/Grb2 complex and thus uncoupling the Ras pathway from BCR 
signalling (389). This section of the study focusses on the Ras/MAPK pathway to 
verify if co-ligation o f the BCR and FcyRIIb receptor would have similar inhibitory 
effects as seen on the PI3K pathway. Once again, A20 cells were stimulated for 5 
minutes with either F(ab’)2 fragments of RAMIG or intact RAMIG. Since 
phosphorylation of ERK 1/2 is necessary for its activation, a phospho-ERKl/2 
antibody was used to monitor ERK 1/2 phosphorylation as an indirect marker o f ERK 
activation. Using this approach, it was apparent that 5 minute stimulation with F(ab’)2 
fragments of RAMIG resulted in a robust phosphorylation of ERK1/2, compared to a 
diminished response following co-ligation o f the BCR and FcyRIIb receptor (Figure 
36).
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Figure 33. Co-ligation of the BCR and FcyRIIb Receptor Inhibits the 
Intracellular Ca2+ Mobilisation in A20 cells
Intracellular free calcium concentration ([Ca2+]0 of A20 cells was determined by pre- 
loading the cells (2x l06/ml/sample) with 5 pM of Fura-2 AM at 37°C for 30 minutes. 
Cells were washed free of excess Fura-2 using HBSS buffer supplemented with 100 
pM Ca2+ and 1 mM Mg2+ and re-suspended at 2 x l0 6/ml. Fura-loaded cells were 
aliquoted into a 2-ml cuvette. To the cell suspension 20 pi of a 100 mM calcium 
chloride stock (final [1 mM]) was added and allowed to equilibrate at 37°C in the 
spectrofluorimeter for 5 minutes. Prior to the addition o f the agonists, a basal Ca2+ 
measurement was taken for 30 seconds. The agonist-induced responses, with either 
intact RAMIG (15 pg/ml) or F(ab’)2 fragments o f RAMIG (10 pg/ml) were 
monitored for at least 500 seconds and were detected on the spectrofluorimeter 
(Photon Technologies). Data are from a single experiment representative of 2 others.
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Figure 34. SHIP is a Target of BCR-activated Phosphotyrosine Kinases.
A20 cells were aliquoted in 0.5 ml at lx l0 7cells/ml and either left unstimulated (C) or 
stimulated for the indicated time with either 10 |ig/ml of F(ab’)2 fragments of 
RAMIG or 15 |Ug/ml o f intact RAMIG. SHIP was subsequently immunoprecipitated 
from cell lysates using a goat anti-SHIP polyclonal antibody. Immunoblotting with 
the anti-phosphotyrosine antibody 4G10 was used to detect tyrosine phosphorylated 
SHIP. Data are from a single experiment representative o f 2 others.
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Figure 35. Co-ligation of BCR and FcyRIIb Receptor Reduces the Levels of 
PI(3,4,5)P3 in A20 Cells.
A20 (2xl07/ml) cells were labelled with [32P] orthophosphoric acid for 1.5 h. 
Following the removal o f un-incorporated label, cells (2xl06/ml) were either left 
unstimulated (Ctrl) or stimulated with either F(ab’)2 fragments of RAMIG or intact 
RAMIG for 1 minute. Reactions were terminated with chloroform/methanol/water, 
and phospholipids extracted, deacylated and fractionated by HPLC. Data are from a 
single experiment representative of 3 others.
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Figure 36. Co-ligation of the BCR and FcyRIIb Receptor Reduces BCR- 
mediated PKB and ERK1/2 phosphorylation in A20 Cells.
A20 cells were aliquoted in 0.5 ml at 2x 106cells/ml and left unstimulated (C) or 
stimulated for 5 minutes with either 10 pg/ml of F(ab’)2 fragments of RAMIG or 15 
ftg/ml o f intact RAMIG. The equivalent to 2 x l0 5 cells of each sample was separated 
by SDS-PAGE. Immunoblotting with either the Ser473 PKB (A) or p44/42 
phosphospecific ERK1/2 (B) antibody was used to detect phosphorylated PKB and 
ERK1/2. The immunoblot was stripped and reprobed with the pan-ERK antibody that 
recognises both phosphorylated and non-phosphorylated forms of ERK to allow 
parity of loading to be examined (C). Data are from a single experiment 
representative of 2 others.
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SHIP is Not a Target of CXCL12-activated Phospho-tyrosine Kinases
The next step was to establish whether CXCL12-mediated responses led to the 
tyrosine phosphorylation of SHIP and whether stimulation of CXCR4 influenced the 
kinetics of FcyRIIb-mediated tyrosine phosphorylation of SHIP. A20 cells were either 
stimulated with CXCL12 alone for the indicated times, or with intact RAMIG in 
addition to CXCL12. Western blot analysis of SHIP immunoprecipitates using anti- 
phosphotyrosine antibodies revealed that SHIP was not tyrosine phosphorylated 
following stimulation of CXCR4 alone and that FcyRIIb-mediated tyrosine 
phosphorylation of SHIP was not affected following stimulation of CXCR4 (Figure 
37).
Co-ligation of the BCR and FcyRIIb Receptor Abrogates CXCL12-
stimulated ERK1/2 and PKB phosphorylation in A20 Cells
To investigate whether FcyRIIb-activated SHIP can inhibit biochemical signals 
elicited by CXCR4, the effects o f co-ligating the BCR and FcyRIIb receptor on 
CXCL12-mediated PKB and ERK1/2 phosphorylation were examined. The data 
presented in Figure 37 show that stimulation of A20 cells with 10 nM of CXCL12 for 
2 minutes induced a robust PKB and ERK1/2 phosphorylation (lane 2), compared to 
the unstimulated control (lane 1). Co-ligation of the BCR and FcyRIIb receptor 
resulted in the phosphorylation of PKB and ERK1/2 at low concentrations but higher
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concentrations resulted in a gradually diminished signal (lanes 3-7). This is 
presumably because low concentrations of RAMIG would bind predominantly to the 
BCR, whereas higher concentrations also bind to the lower affinity FcyRIIb receptor, 
which elicits inhibitory effects that counteract the positive signals from the BCR. In 
contrast, activation of the BCR alone with F(ab’)2 fragments o f RAMIG showed a 
concentration-dependent PKB and ERK1/2 phosphorylation (lanes 13-17). Pre­
incubation of cells for 30 minutes with 150 |ig/ml of intact RAMIG, which failed to 
elicit significant phosphorylation of PKB/ERK1/2 above basal levels, followed by 
stimulation with 10 nM of CXCL12 for 2 minutes, resulted in the inhibition of both 
PKB and ERK1/2 phosphorylation (lane 12), when compared to stimulation with 
CXCL12 alone (lane 2) (Figure 38).
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Figure 37. SHIP is Not a Target of CXCL12-activated Phospho-tyrosine Kinases
A20 cells were aliquoted in 0.5 ml at lx l0 7cells/ml and either left unstimulated (C) or 
stimulated for the indicated time with either 10 |Lig/ml F(ab’)2 or 15 |ig/ml intact 
RAMIG (A), or either 10 nM CXCL12 or 15 (ig/ml of intact RAMIG and 10 nM 
CXCL12 (B). (Figure 35A is the same experiment as Figure 32 and is duplicated here 
for ease of analysis.) SHIP was subsequently immunoprecipitated from cell lysates 
using a goat anti-SHIP polyclonal antibody. Immunoblotting with the anti- 
phosphotyrosine antibody 4G10 was used to detect tyrosine phosphorylated SHIP. 
Data are from a single experiment representative of 2 others.
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Figure 38. Co-aggregation of the BCR and FcyRIIb Receptor Reduces CXCL12- 
stimulated Phosphorylation of PKB and ERK1/2.
A20 cells (2x l06/ml) were either left unstimulated, (C) (lane 1); or stimulated with 
either 10 nM of CXCL12 for 2 minutes (lane 2), or 1.5-150 pg/ml o f intact RAMIG 
for 30 minutes (lanes 3-7), or 1-100 pg/ml o f F(ab’)2 fragments of RAMIG for 30 
minutes (Janes 13-17). Additionally, some cells were pre-incubated with RAMIG for 
30 minutes prior to addition of 10 nM CXCL12 for a further 2 minutes. The 
equivalent to 2 x l0 5 cells o f each sample was separated by SDS-PAGE. 
Immunoblotting with either the p44/42 phosphospecific ERK1/2 or Ser473 PKB 
antibody were used to detect phosphorylated ERK1/2 and PKB. Data are from a 
single experiment representative o f 2 others.
Chapter 5: Results and Discussion 2 154
The Effect of Expressing a Constitutively Active SHIP Mutant on 
CXCL12-mediated PI(3,4,5)P3 levels and PKB Phosphorylation in the 
Jurkat Leukaemic T cell Line
Having demonstrated that tyrosine phosphorylation of SHIP in B cells correlates with 
a reduction of CXCL12-mediated PKB and ERK1/2 phosphorylation (Figure 38), 
attention was turned to a T cell model which expresses a tetracycline-regulated, 
constitutively active SHIP mutant. The Jurkat T cell line, which does not normally 
express either phosphatases SHIP or PTEN (388), were stably transfected with a 
chimeric protein which contained the phosphatase core o f SHIP-1 fused to the 
extracellular/transmembrane region of the rat CD2 (CD2:SHIP) (293). The resulting 
membrane-localised SHIP catalytic domain was characterised as exhibiting 
constitutive 5’-inositol lipid phosphatase activity. As a negative control Jurkat cells 
were also transfected with a point-mutated version of SHIP-1, in which the cysteine 
residue at position 701 within the catalytic signature motif was mutated to alanine 
(CD2:C701ASHIP). This mutant retains some activity, although it is at least 10-fold 
less active than CD2:SHIP (293).
CXCL12 stimulation experiments were conducted in CD2:SHIP clones in the 
presence or absence of expression (i.e., precultured without or with tetracycline, 
respectively). In response to CXCL12 stimulation, increases in PI(3,4,5)P3 above 
basal were detected after 30 seconds in nonexpressing, CD2:SHIP clones (i.e., cells
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incubated in the presence of tetracycline). The expression of CD2:SHIP (i.e., clones 
incubated in the absence of tetracycline) led to a 33% inhibition of CXCL12- 
stimulated PI(3,4,5)P3 (Figure 39). The inhibition of chemokine-stimulated 
PI(3,4,5)P3 by CD2:SHIP confirms that this construct does indeed disrupt PI(3,4,5)P3, 
by reducing PI(3,4,5)P3 to PI(3,4)P2. The extent of PI3K activation can also be 
assessed indirectly by monitoring the phosphorylation of the serine/threonine kinase 
PKB, whose recruitment and subsequent activation is entirely dependent on D-3 
phosphoinositide lipid accummulation (167). CXCL12 stimulation time-course 
experiments were conducted in CD2:SHIP and CD2:C701ASHIP clones in the 
presence or absence of expression. CXCL12-mediated increases in PKB 
phosphorylation above basal were detected after 1 minutes in nonexpressing, 
CD2:SHIP clone (Figure 40(i), lanes 1, 3, 5, 7 and 9). The expression of CD2.SHIP 
led to an inhibition of basal and CXCL12-stimulated PKB phosphorylation (Figure 
40(i), lanes 2, 4, 6, 8, and 10). CXCL12-mediated increases in PKB phosphorylation
701above basal were detected after 2 minutes in nonexpressing, CD2:C ASHIP clones 
(Figure 40(ii), lanes 1, 3, 5, 7 and 9). However, expression of CD2:C701 ASHIP did 
not result in the inhibition of CXCL12-mediated PKB phosphorylation (Figure 40(ii), 
lanes 2, 4, 6, 8, and 10). CD2:SHIP and CD2:C701 ASHIP expression was assessed by 
probing immunoblots with a rCD2 antibody (Figure 40(ii)).
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The Effect of a Constitutively Active SHIP mutant on CXCL12-mediated
Chemotaxis
PI3Ks and their lipid product PI(3,4,5)P3 have been widely implicated in controlling 
cell migration and polarity (390). During leukocyte chemotaxis, type IA PI3Ks are 
required for lamellipodium extension and migration towards colony-stimulating 
factor 1 (CSF-1) (391), whereas type IB PI3Ks are required for neutrophil chemotaxis 
to a variety o f inflammatory mediators that signal via GPCRs (201,392,393). 
Moreover, optimal chemotactic response of leukemic T cells to CXCL12 requires the 
activation of both class IA and class IB PI3K (287). On the understanding that SHIP 
can de-phosphorylate PI(3,4,5)P3 to PI(3,4)P2, it would be plausible to speculate that 
SHIP may inhibit the directional movement of cells in response to a given 
chemoattractant stimulus. Experiments were designed to determine whether SHIP 
plays a role in the regulation of CXCL12-mediated chemotaxis. These data showed 
that chemotaxis of SHIP-expressing Jurkat cells (CD2:SHIP) in response to CXCL12 
was markedly inhibited compared to cells not expressing SHIP. However, cells 
expressing the inactive form of SHIP (CD2:C701A SHIP) responded to CXCL12 
with a similar chemotactic index compared to those not expressing the inactive 
mutant (Figure 41).
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Figure 39. The Effect of a Constitutively Active SHIP m utant on CXCL12- 
mediated Lipid Accumulation
Jurkat cells stably transfected with CD2:SHIP were cultured overnight with or 
without Tetracycline (TET) (2 pg/ml) and subsequently labelled with [32P] 
orthophosphoric acid for 4 h. Following the removal of un-incorporated label, cells 
(2x l07/ml) were stimulated with CXCL12 (10 nM) for 30 seconds. Reactions were 
terminated with chloroform/methanol/water, and phospholipids extracted, deacylated 
and fractionated by HPLC. 18 and 33% represents the percentage inhibition of 
PI(3,4,5)P3 accumulation caused by expressing CD2:SHIP. The percentage inhibition 
o f CD2:SHIP expression are shown on the graph (A). Samples o f cells prior to 
labelling were lysed and western blotted with anti-rCD2 mAb 0X 34 to confirm the 
expression of the construct upon removal o f tetracycline (B). These data are from a 
single experiment representative o f 3 others.
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Figure 40. The Effect of a Constitutively Active SHIP M utant on CXCL12- 
mediated PKB phosphorylation.
Jurkat cells, stably transfected with CD2:SHIP (i) or CD2:C701A SHIP (ii), were 
cultured overnight either with (+, lanes 1, 3, 5, 7 and 9) or without (-, lanes 2, 4, 6, 8 
and 10) tetracycline (tet) (2 pg/ml). 0.5 ml aliquots at 2x l06cells/ml were either left 
unstimulated (C) or stimulated with 10 nM CXCL12 for the times indicated. The 
equivalent to 2 x l0 5 cells of each sample was separated by SDS-PAGE.47^Immunoblotting with either the anti-rCD2 (top panel) or Ser PKB {bottom panel) 
antibody was used to determine the expression o f CD2:SHIP/CD2:C70IASHIP or to 
detect phosphorylated PKB. These data are from a single experiment representative 
of 2 others.
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Figure 41. The effect of a Constitutively Active SHIP m utant on CXCL12- 
mediated Chemotaxis
Jurkat cells transfected with either the CD2:SHIP or CD2:C701 ASHIP construct were 
incubated for 24 h in media in the presence and absence o f tetracycline (Tet). Cells 
( lx l0 6/ml) were subsequently aliquoted in a 96-well chemotaxis chamber along with 
10 nM CXCL12 and incubated at 37°C for 1.5 h. Results are expressed as a mean 
chemotactic index (+/- SEM), which is the ratio of OD readings of the stimulated 
samples against the OD readings o f the control samples incubated with medium 
alone, from quadruplicate wells (A). Data were analysed by Student’s t test to 
compare responses in the presence and absence of SHIP expression (***, p < 
0.00005). Samples o f cells from the chemotaxis experiment were lysed and western 
blotted with anti-rCD2 mAb 0X 34 to confirm the expression o f the construct upon 
removal o f tetracycline (B). These data are from a single experiment representative o f 
3 others.
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Summary of Findings
• Co-ligation of the BCR and FcyRIIb receptor resulted in a prolonged and 
more robust tyrosine phosphorylation of SHIP compared to that seen 
following activation of the BCR alone in A20 cells.
• The augmented tyrosine phosphorylation of SHIP directly correlated with a 
reduction in lipid accumulation as well as in the phosphorylation of both 
ERK1/2 and PKB in A20 cells.
• CXCL12 stimulation did not induce tyrosine phosphorylation of SHIP in A20 
cells.
• Concurrent activation of FcyRIIb receptor and CXCR4 did not influence the 
kinetics of the tyrosine phosphorylation of SHIP in A20 cells.
• Co-ligation of the BCR and FcyRIIb receptor led to the inhibition of 
CXCL12-stimulated ERK1/2 and PKB phosphorylation in A20 cells.
• Using a leukaemic T cell line which expresses an inducible constitutively 
active SHIP mutant (CD2:SHIP), we demonstrated that the induction o f SHIP 
expression led to a substantial inhibition of CXCL12-stimulated PKB 
phosphorylation, lipid accumulation and chemotaxis. These effects were not 
observed in T cells expressing an inactive form of SHIP (CD2:C701 ASHIP).
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5.2 Discussion
The FcyRIIb Receptor Regulates BCR-mediated Responses
Many studies have demonstrated that co-ligation of the BCR and FcyRIIb receptor 
results in the recruitment of SHIP and subsequent reduction in PI3K-dependent, 
BCR-mediated responses, such as antibody production and proliferation 
(221,383,394,395). The catalytic function of SHIP converts PI3K-dependent 
PI(3,4,5)P3 to PI(3,4)P2 and thus prevents the binding of PH domain-containing 
proteins like Btk and PKB from binding to PI(3,4,5)P3.
In view of the fact that chemokines are known to induce PI3K-dependent responses, 
we aimed to determine whether a reduction in FcyRIIb-mediated PI(3,4,5)P3 by SHIP 
would inhibit biochemical and functional responses elicited by chemokines. Using 
the B lymphoma cell line A20 as a model, the effects of co-ligating the BCR and 
FcyRIIb receptor were first examined to validate our system. The data presented in 
this section verified that co-ligation of the BCR and FcyRIIb receptor attenuated 
BCR-mediated calcium mobilisation, PI(3,4,5)P3 accumulation and PKB and ERK1/2 
phosphorylation. Similarly, co-ligation o f the BCR and FcyRIIb receptor was also 
found to inhibit CXCL12-mediated PKB and ERK1/2 phosphorylation.
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The second model used in this study to establish whether SHIP can regulate 
chemokine signalling and chemotaxis was the Jurkat T cell model, which expresses a 
tetracycline-regulated, constitutively active SHIP mutant. SHIP-expressing Jurkat 
cells were found to inhibit CXCL12-mediated PI(3,4,5)P3 accumulation, PKB 
phosphorylation and cell migration, compared to non-expressing cells.
Co-ligation of the BCR and FcyRIIb Receptor Inhibits CXCL 12- 
mediated ERK1/2 and PKB Phosphorylation
The interaction of SHIP with the ITIM motif of the FcyRIIb receptor is well 
documented by D ’Ambrosio et al (1996) (212) and Fong et al (1996) (213), although 
the effects SHIP may exert on other independently activated receptors is ill defined. It 
is evident from the results o f this research that activation of SHIP is dependent on the 
co-ligation of the BCR and FcyRIIb receptor, as assessed by the inability of CXCL12 
to induce the tyrosine phosphorylation of SHIP. Moreover, co-ligation of the BCR 
and FcyRIIb receptor prior to CXCL 12 stimulation did not influence the tyrosine 
phosphorylation of SHIP following co-ligation alone. In contrast, ligation of the 
FcyRIIb receptor prior to CXCL12 stimulations, led to the inhibition of both ERK1/2 
and PKB when compared to CXCL 12 responses alone.
We have been unable to demonstrate a direct association between CXCR4 and SHIP, 
however, SHIP may yet interact with CXCR4 via its SH2 domain and the failure to
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detect CXCR4-SHIP complexes may be explained if this association occurs at very 
low stoichiometry and thus, below the detectable limits of the immunoblotting assay 
used in this study. Alternatively, the CXCR4-SHIP associations may be o f low 
affinity, such that they are easily disrupted by the NP40 detergent present in the cell 
lysis buffer used in this study.
Given the lack o f a recognised SHIP-binding motif within the CXCR4 cytoplasmic 
tail, it is possible that CXCR4 couples to SHIP via intermediate adaptor molecules. 
The presence of proline-rich domains, SH2 domains and binding sites for 
phosphotyrosine binding domains within SHIP gives it the potential for diverse 
biochemical interactions with a plethora o f other proteins. If such protein complexes 
do exist, they may occur very transiently and at low stoichiometry and/or affinity 
such that they may not be maintained or detected in the CXCR4 immune complexes 
using the approaches described in this study. Although the mechanisms by which 
CXCR4 interacts with SHIP remain unclear, CXCR4 is reported to activate the 
protein tyrosine phosphatase (PTP) SHP2 (396). Tyrosine-phosphorylated SHP2 can 
act as an adaptor molecule and has been shown to bind to SHIP as well as several of 
the src-related tyrosine kinases, lyn and fyn (397-399). Association of SHIP with 
SHP2 occurs through the direct interaction of the SH2 domain of SHIP with a 
pYXN(I/V) sequence within SHP2 (398). Hence, it is possible that SHP2 may be 
involved in mediating tyrosine phosphorylation of either intermediate proteins or 
SHIP in response to CXCR4 ligation.
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Although the CXCR4-stimulated increase in enzyme activity present in SHIP 
immunoprecipitates correlates with tyrosine phosphorylation, a requirement for 
tyrosine phosphorylation in SHIP activation remains to be established. Nevertheless 
the data from this study appear to contradict observations in other systems where 
SHIP has been reported to be negatively regulated by tyrosine phosphorylation (400). 
Moreover, the enzymatic activity of SHIP immunoprecipitated from growth factor- 
stimulated cells is the same as that derived from unstimulated cells, but if SHIP is 
immunoprecipitated from these cells with anti-phosphotyrosine or anti-Shc 
antibodies, then much more enzyme activity can be obtained from growth factor- 
stimulated cells (401). Our data indicate that T cells may possess an entirely different 
means for SHIP activation after CXCR4 ligation, although at present what function 
the tyrosine phosphorylation of SHIP serves is still unclear. One possibility is that 
tyrosine phosphorylation o f SHIP is required for its relocalisation to the plasma 
membrane, since phosphotyrosine residues may mediate interaction with adaptor 
proteins.
The Mechanisms which Lead to FcyRIIb-dependent Activation of SHIP
It is possible that the inhibition of CXCL12-mediated, PI3K-dependent PKB 
phosphorylation occurs through a similar mechanism to that described for BCR- 
mediated responses by Carver et al (2000) (218), where PKB is prevented from
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relocating to the membrane as a result o f SHIP-mediated PI(3,4,5)P3 degradation 
(Figure 42).
FcyRIIb BCR
Prnlife ration  
A ntibody production
C hem otaxis
Figure 42. The Catalytic Activity of SHIP Reduces the Levels of PI(3,4,5)P3 in 
the Cell
Co-ligation o f the BCR and FcyRIIb receptor leads to the recruitment of SHIP to the 
ITIM motif o f FcyRIIb and subsequent reduction in PI(3,4,5)P3. This catalytic role of 
SHIP inhibits BCR-mediated, PI3K-dependent responses such as proliferation and 
antibody production. FcyRIIb-mediated reduction of PI(3,4,5)P3 by SHIP, may also 
inhibit PI3K-dependent responses mediated by independently activated receptors 
such as chemokine receptors. For instance, PI(3,4,5)P3 plays a central role in 
chemotaxis. An initial burst o f GPCR-stimulated PI3Ky-dependent PI(3,4,5)P3 
accumulation could activate GTP exchange factors of the Rho/Rac family o f small 
GTPases via activation o f the exchange factor P-Rex-1, which is simultaneously 
activated by PI(3,4,5)P3 and py subunits. Motifs on the p85 subunit mediate 
activation o f PI3Ks by the small GTPase R acl, which promote further PI(3,4,5)P3 
accumulation. Red lines represent positive and blue lines represent inhibitory 
signalling pathways.
It is evident that co-ligation o f the BCR and FcyRIIb receptor does not lead to the 
complete inhibition of phosphorylated PKB. Since SHIP catalyses the
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dephosphorylation o f PI(3,4,5)P3 to generate PI(3,4)P2 and PKB has been shown to 
bind PI(3,4,5)P3 and PI(3,4)P2 with equal affinities, the actions of this phosphatase 
would not reduce the entire pool of lipids capable of binding PKB. Thus, the actions 
of PTEN would likely have a greater negative impact on the activation of PKB than 
SHIP. Although the PH domain of PKB has been reported to have dual specificity for 
both PI(3,4,5)P3 and PI(3,4)P2 (402,403), there are substantial in vitro data suggesting 
that PI(3,4)P2 has a higher affinity than PI(3,4,5)P3 for PKB (404-406). The addition 
o f di-C16-PI(3,4)P2 to serum-starved NIH3T3 cells stimulates PKB 
autophosphorylation, while di-C16-PI(3,4,5)P3 causes slight inhibition (404). Studies 
in platelets have also shown that PKB activation correlates with PI(3,4)P2 rather than 
PI(3,4,5)P3 production following thrombin stimulation (404), while integrin cross- 
linking has been reported to generate PI(3,4)P2 but not PI(3,4,5)P3, yet still results in 
PKB activation (407). More recently, it has been suggested that PI(3,4)P2 is essential 
for phosphorylation o f PKB at Ser473 (408). In contrast, a high ratio o f PI(3,4,5)P3 
relative to PI(3,4)2 has been demonstrated to favour PKB activation in T cells, given 
the robust membrane localisation of the PKB-PH domain in unstimulated Jurkats. 
Moreover, the expression of a constitutively active SHIP protein in Jurkat cells was 
shown to cause large increases in PI(3,4)P2 levels that correlated with a reduction in 
Ser473 phosphorylation and relocalisation of GFP-tagged PKB PH domains from the 
plasma membrane to the cytosol (293). Thus, taken together, these studies 
demonstrate that the specificity of PKB for PI(3,4)P2 and PI(3,4,5)P3 remains unclear.
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Three pathways have been described to explain the possible mechanism behind 
FcyRIIb-mediated inhibition of the MAP kinase ERK1/2. Firstly, Hashimoto et al 
(1998) (224) suggested that SHIP inhibits PLCy-induced PKC activation by blocking 
the initial translocation of Btk to the membrane. Secondly, Tridandipani et al (1997) 
(225,389) proposed that SHIP in addition to its catalytic activity, functions as an 
adapter. p62dok, a Ras GAP-associated protein, is highly tyrosine phosphorylated in a 
Lyn-dependent manner upon crosslinking of the BCR with FcyRIIB (409). SHIP 
functions as an adaptor, binding She and p62dok. The interation between p62dok and 
SHIP is mediated by the PTB domain of p62dok and requires tyrosine phosphorylation 
of SHIP, suggesting that it is mediated by phosphorylated NPXY motifs in SHIP. The 
binding of p62dok to RasGAP is thought to inhibit the Raf/MEK/ERK pathway 
through inactivation o f Ras (227). In addition, the association of SHIP with She 
reduces the interaction o f Shc-Grb2 and attenuates the activation of Ras, Raf and 
MAPK induced by positive BCR signalling (389,410). These results show that SHIP 
inhibits cellular activation through competitive binding (Figure 43).
The mechanism whereby SHIP inhibits chemokine-mediated ERK1/2 
phosphorylation may also involve SHIP competing with Grb2 for the binding o f She 
(Figure 44). Several non-receptor tyrosine kinases (NRTKs) and receptor tyrosine 
kinases (RTKs) have been proposed to participate in the pathway linking GPCRs to 
Ras-MAPK (411). Src or Src-like kinases can mediate the phosphorylation o f She 
provoked by P-adrenoceptors and py-subunits (412). In this case, Src stimulation
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appears to require the recruitment o f p-arrestin to GPCR kinase 2 (GRK2)- 
phosphorylated P-adrenoceptors, followed by receptor internalisation and the 
consequent formation of molecular complexes between P-arrestin and Src (413). 
Alternatively, Src can be activated by direct interaction with Goij and G a s (414) or p3- 
adrenoceptors (415). Therefore it is possible that FcyRIIb-mediated recruitment o f 
SHIP could block the formation of Shc/Grb2/Sos complexes induced by antigen as 
well as chemokines.











Figure 43. A Diagram High-lighting the Adaptor Function of SHIP in the 
Inhibitory Regulation of BCR-mediated ERK1/2 Phosphorylation
Stimulation of the BCR with antigen leads to activation o f the ERK1/2/MAPK 
pathway via assembly o f the Shc/Grb2/Sos complex (1). Two mechanisms involving 
the adaptor function o f SHIP have been proposed to inhibit the ERK1/2/MAPK 
pathway: SHIP competes with Grb2 for binding to She and blocks the formation of 
the Shc/Grb2/Sos complex (IA ); or SHIP is recruited to the FcyRIIb receptor and 
binds the RasGAP docking protein p62dok, inhibiting the ERK1/2/MAPK pathway 
through inactivation of Ras (IB).
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5.3 Concluding Remarks
The expression of chemokine receptors on lymphoid cells helps to guide the 
movements of re-circulating lymphocytes within lymphoid tissues (11,416). These 
'lymphoid' or 'homeostatic' chemokines include CXCL12/SDF1, CXCL13/BLC, 
CCL19/ELC and CCL21/SLC. CXCR5 directs B cells to the follicle within a 
secondary lymphoid organ (spleen, lymph nodes, Peyer's patches and tonsil) where 
they can encounter antigen (138,417). The antigen-engaged B cell up-regulates the 
expression of CCR7, guiding its movements to the boundary of the follicle and T cell 
zone, where it receives T cell help (122,418,419). The B cells then undergo 
proliferation and many of the dividing cells begin making secretory immunoglobulin 
and become plasmablasts (420). This process is paralleled with a decreased 
responsiveness to both CXCR5 and CCR7 and increased responsiveness to CXCR4 
(421,422).
Some plasma cell precursors, directed by CXCR4, leave the spleen and migrate to the 
bone marrow via the blood. In the lymph node, after activation and differentiation, 
plasmablasts travel to the medullary cords in a partially CXCR4-dependent manner. 
In this compartment they may terminally differentiate to plasma cells or pass into 
medullary sinuses to exit from the lymph node via the lymph. Carried into 
circulation, IgM or IgG plasma cell precursors may home to the bone marrow in a 
CXCR4-dependent manner (386). Thus, CXCR4 is not only required for plasmablasts
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to migrate from the junction zones into the red pulp during terminal differentiation to 
plasma cells but also for the homing of plasma cells to the bone marrow.
FcyR IIb
In the setting described above, co-ligation of the BCR and FcyRIIb may not only 
function to reduce antibody production but also inhibit CXCR4-mediated trafficking 
of antibody secreting cells.
ERK1/2
Figure 44. A Diagram High-lighting the Adaptor Function of SHIP in the 
Inhibitory Regulation of CXCL12-mediated ERK1/2 Phosphorylation
G(3Y subunits have been shown to induce ligand-independent tyrosine phosphorylation 
of RTKs leading to activation o f the ERK1/2/MAPK pathway via assembly o f the 
Shc/Grb2/Sos complex (1). Co-ligation o f the BCR and FcyRIIb results in the 
recruitment of SHIP which has been shown to compete with Grb2 for the binding of 
She. It is possible that FcyRIIb-mediated recruitment of SHIP could block the 
formation of Shc/Grb2/Sos complexes induced by antigen as well as chemokines (2).
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Chapter 6
Results: The Importance of PI3K-C2P in CXCR4 Internalisation 
6.1 Introduction
At present, much of the information concerning the molecular mechanisms for GPCR 
sequestration and down-regulation is derived from the studies of P2-adrenergic 
receptors (P2-AR). This system has demonstrated the importance of adaptor proteins 
such as clathrin, P-arrestin and adaptin-2 (AP2) and enzymes such as Rab GTPases 
and PI3Ks in the regulation of signalling and internalization. Due to the large number 
of GPCRs and the diverse cellular function evoked by each individual receptor, it is 
conceivable that multiple mechanisms may be employed. Research into the regulation 
of chemokine-mediated responses has focussed primarily on CXCR2 (423-426) and 
CXCR4 (259,289,427-429).
Like most GPCRs, chemokine receptors undergo rapid desensitisation, internalisation 
and recycling after engaging with their ligands (428,430-433). This is believed to be 
an important mechanism by which inflammatory processes and HIV-1 infection are 
controlled. Many chemokine receptors internalise through phosphorylation-dependent 
processes involving the binding of p-arrestins to the receptors that have been 
phosphorylated by GRKs (259,426,434-438). A C-terminal serine-rich domain is 
required in CXCR4 for ligand-induced endocytosis of CXCR4 (438). p-arrestins
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serve as adaptor proteins specifically targeting agonist-occupied receptors to clathrin- 
coated vesicles. A number of proteins involved in plasma membrane clathrin-coated 
pit function, such as AP2 and dynamin, are known to interact with phosphoinositides 
(439). Given that 3-phosphoinositides direct an array o f molecules to different 
positions within the cell in response to different stimuli, some degree of spatial and 
temporal regulation o f 3-phosphoinositide production must exist.
Whilst class I PI3Ks have been shown to interact directly with P-adrenergic receptor- 
kinase and PI(3,4,5)P3 production is required for p-adrenoreceptor endocytosis, to 
date a role for class I PI3K in chemokine receptor internalisation/recycling has yet to 
be determined (440,441). Class II PI3Ks are thought to regulate clathrin-mediated 
membrane trafficking, where clathrin functions as an adaptor for PI3K-C2a (285). In 
addition, PI3K-C2a has been shown to be concentrated in the trans-Golgi network 
and present in clathrin-coated vesicles (285,286). Based on this observation, Class II 
PI3Ks may play a role in receptor intemalisation/desensitisation and/or recycling to 
the plasma membrane, however the role of PI3K-C2P has not been examined. In 
conjunction with Prof. Ann Richmond (Vanderbilt University, Nashville USA), we 
investigated the subcellular localisation of PI3K-C2p with the goal of determining 
whether this PI3K could play a role in chemokine receptor internalisation/recycling. 
The human embryonic kidney cell line, HEK-293, was used in this section o f the 
study because these cells do not endogenously express chemokine receptors and are 
easily transfected.
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Generation of an EGFP-CXCR4 plasmid
To overcome initial methodological problems concerning the immunostaining of 
multiple proteins during receptor recycling, the first task was to generate an EGFP- 
CXCR4 construct. The problems that arose were not only down to the availability of 
antibodies but also due to the species in which they were derived. The aim was to 
perform triple subcellular staining visualisation experiments of CXCR4, PI3K-C2P 
and AP2. Since the commercial PI3K-C2p antibody was generated in a mouse, and 
the AP2 antibody was generated in a rabbit, the human CXCR4 antibody would have 
to be generated in a goat. Unfortunately, the mouse anti-goat secondary antibody 
required to detect the goat anti-human CXCR4 may cross-react with the primary 
mouse PI3K-C2p antibody, hence, the need to generate a fluorescent tagged CXCR4 
construct. Using an EGFP-CXCR4 construct meant that the detection of CXCR4 
would not require a fluorescent-tagged secondary antibody and thus permitting the 
straightforward detection of 3 different proteins at the same time.
The technique of polymerase chain reaction (PCR) was used to amplify the CXCR4 
DNA sequence. Two primers (synthetic DNA oligonucleotides) were first designed, 
one complementary to each strand of the DNA double helix and lying on opposite 
sides of the region to be amplified. The PCR product was inserted into a pEGFP-Nl 
vector and cloned within competent cells. Following purification, the plasmid DNA 
was confirmed as EGFP-CXCR4 by two sets of restriction enzymes. The first 
cocktail contained X hol and H indlll which cleaved the plasmid creating 2 bands
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representing the 4.7 kb vector and the 1.1 kb CXCR4 insert. Many proteins are 
approximately 1 kb in size therefore an additional restriction digest was performed 
using Xhol and BamHI. The BamHI restriction site is not only present in the vector 
but also at 0.5 kb within the CXCR4 insert. X hol and BamHI cut the vector at 3 
points to produce a 0.64, 0.5 and 4.7 kb bands (Figure 45). The undigested band at 
1.14 kb represents the CXCR4 insert plus the section of the vector up to the BamHI 
restriction site (refer to the Vector Map detailed in Chapter 3).
PI3K-C2P co-associates with the adaptor AP2
In eukaryotic cells, the formation and transport of vesicles from both the plasma 
membrane and trans-Golgi network (TGN) to endosomes involves the assembly of 
clathrin-coated vesicles (CCVs) (442,443). Polymerisation of clathrin with adaptor 
protein complexes in the cell is associated with phosphoinositide interactions and an 
array of receptors and regulatory molecules such as the GTPase ADP-ribosylation 
factor-1 (444). Tyrosine- and dileucine-based motifs represent two sorting signals 
contained within the cytoplasmic portion of several receptors and transmembrane 
glycoproteins. Such motifs mediate interactions with either the p2 subunit of AP2 or 
the p i subunit of API to select proteins for inclusion into the vesicle and facilitate 
their transfer from one part o f the cell to another (281,282). A long-standing question 
remains as to how the adaptor complexes can specifically target selected intracellular 
membranes. Since Class I PI3Ks have been shown to recruit AP2 to the receptor/p-
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arrestin complex, adaptor complexes may interact with the D3-phosphoinositide 
products of PI3K isoforms or the enzymes themselves. Using a GST-AP2P fusion 
protein we first set out to investigate whether AP2 associates with the Class II PI3K- 
C2P in vitro.
GST-AP2p bound to glutathione beads were incubated with HEK-293 cells lysates. 
The proteins associating with the GST alone and GST-AP2 fusion protein were 
separated by SDS PAGE and immunostained with an antibody specific for Class II 
PI3K-C2P. A band corresponding to the molecular weight of PI3K-C2P (165kDa) 
was found to co-precipitate with the GST-AP2P fusion protein, but not with GST 
alone (Figure 46). Identical samples were immunostained with an antibody specific 
for GST, to verify the presence o f the fusion protein and GST alone. The additional 
bands that were detected by the GST antibody may either be degradation products of 
the GST-AP2p fusion protein or alternatively a result o f non-specific binding of the 
GST antibody.
























Figure 45. A restriction enzyme digest of the EGFP-CXCR4 plasmid.
Following a maxi prep of 2 positive clones (2 and 8) selected from 8 mini cultures, 
two separate digests were carried out to verify that the plasmid DNA was CXCR4. 
The first digest included the restriction enzymes Xhol and HindiII which resulted in 
the formation of 2 bands representing the vector and the insert CXCR4. The second 
digest included the restriction enzymes Xhol and BamHI which cut the vector in such 
a way that a 0.64, 0.5 and a 4.7 kb band should be produced if the insert has been 
introduced correctly. Refer to the vector map detailed in Materials and Methods. Data 
are from a single experiment representative o f 3 others.
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Figure 46. PI3K-C2p co-associates with GST-AP2p
Lysates derived from HEK-293 cells were incubated with glutathione-bound GST- 
AP2 fusion proteins overnight at 4°C. These data show western blot analysis o f GST 
pull downs o f HEK-293 cells using either an antibody specific for (A) murine PI3K- 
C2p; or (B) rabbit GST. Data are from a single experiment representative of 3 others.
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The co-localisation of AP2 with GFP-CXCR4
(3-arrestins have been shown to bind to clathrin with high affinity (445), although they 
are not constitutively associated with clathrin-coated vesicles (446), nor do they 
promote clathrin-coat assembly (447). These studies imply that other adaptor proteins 
are also involved in this process. In fact, recent studies on the (32-adrenergic receptor 
(P2-AR) have shown that adaptin 2 (AP2) functions as a clathrin adaptor for the 
endocytosis of P2-AR (448). The role of the AP2 within chemokine-mediated 
receptor internalization is ill-understood, so experiments were designed to investigate 
the role of AP2 in CXCL12-mediated internalization of CXCR4. EGFP-CXCR4 
transiently transfected HEK-293 cells were stimulated with CXCL12 (10 nM) over a 
time course manner of 0-30 minutes (Figure 47). Independently of agonist, EGFP- 
CXCR4 was consistently expressed at the plasma membrane 48 hr post-transfection. 
Following addition of CXCL12, EGFP-CXCR4 re-distributes from the membrane 
and appears in the cytosol with punctate distribution at approximately 5 minutes. The 
majority of the EGFP-CXCR4 receptor is internalised at 5 minutes but tends to re­
appear at the membrane between 15 and 30 minutes. Cyanine 3-conjugated AP2 (red) 
has some constitutive membrane association but is also present at low levels in the 
cytoplasm. Upon stimulation of EGFP-CXCR4 with CXCL12, the localisation of 
AP2 with the plasma membrane is markedly reduced at 2 and 5 minutes post­
stimulation, followed by an increase in cytoplasmic AP2 at 15 minutes. The 
constitutive AP2 is shown to co-localise with the membrane-bound EGFP-CXCR4 in
Chapter 6: Results and Discussion 3 179
regions indicated by yellow colouring. Following stimulation of EGFP-CXCR4 with 
CXCL12, the co-localisation of AP2 with EGFP-CXCR4 is also evident in the 
cytoplasm (Figure 47).
The co-localisation of PI3K-C2P with AP2 and EGFP-CXCR4
Previously the Class II PI3K-C2a has been shown to be highly enriched in clathrin- 
coated vesicle fractions (449), to be constitutively associated with phospholipid 
membranes and disperse to perinuclear sites consistent with the ER. 
Immunofluorescence assays demonstrated that the distribution o f PI3K-C2a within 
the perinuclear sites paralleled with that of y-adaptin (AP-1) (285). Based on these 
observations, the role and distribution of PI3K-C2p was investigated. HEK-293 cells 
transiently transfected with EGFP-CXCR4 were stimulated for 5 minutes with 10 nM 
CXCL12 (Figure 48). The 5 minute time point was chosen as the optimal point at 
which CXCR4 was seen to internalise (Figure 47). The localisation of EGFP-CXCR4 
changed in response to CXCL12 from the plasma membrane to a punctate 
distribution in the cytosol. Cyanine 3-conjugated PI3K-C2p (red) is shown to be 
predominantly and uniformly localised within the cytosol, however a punctate 
distribution can also be seen along the plasma membrane. Stimulation with CXCL12 
leads to the re-localisation o f cytoplasmic PI3K-C2P to perinuclear regions o f the 
cell. Cyanine 5-conjugated AP2 follows a similar distribution to PI3K-C2P, where it 
is mainly distributed in the cytoplasm and re-distributes to regions adjacent to the
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nucleus following stimulation with CXCL12. The overlay image shows that prior to 
stimulation with CXCL12, a small proportion of PI3K-C2P co-associates with EGFP- 
CXCR4 at the plasma membrane (yellow) whilst the majority co-associates with AP2 
within the cytoplasm (pink). On addition of CXCL12, co-localised PI3K-C2p and 
AP2 redistributes to perinuclear regions of the cell. CXCL12-mediated internalisation 
o f EGFP-CXCR4 co-localises with AP2 within the cytoplasm (pale blue) with some 
areas showing colocalisation of AP2, PI3K-C2P and EGFP-CXCR4 (white).




-  «  ■5 min
Overlay
Green = EGFP CXCR4 RED = AP2 
Yellow = EGFP-CXCR4/AP2
Figure 47. Co-localisation of EGFP-CXCR4 with mouse anti-AP2 in HEK-293 
cells.
GFP-CXCR4-expressing HEK-293 cells were stimulated at intervals between 2 and 
30 minutes with 10 nM CXCL12 and fixed with methanol. The cells were 
immunostained with a murine antibody specific for AP2. As described in Materials 
and Methods a cyanine 3 -conjugated secondary antibody was then used to detect 
AP2-p (red). Images o f the cells were obtained by confocal microscopy. The coloured 
arrows indicate the areas o f individual and co-localised proteins. Data are from a 
single experiment representative of 3 others.
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Green = EGFP-CXCR4 Pink = PI3K-C2p/AP2 
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Figure 48. The co-localisation of PI3K-C2P with GFP-CXCR4 and AP2-p
HEK-293 cells, transiently transfected with GFP-CXCR4, were stimulated in a time 
dependent manner with 10 nM CXCL12 and fixed with methanol. The cells were 
immunostained with a cocktail o f antibodies specific for PI3K-C2(3 and the adaptor 
protein AP2-p. Murine cyanine 3- and rabbit cyanine 5 -  conjugated secondary 
antibodies were used to detect either PI3K-C2P or AP2-P respectively. Images o f the 
cells were obtained by confocal microscopy. The coloured arrows indicate the areas 
o f individual and co-localised proteins. Data are from a single experiment 
representative of 3 others.
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The role of PI3K-C2P in the Recycling Endosome
Intracellular trafficking o f membrane receptors is tightly regulated by a subfamily of 
ras-like small GTPases (Rab GTPases). Approximately 40 members of Rab GTPases 
have been identified, and each is believed to be specifically associated with a 
particular organelle or pathway. The recycling endosome is known to be regulated by 
R ab lla  and Rab25 (450-452). Research into the family of Rab GTPases is in its 
infant stage therefore most members have yet to be investigated with regard to 
chemokine receptor trafficking. Since EGFP-CXCR4 appeared to recycle back to the 
plasma membrane around 15 minutes post stimulation with CXCL12 (Figure 47), we 
aimed to investigate the role o f PI3K-C2P within the recycling endosome by 
focussing on the co-localisation with R ab lla  (Figure 49). As seen in previous 
experiments, EGFP-CXCR4 is localised at the plasma membrane and in response to 
10 nM of CXCL12, EGFP-CXCR4 internalises into the cytoplasm. The cytoplasmic 
distribution of cyanine 3-conjugated PI3K-C2P (red) and cyanine 5-conjugated 
R ab lla  (blue), localises to perinuclear regions of the cell in response to CXCL12. 
The overlay image shows cytoplasmic co-association of PI3K-C2P with R ab lla  
(pink) and some co-association of PI3K-C2P with EGFP-CXCR4 at the plasma 
membrane (yellow). Following the addition of CXCL12, there appears to be an 
increase in the co-association of PI3K-C2P and R ab lla , as demonstrated by the 
enhanced pink colour. A small proportion of CXCL12-mediated internalised EGFP- 
CXCR4 is shown to co-localise with PI3K-C2p (yellow) and with both Rablla and 
PI3K-C2P (white).
Chapter 6: Results and Discussion 3 184
Co-localisation of PI3K-C2p with phospho-PKB at the leading edge
Directional cell movement is known to involve the rapid activation of PI3K at the 
leading edge, leading to the production of PI(3,4,5)P3 and PI(3,4)P2, PH domain 
localization and movement up the chemoattractant concentration gradient (453). This 
part of the study focussed on the co-localisation o f PI3K-C2p with the classical PH 
domain containing protein PKB in the presence o f a chemokine gradient. Transiently 
transfected CXCR4 HEK-293 cells were presented with a gradient of CXCL12 for 5 
minutes and fixed in methanol (Figure 50). Cyanine 3 (red) and cyanine 5 (green) 
conjugated secondary antibodies were used to detect the localisation of PI3K-C2p 
and phospho-thr308-PKB respectively, in migrating CXCR4 expressing HEK-293 
cells. PI3K-C2P (B) and phospho-thr308-PKB (A) are predominantly distributed 
thoughout the cytoplasm however, a small proportion of these proteins are 
concentrated at leading edge o f the cell in the direction of the chemokine gradient. 
The overview image (C) shows the co-localisation of these two proteins (yellow) 
which appears to be predominantly within the pseudopod.
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Green = EGFP-CXCR4 Pink = PI3K-C2p/Rab11a 
RED = PI3K-C2p Yellow = EGFP-CXCR4/PI3K-C2p 
Blue = Rab11 a White = PI3K-C2p/Rab11a/CXCR4
Figure 49. The co-localisation of PI3K-C20 with GFP-CXCR4 and R ab lla .
GFP-CXCR4-expressing HEK-293 cells were stimulated in a time dependent manner with 10 
nM CXCL12 and fixed with methanol. The cells were immunostained with a cocktail of 
antibodies specific for PI3K-C2p and the enzyme Rablla. Murine cyanine 3- and rabbit 
cyanine 5- conjugated secondary antibodies were used to detect either PI3K-C2[3 or Rabl la 
respectively. Images of the cells were obtained by confocal microscopy. The coloured 
arrows indicate the areas of individual and co-localised proteins. Data are from a single 
experiment representative of 3 others.
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Figure 50. PI3KC2|3 Co-localises with phospho-thr308-PKB at the Leading Edge.
HEK-293 cells (5x l05/ml) transiently transfected with CXCR4 were plated onto 
cover slips and left to adhere overnight in an incubator at 37°C. Cells were 
subsequently transiently transfected with CXCR4 and left to recover for 48 h. Cover 
slips were transferred into large petri dishes (See picture of apparatus above), 
stimulated with CXCL12 (10 nM) for 5 minutes and fixed in methanol. Cover slips 
were then incubated with a phospho-specific antibody to phospho-thr -PKB and 
PI3K-C2|3 for 30 minutes at RT. Following several washes with PBS, the cover slips 
were incubated with the murine cyanine 3- and rabbit cyanine 5- conjugated 
secondary antidbodies to detect either PI3K-C2J3 (B) or phospho-thr308-PKB 
respectively (A). Finally the cover slips were mounted onto slides using an anti-fade 
mounting media and viewed on a semi-confocal/convoluting microscope. The white 
arrows indicate the areas o f individual and co-localised proteins. Data are from a 
single experiment representative of 3 others.
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Summary of Findings
• This study successfully designed, generated and expressed an EGFP-CXCR4 
plasmid DNA construct.
• CXCL12 stimulated the internalisation of the EGFP-CXCR4 protein.
• PI3K-C2p co-localises with AP2-p in HEK-293 cells
• AP2-P is shown to constitutively co-localise with CXCR4 at the membrane.
• PI3K-C2p co-localises with AP2 in response to CXCL12.
• PI3K-C2p co-localises with phospho-thr308-PKB at the leading edge o f cells 
responding to a gradient of CXCL12.
Chapter 6: Results and Discussion 3 188
6.2 Discussion
Phosphoinositides in Membrane Transport
Phosphoinositides are localised to the cytoplasmic face o f cellular membranes where 
they can be substrates for numerous enzymes, including PI3Ks. These reactions 
rapidly and effectively alter the levels o f particular phosphoinositides in specific 
regions of the membrane. There is a growing body of evidence indicating that 
changes in the phosphorylation state of the inositol ring of phosphoinositides regulate 
key steps in vesicular membrane traffic (454). PI(4,5)P2, has been described as a key 
regulator of the formation, scission and uncoating of clathrin-coated vesicles (CCVs). 
Several proteins implicated in endocytosis, including epsin, CALM (clathrin 
assembly lymphoid myeloid leukemia protein) and A P I80 (a brain specific CALM- 
homologue) bind specifically to PI(4,5)P2. However, exactly how A P I80 and epsin 
regulate the initial steps of clathrin-mediated endocytosis is not known, but it is likely 
that the interaction with PI(4,5)P2 tethers the clathrin lattice to the plasma membrane 
(455). Other proteins involved in clathrin-mediated endocytosis have been found to 
bind to PI(4,5)P2, including the GTPase dynamin, which is essential for scission of 
CCVs from the plasma membrane. Recent data show that both binding and hydrolysis 
o f GTP by dynamin are required for the late stages of CCV formation (456).
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The clathrin adaptor, AP2, is a target of 3-phosphoinositides, where the interaction 
with these lipids has been shown to regulate the recognition of endocytic signals and 
provide a distinct mechanism for increasing the specificity of sorting (457). The PI3K 
product PI(3)P has also been demonstrated to play a major role in endocytic 
trafficking. Studies employing a tandem FYVE domain as a probe for PI(3)P indicate 
that PI(3)P is highly enriched on early endosomes and in the internal vesicles of 
multivesicular endosomes and yeast vacuoles (458). Thus, it appears, the participation 
of specific phosphoinositides in membrane trafficking may reflect the ability o f their 
phosphorylated inositol groups to bind specific proteins and protein modules.
Since membrane phosphoinositides can interact directly with molecules of the vesicle 
budding, docking and fusion machinery, cellular reactions that alter the levels of 
phosphoinositides might provide the fundamental matrix for the efficient regulation 
of vesicular traffic (459).
The Role of PI3Ks in Receptor Trafficking
The alteration of phosphoinositide levels by lipid kinase activity has been shown to 
be important for incorporation of mannose-6-phosphate receptors into clathrin-coated 
buds in TGN (460). Because a key enzyme for the generation of phospholipids is 
PI3K, it suggests a possible role for PI3K in the internalisation of receptors. The G- 
protein coupled receptor kinase, pARKinasel has been shown to directly interact with
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the PIK domain of PI3K to form a cytosolic complex. Overexpression of the PIK 
domain displaced endogenous PI3K from pARKl and prevented pARK 1-mediated 
translocation of PI3K to activated P2ARS. Furthermore, disruption of the 
PARK1/PI3K interaction inhibited agonist-stimulated AP2 recruitment to the P2AR 
and receptor endocytosis (280). Class I PI3Ks have also been shown to be required 
for the endocytosis of transferrin receptors which in this system occurs directly from 
the early endosome and independently of the recycling endosome (283).
Class II PI3Ks have also been shown to play a role in clathrin-mediated membrane 
trafficking. PI3K-C2a is reported to bind directly to clathrin, where clathrin 
stimulates the catalytic activity of PI3K-C2a, especially towards PI(4,5)P2 (286). 
Endogenous PI3K-C2a is found in CCVs at the plasma membrane and in the TGN 
(285,286). Overexpression o f PI3K-C2a inhibits clathrin-mediated endocytosis and 
sorting in the TGN (286). Thus, it is possible that the class II PI3Ks may contribute to 
the local phosphoinositide production in clathrin-coated pits, which may facilitate the 
recruitment of inositide binding proteins within the coat such as AP2, dynamin, 
synaptojanin and arrestin.
Agonist-induced endocytosis o f most GPCRs occurs primarily via clathrin-coated 
vesicles. Previous studies have shown that CXCL12-mediated internalisation of 
CXCR4 involves GRKs, which function as adaptor molecules between the receptor 
and regulatory proteins such as P-arrestin and dynamin (254,259,428). The functions
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of (3-arrestins, dynamin and AP2P have all been found to involve binding to inositol 
lipids or inositol phosphates (461).
Since AP2 functions as an adaptor for clathrin and clathrin for PI3K-C2a, it is 
possible that class II PI3Ks participate in shared protein complexes with AP2. The 
data in this study revealed that a small proportion of AP2 constitutively co-localises 
with EGFP-CXCR4 at the plasma membrane. One possible explanation for this is the 
ability of the cell to mediate ligand-independent receptor recycling. This study also 
demonstrates that AP2 constitutively co-localises with PI3K-C2P in a uniform 
distribution within the cytoplasm, in CXCR4-expressing HEK-293 cells. Constitutive 
co-localisation of PI3K-C2p with AP2 suggests that PI3K-C2p may facilitate the 
recruitment of AP2 to the membrane where it is required for clathrin-coated pit 
formation. In response to CXCL12, the co-localised AP2 and PI3K-C2p appears to 
re-distribute to perinuclear regions of the cell. A similar distribution of PI3K-C2a 
and API has been reported, where the perinuclear regions of the cell have been 
identified as the endoplasmic reticulum or Golgi apparatus (285). However, API is 
present on vesicles derived from the Golgi apparatus, whereas AP2 is found on 
vesicles produced from the plasma membrane. In other studies, the perinuclear region 
of the cell has been described as the pericentriolar or perinuclear recycling 
compartment (PNRC) (462). This organelle is formed by tubulo-vesicular structures 
that gather recycling molecules directed to the plasma membrane once they have been 
separated from their cargo headed for the lysosomes (463). Since R ab lla , a small
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GTP-binding protein, has been found mainly associated with the PNRC by Trischler 
et al. (464), we set out to determine if R ab lla  co-associates with EGFP-CXCR4 and 
PI3K-C2p.
R ablla and PI3K-C2|3 may regulate recycling of the chemokine receptor 
CXCR4
Recent studies have demonstrated that GPCRs are also found in perinuclear recycling 
endosomes during their intracellular trafficking steps (462,465). As mentioned 
previously, the recycling endosomes are distinguished from other endosomes by 
selective retention of recycling proteins and the presence of the small GTPase Rabl la  
(466,467). The cellular functions of Rab proteins are implemented by their ability to 
couple a structural GDP/GTP switch, common to all GTP-binding of the Ras 
superfamily, to a membrane/cytosol switch that depends on lipid modifications 
attached to their C-terminus, termed prenylation (468). In the simplest scheme, GDP- 
bound Rab proteins are maintained by GEFs. PI(3,4,5)P3 directly and strongly 
activates the GEF activities of P-Rexl and SWAP-70 through binding via PH 
domains (469). Thus, it is possible that the activation of GEFs required for Rab 
activation may also bind to PI3K-dependent D-3 phosphoinositides. Rab5 has 
previously been shown to activate both PI3K-dependent and PI3K-independent 
effectors that act in parallel to promote phagosome maturation (470), but the 
involvement of the class II PI3Ks was not investigated. Investigation of class II
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PI3Ks within the recycling endosome showed that PI3K-C2(3 co-localised with 
R ab lla  within the cytoplasm of EGFP-CXCR4-expressing HEK-293 cells. In 
addition a small proportion of internalised EGFP-CXCR4 co-localised with both 
PI3K-C2(3 and Rabl la  following stimulation of cells with CXCL12.
Taken together these results suggest that CXCL12 induces the internalisation of 
CXCR4. We propose that PI3K-C2(3 contributes to local phosphoinositide production 
in growing clathrin-coated pits. AP2 may be recruited to the plasma membrane and 
bind PI3K-C2p-mediated D-3 phosphoinositide lipids and function as an adaptor for 
clathrin. These data also show that a proportion of internalised CXCR4 recycles back 
to the plasma membrane via the perinuclear recycling endosome, regulated by 
R ab lla . Activation o f R ab lla  may be dependent on the binding of GEFs to PI3K- 
C2P-mediated D3-phosphoinositides.
A role for Class II PI3K in CXCL12-mediated chemotaxis
One of the most important functions of chemokine receptors is receptor-mediated 
chemotaxis. Because inhibition of agonist-induced receptor endocytosis impairs the 
cell chemotaxis, it has been suggested that receptor internalization and recycling to 
the cell membrane may provide an on-off mechanism for the receptor-mediated 
chemotaxis or may be required for detection/response to the chemokine concentration 
gradient (426). Inhibition of agonist-induced receptor sequestration by mutation in
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the carboxyl terminus of CXCR2 was shown to inhibit ligand-mediated chemotaxis 
of HEK-293 cells (423). During chemotaxis several studies have reported that PKB is 
selectively recruited via its PH domain at the leading edge of cells following 
chemoattractant stimuli (471). It is well-known that PI(3,4,5)P3 is a major product of 
class IA PI3Ks that leads to the recruitment o f PKB. Class II PI3Ks may also 
contribute to the phosphoinositide production at the leading edge of a cell, since in 
the presence phosphatidylserine, they can also phosphorylate PI(4,5)P2. In addition, 
chemokines have been shown to activate class II PI3Ks in vitro which are thought to 
be responsible for mediating the in vivo formation of D-3 phosphoinositide lipids 
(197). Immunofluorescence analysis of fixed cells responding to a gradient of 
CXCL12 suggested that PKB308 co-localised with PI3K-C2(3 (yellow) at the leading 
edge of the cell in a time dependent manner. These data suggest that class II PI3Ks 
can contribute to phosphoinositide production and may also function to recruit PKB 
to the leading edge of chemotaxing cells.
6.3 Concluding Remarks
We propose that PI3K-C2(3-mediated phosphoinositide production may be involved 
in the recruitment o f AP2 to the CXCR4 receptor complex, where AP2 is likely to 
function as an adaptor for clathrin. Internalisation and subsequent recycling of 
CXCR4 appears to occur via the recycling endosome, regulated by R ab lla . PI3K- 
C2p-mediated phophoinositide production may be important for the binding and
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activation o f GEFs that are necessary for R a b lla  activation. Finally, we show that 
PI3K-C2p localises to the leading edge of a migrating cell, where it appears to co­
associate with PKB.
PDKC2p
( AP-2 C Clathrin
.iPpK-C2fi




’ GolgiPerinuclear Recycling Compartment,. Nucleus
Figure 51. A Model Depicting the Function of Class II PI3Ks in Receptor- 
mediated Endocytosis
The mechanism o f receptor cycling is a multi-step process involving the recruitment 
of many regulatory proteins and adaptor molecules, the majority o f which bind to 
inositol lipids. The alteration o f phosphoinositide levels by lipid kinase activity has 
been shown to be important for the incorporation of receptors into clathrin-coated 
buds. This diagram illustrates the areas in which we believe the class II PI3Ks are 
involved.
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Chapter 7
7.1 Overall Discussion and Future Directions
The signalling pathways that are mediated by chemokines and their respective 
receptors are complex and remain to be fully characterised. As described in the 
introduction the pathways stimulated by CCL1 have not been examined which 
provided an exciting window of opportunity in which to investigate. Using the 
CXCR4/CXCL12 receptor system as a model, the pathways identified following 
CCL1 stimulation have been shown in this study to be comparable. This does not 
imply that all chemokines elicit identical pathways because this is not the case. There 
appear to be similarities in the pathways that are mediated by different chemokines 
however it is evident that some chemokines may activate signalling pathways that 
others do not. Chemokine-mediated chemotaxis for example has been reported to be 
both PI3K-dependent (287) and independent (317). Studies of leukocytes from PI3Ky 
knock-out mice reveal that PI3Ky is involved in chemoattractant-mediated motility 
and cell migration (472,473), although neutrophils are reported to be dependent on 
PI3K8 for the directional component of chemotaxis (333). Alternatively, signalling 
pathways may be cell specific, where certain cell types lack a particular pathway or 
protein. Taking this into account, data from studies using cell lines must be used as a 
guide. The Jurkat T cell line for example is known to lack both lipid phosphatases
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SHIP and PTEN which would have dramatic effects on the constitutive levels of
PI(3,4,5)P3.
The data generated in this study have, for the first time, highlighted signalling 
pathways that are important for CCL1-mediated cell migration. Research in this field 
has shown that the binding o f chemokines to their receptors is followed by the 
involvement of heterotrimeric G proteins, adenylyl cyclase, PLC, PLA, PLD, protein 
tyrosine and serine/threonine kinases, lipid kinases (PI3K), the Rho family o f small 
GTPases (199,474), and the triggering of intracellular second messengers such as 
cAMP, phosphoinositides and calcium (77). Similarly, this study has demonstrated 
that CCL1-mediated migration of HUT-78 cells requires G proteins, PLC, PI3K, PKC 
and calcium. However, there remains a multitude of signalling molecules implicated 
in chemotaxis that have yet to be elucidated.
One of most impressive effects o f chemokines on leukocytes are the morphological 
changes: the cytoskeleton is rearranged, integrin-mediated focal adhesions are 
formed, and the cell binds and detaches from the substrate in a coordinated manner 
with extension and retraction of pseudopods to execute the directional migration 
(475). The mechanisms thought to regulate the cytoskeletal rearrangements 
underlying leukocyte polarization and migration are a complex system of signal 
transduction molecules, including tyrosine kinases, lipid kinases, second messengers 
and members of the Rho family of small GTPases. Two members of the family o f
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small GTPases, Racl and Cdc42, signal the formation of lamellipodia and filopodia, 
resepectively (476). Potential pathways for the transduction of signals from active 
Rac and Cdc42 to actin polymerization into lamellipodia and filopodia have been 
uncovered (Figure 52). Of the many effector proteins that interact specifically with 
GTP-Cdc42, only the haematopoietic Wiskott-Aldrich-syndrome protein (WASP) 
and its ubiquitous family member N-WASP provide a direct link to actin assembly 
through activation of the nucleating activity of the Arp2/3 complex (477). Another 
signalling pathway implicated in lamellipodium formation involves the PAK protein 
family. These serine/threonine kinases were identified as direct downstream effectors 
o f Rac and Cdc42. PAKs are engaged in multiple signalling pathways, some of which 
might be coupled directly to lamellipodium protrusion. For instance, PAK interaction 
with Cdc42/Rac increases the levels of phosphorylated MLC thought to be required 
for the anchorage of lamellipodia. In addition, PAKs were shown more recently to 
activate Lim kinases to phosphorylate and thereby block the severing/depolymerizing 
activity of cofilin, which is proposed to affect lamellipodium turnover (478).
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Figure 52 Signalling Pathways Implicated in Cell Migration
This figure illustrates the pathways that have been identified in this thesis and shows 
how they may fit in with the known mechanisms o f cell migration.
Rho activity in migrating cells is associated with focal adhesion assembly and cell 
contractility, and is responsible for cell body contraction and rear end retraction. One 
important Rho target involved in stimulating actin: myosin filament assembly and 
therefore contractility is the Ser/Thr kinase pl60ROCK. Rho and pl60ROCK have 
been shown to be essential for detachment of the back o f migrating cells such as 
leukocytes and macrophages (479,480). pl60ROCK interacts with and 
phosphorylates the myosin binding subunit (MBS) of MLC phosphatase and thereby 
inactivates it (481). This leads to increased levels of myosin phosphorylation, which
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then can cross-link actin filaments and generate contractile force. At the rear of a 
migrating cell, this promotes movement of the cell body and facilitates detachment of 
the cell rear (482). Clearly, Rho activity at the front of a migrating cell is 
incompatible with membrane protrusion and hence mechanisms must be in place to 
inhibit its activity at the leading edge. One way this might occur is through Rac. The 
biochemical mechanisms involved are not entirely clear; one suggestion is that 
p65PAK phosphorylates and inactivates MLCK, leading to decreased levels of 
myosin phosphorylation (483). However, others have reported that p65PAK can 
phosphorylate myosin light chain directly, thus enhancing cell contractility (484). 
Thus, Rho GTPases are key players in the process of cell migration and their ability 
to cycle between active and inactive states allows the cell to respond rapidly to 
extracellular cues.
Interestingly, ligand-stimulated receptor endocytosis has also been demonstrated to 
be essential for chemotaxis. Inhibition o f agonist-induced receptor sequestration by 
mutation in the carboxyl terminus of CXCR2 was shown to inhibit ligand-mediated 
chemotaxis (423). Given that PI3Ks contribute to the level of phosphoinositides, 
which play a central role in receptor recycling this study investigated the role of the 
class II PI3K-C2(3. The data revealed that PI3K-C2(3 appeared to be involved in the 
internalisation and recycling o f CXCR4 and was also shown to be concentrated at the 
leading edge of a migrating cell.
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PI3Ks and their lipid product PI(3,4,5)P3 have been widely implicated in controlling 
cell migration and polarity (390). During leukocyte chemotaxis, type IA PI3Ks are 
required for lamellipodium extension and migration towards colony-stimulating 
factor 1 (485), whereas type IB PI3Ks are required for neutrophil chemotaxis to a 
variety of inflammatory mediators that signal via GPCRs (392,393). GFP-tagged PH 
domains have been used to visualize bursts of PI(3,4,5)P3 induced in response to 
extracellular stimuli, and studies reported in Dictyostelium, neutrophils and 
fibroblasts reveal co-localisation with centers of actin polymerization at the front of 
the migrating cell (486-488). Rac activation has been shown to stimulate PI3K, 
leading to the accumulation o f PI(3,4,5)P3 and filamentous actin at the leading edge
(184.475.486). Disruption of this positive feedback loop results in an erratic, 
nonpolarized cell response to chemoattractants (330,489).
Studies in Dicytostelium have shown that the localisation of PI3K at the front is 
coupled to a restricted distribution of its antagonist, the PI(3,4,5)P3 phosphatase 
PTEN, at the rear and lateral edges, and that this is essential for chemotaxis
(328.329.487). Since SHIP is also a PI(3,4,5)P3 phosphatase that cleaves the 5’ 
phosphate of PI(3,4,5)P3 to generate PI(3,4)P2, it is possible that SHIP may also 
function at the sides and back o f the cell to reduce the levels of PI(3,4,5)P3. The data 
presented in this study demonstrated that constitutively expressed SHIP led to the 
reduction of CXCL12-mediated cell migration, implying that a global reduction in 
PI(3,4,5)P3 levels prevented the cell from polarizing and distinguishing front from
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back. Alternatively, whilst PTEN functions to regulate the levels of PI(3,4,5)P3 at the 
sides and back of the cell to promote forward movement, SHIP may be required at the 
leading edge to discontinue cell migration.
In summary, this study has focussed on three areas: signalling pathways; inhibitory 
regulation by the inositol-lipid phosphatase SHIP and receptor recycling, all of 
which, in some way or another appear to be involved in cell migration. Thus, despite 
the vast number of still remaining un-answered questions concerning the signalling 
pathways that regulate cell migration, this work has built the foundations upon which 
to further dissect the mechanism of signalling through chemokine receptors, these 
central mediators o f leukocyte migration.
7.2 Future Directions
• The data presented within this study were generated using cell lines however, 
it is acknowledged that the use of transformed cell lines and expression of 
mutated proteins may not accurately reflect physiological events. Future 
experiments should be carried out using normal peripheral blood derived T 
cells.
• Once a functional human antibody specific for CCR8 is made available the 
immunofluorescence analysis of receptor endocytosis could be investigated. It
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would be interesting to see if PI3K-C2p had an equivalent involvement in the 
regulation of CCR8 to that demonstrated with CXCR4.
• Further investigation into the regulation of CXCR4 sequestration would be of 
great interest. Future studies could investigate Hsc/Hsp70 Interacting Protein 
(Hip) which has recently been shown to associate with CXCR2 and regulate 
receptor signalling and trafficking. In addition, myosin Vb, a member of the 
class V unconventional myosins is reported to interact with R a b lla  in the 
recycling of the transferrin receptor to the plasma membrane. Having 
demonstrated that CXCR4 co-associates with Rabl la, the next stage would be 
to see if myosin Vb was also involved.
• Further analysis is required to determine the exact role of PI3K-C2p in 
chemotaxis, whether it may be required for the production of lipid products or 
have some other unknown function. A possible approach may be to design 
imaging experiments to investigate the localisation of Class II PI3Ks with 
regulatory components.
• Having demonstrated that PI3K regulates CCL1-mediated chemotaxis of 
HUT-78, it would be interesting to determine which isoforms of PI3K are 
important. This could be achieved using chemically synthesised siRNA 
oligodeoxyribonucleotides to specifically inhibit the different isoforms.
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Antisense agents are valuable tools to inhibit the expression of a target gene in 
a sequence-specific manner.
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Appendix 1
Lysis Buffer (pH 7.5)
g/lOOml
20mM Tris (MW: 121.1) 0.242
137mM NaCl (MW: 58.44) 0.801
lOmMNaF (MW: 41.99) 500mM stock 2 ml
ImM EDTA (MW: 41.99) lOOmM stock: 372.24mg/10ml 1 ml
10% glycerol (w/v) 10.0
1% NP-40 (w/v) 1.0
ImM Sodium Orthovanadate (MW: 183.9) 500mM stock 0.2 jil/ml
ImM PMSF (MW: 174.2) 500mM stock in DMSO 2 pl/ml
Aprotinin (2mg/ml) stock 2 pl/ml
Leupeptin (2mg/ml) stock 2 pl/ml
Pepstatin (5mg/ml) stock 2 pl/ml




0.1% Tween-20 (TBST only) 10.0 ml
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2x Sample Buffer (pH 6.8) g/100 ml
125mM Tris 1.51
4% SDS 4.0
10% Mercaptoethanol (v/v) 10.0 ml
20% Glycerol (w/v) 20.0
0.04% Bromophenol Blue 0.04








SDS-PAGE Gel Solutions made with Resolving and Stacking Gel 
Buffers containing 0.4% SDS
Resolving Gel (20 ml)
Stacking 
Gel (12ml)
5% 7.50% 10% 12% 14% 15% 5.00%
dH20 11.51 ml 9.84 ml 8.17 ml 6.84 ml 5.51 ml 4.84 ml 6.85 ml
Resolving Gel 
Buffer (pH8.8) 5.0 ml 5.0 ml 5.0 ml 5.0 ml 5.0 ml 5.0 ml
Stacking Gel 
Buffer (pH 6.8) 3.0 ml
Bis-Acryl (30%) 3.33 ml 5.0 ml 6.67 ml 8.0 ml 9.33 ml 10.0 ml 2.0 ml
10% AMPS 150 pi 150 pi 150 pi 150 pi 150 pi 150 pi 150 pi
TEMED 15 pi 15 pi 15 pi 15 pi 15 pi 15 pi 10-15 pi
PCR -  Master Mix
QIAGEN Taq DNA Polymerase Kit
10X Expand Buffer 5 p.1
dNTP (10 mM) 0.4 jxl
3’ (25 pM) 1 |Xl
5’ (25 pM) 1 jxl
MgCl2 (25 mM) 1.5 JL ll
Taq DNA Polymerase 0.2 |L i l
hCXCR4 Template cDNA* (0.1 |ig/ml) 2 pi
dH20 39 \i\
TOTAL 50 |il
* Template cDNA of human CXCR4 was previously sequenced by Prof. Ann 
Richmond from Vanderbilt University and used in this PCR master mix.
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PCR-2% Agarose Gel in 0.5x TBE
Agarose Powder 4 g
lx  TBE 200 ml
Ethidium Bromide 4 0  jllI
Digestion Mixture
PCR Product EGFPN1 Vector
2 pi Restriction Enzyme Buffer B (Promega) 2 pi
1 pi Xhol (10 Units/pl) 1 pi
1 pi Hindlll (10 Units/pl) 1 pi
16 pi PCR/EGFPN1 6 pi
0 pi dH20 10 pi
20 pi TOTAL 20 pi
PCR-1 Ox TBE Stock
per 1 L in MilliQ
Tris Base 108g
Boric Acid 55g
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